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Hormones and vitamins – orchestrators of dendritic cells and cancer 
Hormones and vitamins 
Hormones and vitamins are micro-environmental factors that orchestrate the function of cells 
through downstream signaling via their respective receptors. Hormones are small molecule 
messengers produced by specialized organs called endocrine glands. The major glands include the 
sex organs, pancreas, adrenal glands, pituitary glands and thyroid glands each of which secretes a 
specific repertoire of hormones. In addition to these dedicated organs, hormones are secreted by 
virtually every cell of the body. Hormones comprise an important class of signaling molecules and 
play key roles in a variety of physiological processes ranging from growth and reproduction over 
metabolism to immune responses. Consequently, hormonal malfunctions can lead to a disturbed 
homeostasis and development of pathologic conditions such as osteoporosis, infertility, diabetes and 
immune disorders1-4. 
Eat your vegetables! A sentence that sets you back to your childhood and that is associated with the 
question: Why? Vitamins are vital nutrients by definition, essential organic compounds that cannot 
be synthesized in adequate amounts by an organism and thus must be acquired externally from the 
diet.5 All 13 human vitamins can be obtained from vegetable sources with the exception of vitamin 
B12, which is only present in animal products. As vitamins are essential nutrients, lack thereof is 
associated with a variety of pathologic conditions affecting organ functions, the nervous and immune 
systems. Education on natural food sources and chemical supplementation with vitamins has 
diminished the prevalence of associated diseases. However, even nowadays common deficiencies 
include Vitamin A and Vitamin D, accounting for mortality, blindness and demineralization of bones, 
respectively.6-11  
 
 
 
Figure 1: Involvement of NRs in physiological functions. Nuclear Receptors (NR) and their ligands (hormones and 
vitamins) are implicated in a variety of physiological processes and related diseases; i.e. metabolism, nervous system, 
reproductive system, endocrine system, cell division, immune system and cardiovascular system. Three to four 
prominent examples of involved NRs are shown per process. Abbreviations see table 1.  
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The Nuclear Receptor Superfamily 
Most hormones and vitamins are ligands for the Nuclear Receptor (NR) superfamily of transcriptional 
regulators. NRs encompass a unique class of ligand activated transcriptional regulators which is 
phylogenetically conserved among the metazoan kingdom.12 Individual gene counts, however, differ 
a lot between species. The human genome contains 48 genes, similar to the murine genome with 50 
genes (Table 1); whereas the genome of Caenhorhabditis elegans comprises approximately 270 NR 
genes.13 In line with their hormone and vitamin ligands, NRs are key-regulators in a diversity of 
physiological functions, including reproduction, development, homeostasis, metabolism, cell 
differentiation and immune responses (Figure 1).14 Malfunction of receptor mediated signaling 
therefore is associated with diseases like infertility, diabetes, chronic inflammatory diseases and 
cancer.14-16 
The cloning of the first NR in 1958, the glucocorticoid receptor (GR) 17, was the key to the 
identification of the NR superfamily. All family members share a common modular organization 
which allowed for the prediction of new receptors based on their homology. NRs are typically 
composed of 3 main functional domains, the amino-terminal activation function (AF1) domain, the 
DNA binding domain (DBD) and the carboxy-terminal ligand binding domain (LBD) (Figure 2A).18-20 
They are generally divided into three main subclasses. Type I NRs comprise the steroid receptors, 
including the Estrogen Receptor (ER), Progesterone Receptor (PR), Androgen Receptor (AR) and 
Glucocorticoid Receptor (GR) (Table 1). Steroid receptors are classically sequestered in the cytoplasm 
of cells by binding to heat shock proteins. Ligand binding induces dissociation of the chaperone 
complexes and translocation to the nucleus where the receptors can bind to specific DNA sequences. 
Binding to these DNA response elements will lead to recruitment of coactivator complexes ultimately 
resulting in transcriptional activation of the target gene. Type II NRs encompass the Retinoid X 
Receptor (RXR) heterodimers. Well-known members of this class are the Retinoic Acid Receptor 
(RAR), peroxisome proliferator-activated receptors (PPAR) and the Vitamin D Receptor (VDR) (Table 
1). In contrast to type I NRs, type II receptors generally reside in the nucleus in the absence of ligand. 
They bind to their response elements and are often in complex with corepressor proteins. Upon 
ligand binding, conformational changes occur, corepressor proteins are released, coactivators are 
recruited and transcription is initiated.20-24 An additional subfamily are the so called orphan 
receptors, including the RAR related orphan receptors (ROR) and the NR4A family members Nur77 
(growth factor-inducible immediate early gene nur/77 like receptor), NURR1 (Nur-related protein 1) 
and NOR1 (Neuron-derived orphan receptor 1) (Table 1). These receptors have been identified 
according to sequence homologies and could not be linked to any natural ligand, yet. Orphan 
receptors often bind DNA as monomers, but are known to dimerize as well. Some of these receptors 
are known to be constitutively active, whereas induced transcriptional activation may be mediated 
by yet unidentified natural ligands, changes in expression patterns or alternatively by 
posttranslational modifications.25 Phosphorylation is known to target all NRs and alter their 
transcriptional activity subsequent to ligand stimulation.26 Such modifications might directly regulate 
transcriptional activity of orphan receptors, as they potentially miss natural ligands. 
The regulation of cellular functions by hormones, vitamins and NRs is not restricted to the described 
classical mechanisms of transcription repression and activation (Figure 2B). Many NR ligands have 
been shown to exert non-genomic functions, i.e. rapid activation of plasma membrane ion channels, 
adenylate cyclase (AC), protein kinases A and C (PKA, PKC), Src tyrosine kinase, phosphatidyl-inositol-
3-kinase (PI3K), extracellular-regulated kinase (ERK), p38 mitogen-activated kinase (p38MAPK), c-Jun 
N-terminal kinase (JNK), phospholipases C and D (PLC, PLD) and several phosphatases (PP1, 
1 
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PP2A).27,28 The molecular mechanisms underlying these non-genomic functions of NR ligands are still 
controversial and might be explained by two different theories. On the one hand, studies have shown 
the existence of membrane bound steroid receptors, like ER and PR.29-31 Other steroid hormone 
receptors such as GR and AR are likely to associate with the membrane too, as ER and PR membrane 
bound forms most probably depend on palmitoylation, which also occurs in GR and AR.29 On the 
other hand, rapid non-genomic actions of NR ligands also occur in NR deficient cells suggesting the 
existence of non-classical, alternative receptors. In line with this theory, thyroid hormones have been  
shown to signal through integrins and estrogens are thought to activate G protein coupled oestrogen 
receptor 1 (GPER1/GPR30).32-36 Current literature on both theories, however, provides conflicting 
data; especially regarding the membrane bound PRs and GPER1/GPR30.37,38 Dedicated studies to 
elucidate the molecular mechanisms of the non-genomic actions of NRs are thus needed and will 
probably uncover tissue and cell specific receptor pathways. 
 
Tabel 1: The nuclear receptor superfamily in mouse and human  
Abbreviation Family 
member 
Receptor name NR 
subclass 
Natural Ligand (synthetic 
agonist) 
Human 
(48) 
Mous
e (50) 
1 DAX1 NR0B1 Dosage-sensitive sex 
reversal-adrenal 
hypoplasia congenita 
critical region on the x 
chromosome, gene 1 
 
 
Orphan 
 
 
NA 
x x 
2 SHP NR0B2 Small heterodimeric 
partner 
Orphan NA x x 
3 TR-α NR1A1 Thyroid hormone 
receptor α 
Class I Thyroid hormone (GC-1) x x 
4 TR-β NR1A2 Thyroid hormone 
receptor β 
Class I Thyroid hormone (GC-1) x x 
5 RAR-α NR1B1 Retinoid acid receptor α Class II Vitamin A (Am-580, arotinoid 
acid) 
x x 
6 RAR-β NR1B2 Retinoid acid receptor β Class II Vitamin A (arotinoid acid) x x 
7 RAR-γ NR1B3 Retinoid acid receptor γ Class II Vitamin A (arotinoid acid) x x 
8 PPAR-α NR1C1 Peroxisome proliferator 
activated receptor α 
Class II Fatty acid/lipids 
(Troglitazone, GW409544, 
GW7647, Pirinixic acid, 
Palmitic acid, Leukotriene B4) 
x x 
9 PPAR-δ NR1C2 Peroxisome proliferator 
activated receptor δ 
Class II Fatty acids/lipids (GW0742, 
Eicosapentaenoic acid) 
x x 
10 PPAR-γ NR1C3 Peroxisome proliferator 
activated receptor γ 
Class II Fatty acids/lipids 
(Rosiglitazone, Troglitazone, 
GW1929, GW409544, 
GW7647) 
x x 
11 REV-ERB α NR1D1 Rev-Erb α Orphan NA x x 
12 REV-ERB β NR1D2 Rev-Erb β Orphan NA x x 
13 ROR-α NR1F1 RAR-related orphan 
receptor α 
Orphan Melatonin (CGP 52608) x x 
14 ROR-β NR1F2 RAR-related orphan 
receptor β 
Orphan Vitamin A x x 
15 ROR-γ NR1F3 RAR-related orphan 
receptor γ 
Orphan Vitamin A X x 
16 LXR-β NR1H2 Oxysterol receptor β Class II Oxysterol (T0901317, 
GW3965) 
X x 
17 LXR-α NR1H3 Oxysterol receptor α Class II Oxysterol (T0901317, 
GW3965) 
x x 
18 FXR-α NR1H4 Farnesoid receptor α Class II Bile acid (GW4064, 6-Ethyl-
CDCA) 
x x 
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19 FXR-β NR1H5 Farnesoid receptor β Class II Bile acid (GW4064, 6-Ethyl-
CDCA) 
 X 
20 VDR NR1i1 Vitamin D3 receptor Class II Vitamin D x X 
21 PXR Nr1i2 Pregnane X receptor Class II Xenobiotics (Hyperforin, 
Rifampicin, Pregnenolone 
carbonitrile,SR12813, 
T0901317, 24(S),25-
Epoxycholesterol, butamben) 
x X 
22 CAR NR1i3 Constitutive 
Androstane Receptor 
Class II Lipids, Androstanol (CITCO, 
Phenobarbital, ATE) 
x x 
23 CAR-β NR1i4 Constitutive 
Androstane Receptor β 
Class II Lipids, Androstanol ( 
TCPOBOP) 
 x 
24 HNF4-α NR2A1 Hepatocyte nuclear 
factor 4 receptor α 
Orphan Fatty acids,  Palmitoyl 
coenzyme A 
x x 
25 HNF4-γ NR2A2 Hepatocyte nuclear 
factor 4 receptor γ 
Orphan Fatty acids x x 
26 RXR-α NR2B1 Retinoid X receptor α Class II Vitamin A (LGD 100268, 
GW0791) 
x x 
27 RXR-β NR2B2 Retinoid X receptor β Class II Vitamin A (LGD100268) x x 
28 RXR-γ NR2B3 Retinoid X receptor γ Class II Vitamin A (LGD100268) x x 
29 TR2 NR2C1 TR2 Orphan NA x x 
30 TR4 NR2C2 TR4 Orphan NA x x 
31 TLX NR2E1 Tailless homolog Orphan NA x x 
32 PNR NR2E3 Photoreceptor-specific 
nuclear receptor 
Orphan NA x x 
33 COUP-TFI NR2F1 Chicken ovalbumin 
upstream promoter 
transcription factor I 
Orphan NA x x 
34 COUP-TFII NR2F2 Chicken ovalbumin 
upstream promoter 
transcription factor II 
Orphan NA x x 
35 EAR2 NR2F6 V-erbA related protein Orphan NA x x 
36 ER-α NR3A1 Estrogen receptor α Class I Estrogen x x 
37 ER-β NR3A2 Estrogen receptor β Class I Estrogen x x 
38 ERR-α NR3B1 Estrogen-related 
receptor α 
Orphan NA x x 
39 ERR-β NR3B2 Estrogen-related 
receptor β 
Orphan (GSK4716) x x 
40 ERR-γ NR3B3 Estrogen-related 
receptor γ 
Orphan (GSK4716) x x 
41 GR NR3C1 Glucocorticoid receptor Class I Corticosteroids 
(Dexamethasone, 
Prednisolone, 
Hydrocortisone) 
x x 
42 MR NR3C2 Mineralcorticoid 
receptor 
Class I Aldosterone x x 
43 PR NR3C3 Progesterone receptor Class I Progesterone (R5020) x x 
44 AR NR3C4 Androgen Receptor Class I Testosterone (R1881) x x 
45 Nur77  NR4A1 growth factor-inducible 
immediate early  gene 
nur/77 like receptor 
Orphan/
Class II 
(Cytosporone B ?) x x 
46 NURR1  NR4A2 Nur-related protein 1 Orphan/
Class II 
NA x x 
47 NOR1  NR4A3 Neuron-derived orphan 
receptor 1 
Orphan NA x x 
48 SF-1 NR5A1 Steroidogenic factor-1 
/ELP 
Orphan NA x x 
49 LRH-1 NR5A2 Fetoprotein 
transcription factor 
Orphan NA x x 
50 GCNF NR6A1 Germ cell nuclear factor 
1 
Orphan NA x x 
X, expressed; NA, not available 
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Nuclear Receptor coregulators 
NR activity is critically dependent on the presence of coregulatory proteins that mediate their 
transcriptional function. More than 300 of these molecules have been described until now, displaying 
an enormous diversity and establishing a complex regulatory network.39 NR coregulators are 
classically divided into coactivators and corepressors.40 Coactivators bind to NRs in a ligand 
dependent manner through an α-helical motif with a LXXLL consensus sequence.41 Transcription 
initiation by coactivator complexes is generally mediated by the recruitment of histone 
acetyltransferases (HAT), which cause local acetylation, followed by chromatin decondensation and 
enhanced promoter accessibility. Corepressors on the other hand do generally interact with NRs in a 
ligand independent manner and they comprise the conserved negative motif LXXI/HIXXXI/L. 
Inhibition of transcription by corepressors is mainly mediated by histone deacetylases (HDAC) 
through local acetylation, condensation of chromatin and hindered entry of e.g. polymerases. In 
addition to the characteristic coactivators and corepressors, a few versatile coregulators have been 
identified that were shown to both enhance and dampen NR mediated transcription; these include 
RIP140, PELP1 and DC-SCRIPT.42-45 
DC-SCRIPT (dendritic cell-specific transcript), also known as ZNF366, was first described in 2006 and 
recently shown to act as a coregulator of multiple NRs.44-48 DC-SCRIPT is a highly conserved protein 
and originally identified in a unique immune cell subset, the antigen presenting dendritic cell (DC). 
The DC-SCRIPT protein consists of an N-terminal proline-rich region, 11 Cys2His2-type zinc fingers 
and a C-terminal acidic region. Beyond its zinc fingers, it shares no homology with proteins alike and 
has a restricted expression pattern, including epithelial cells.45 Remarkably, it was shown that DC-
SCRIPT could regulate the activity of several subclasses of NRs. DC-SCRIPT overexpression inhibited 
the activity of the type I NRs ER and PR, whereas, it enhanced the transcriptional activities of the type 
II NRs RAR/RXR and PPAR/RXR.45 
Figure 2: Nuclear receptor structure and transcriptional regulation. (A) Domain organization of NRs. The activation 
function 1 (AF1) domain is involved in constitutive transcriptional activation of NRs. The DNA binding domain (DBD) 
mediates binding to NR specific genomic response elements. The ligand binding domain (LBD) binds ligand, is involved in 
dimerization and contains activation function 2, which mediates ligand dependent transcriptional activation and repression. 
(B) NRs classically regulate gene expression via DNA binding and recruitment of coactivator or corepressor complexes. 
However, NRs and their ligands also exert non-genomic functions through activation of protein kinases A and C (PKA, PKC), 
phosphatidyl-inositol-3-kinase (PI3K), Src tyrosine kinase, extracellular-regulated kinase (ERK), mitogen-activated kinases 
(MAPK), c-Jun N-terminal kinase (JNK), phospholipases C and D (PLC, PLD) and phosphatases (PP1, PP2A). It is still elusive 
whether these functions are mediated by membrane bound NRs or alternative receptors binding NR ligands. 
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In summary, NRs comprise a large superfamily of ligand activated transcription factors involved in 
diverse cellular processes. Therefore, NRs and their coregulators play pivotal roles within 
physiological and pathological functions including cancer- and immunobiology, which will be 
highlighted in the following paragraphs. 
 
Cancer 
Cancer comprises a heterogeneous collection of pathogenic conditions marked by the unregulated 
proliferation of cells. Its development follows six distinct hallmarks: the self-production of growth 
hormones, imperviousness to growth inhibitory signals, avoidance of apoptosis, unlimited 
proliferation, sustained angiogenesis and metastatic capacity.49 Recently, two additional emerging 
hallmarks have been added to the list: the reprogramming of energy metabolism and 
immunosurveillance evasion.50 Generally, cancer growth is either benign (non-aggressive) or 
malignant and thus invasive. Moreover, five major cancer categories are recognized based on the 
histological origin of the malignant cells: sarcoma, myeloma, leukemia, lymphoma and carcinoma. 
The latter arises from epithelial cells and constitutes 80-90% of all cancer cases. A substantial part of 
carcinomas is associated with the endocrine system, as hormones and vitamins are important factors 
in the homeostasis of cell proliferation. 
 
Hormones and vitamins in cancer biology 
Malignant cells maintain, transform and utilize the characteristics of their progenitor cells.51 This 
concept is well established for carcinomas of glandular organs like liver, pancreatic, ovarian, 
testicular, prostate and breast cancer, all of which are highly dependent on the presence of steroid 
hormones, an essential feature of their ancestor cells. Two well studied hormone dependent 
malignancies are breast and prostate cancer. 
Early mammary gland development and cyclic proliferation of mammary duct cells are driven by the 
steroid hormones estrogen and progesterone.52 Both hormones are also well established key factors 
in the development of breast cancer.53-55 70% of breast tumors express stable or elevated levels of 
the ERα and PR.56 Estrogen and progesterone augment proliferation of breast tumor cells by inducing 
the transition from G1- to S-phase. This process is dependent on the hyperactivation of the cycle-
related genes c-myc and cyclin D1 (CCND1).57 Consequently, current therapy regimens include the ER 
antagonist tamoxifen and aromatase inhibitors, which block the production of estrogens. In line with 
the importance of the ERα and PR in breast cancer, the expression of transcriptional coregulators of 
both receptors is also of prognostic significance in breast cancer.58,59 In contrast to the progressive 
role of ERα and PR in breast cancer, RAR and PPARγ are typically referred to as tumor suppressive. 
Stimulation of RAR with retinoic acid (vitamin A) in breast cancer cells triggers cell cycle arrest in the 
G1 phase through induction of the cell cycle regulator Btg-2 and reduced expression of cyclins D1 and 
D3.60,61 Activation of PPARγ inhibits cell proliferation of breast cancer cells and promotes apoptosis. 
Recently, the versatile NR coregulator DC-SCRIPT was shown to dampen the activity of the type I NRs 
ERα and PR, positive regulators of breast carcinogenesis, whereas it enhanced the activity of the type 
II NRs RAR and PPARγ, negative regulators of breast tumor development. Moreover, DC-SCRIPT 
expression positively correlated with disease free survival and was shown to be an independent 
prognostic factor in breast cancer.45,62  
Similar to mammary glands which are dependent on the steroids estrogen and progesterone, the 
development of the prostate and its proper function are critically dependent on androgens.63 
Moreover, this hormone is an important factor in the development and sustained growth of prostate 
1 
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cancer and the vast majority of tumors express the AR.64,65 Activation of AR in prostate cancer cells 
inhibits the expression of the cell cycle inhibitor p16 and induces the expression of the cyclin 
dependent kinases 2 and 4 (CDK2 and CDK4).66 Therefore, hormonal treatment modalities for 
prostate carcinoma comprise AR blocking agents and androgen deprivation. Although almost all 
prostate cancer patients initially respond to anti androgen therapy, most patients will transit into the 
hormone-refractory stage characterized by androgen independent tumor growth.66 Besides the 
involvement of the receptor itself, coregulatory proteins of the AR have also been implicated in 
prostate cancer.67 While AR is important in the initiation and progression of prostate cancer another 
NR, the VDR, has recently been shown to hamper prostate cancer growth.68,69 Stimulation of prostate 
cancer cells with Vitamin D inhibits the transition from G1 into S phase by increased expression of the 
cell cycle repressor p27Kip1, reduced expression of c-myc and impaired activity of CDK2.70,71 
Better understanding of the roles of hormones, vitamins, NRs and their coregulators in hormone 
dependent cancers, as breast and prostate carcinomas, might stimulate the development of novel 
treatment modalities. Given the multifunctional regulatory effect of DC-SCRIPT on type I and type II 
NRs, it is interesting to speculate about the prognostic significance of DC-SCRIPT in prostate 
carcinoma and other hormone dependent cancers.  
 
Immune System 
The equilibrium of tolerance and immunity is constantly perturbed by influences from outside and 
inside the human body like viruses, bacteria and malignant cell formation. Our immune system 
comprises various regulatory mechanisms on a cellular and molecular level that buffer these 
perturbations to warrant a proper physiological balance. Generally, the immune system can be 
divided into the innate and adaptive arm. The innate immune arm constitutes the primary response 
system which works in a non-specific manner without the need of prior exposure to a certain 
pathogen. 
Innate immune cells comprise granulocytes (eosinophil, basophil and neutrophil), mast cells, 
macrophages, natural killer (NK) cells, macrophages and dendritic cells (DC). These cells represent 
the first line of defense; they exert two main functions: 1) direct killing of pathogens and tumor cells 
2) phagocytosis of pathogenic material and intracellular break down thereof into peptides. Immune 
activation of innate cells is mediated by the recognition of pathogen associated molecular patterns 
(PAMP) through pattern recognition receptors (PRR). Four different classes of PRRs are known based 
on protein homologies, signaling motifs and localization.72 The toll like receptor (TLR) family 
comprises transmembrane receptors located at the plasma membrane or in endosomal 
compartments. TLRs recognize a variety of ligands like RNA, DNA, bacterial carbohydrates and 
bacterial peptides. The second class of PRRs are the nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLR). NLRs are located in the cytoplasm and detect PAMPs of intracellular 
pathogens. C-type lectin receptors (CLR) form the third family of PRRs; they cover recognition of 
most human pathogens. Most CLRs are endocytic receptors which bind conserved carbohydrate 
residues. The last class of PRRs constitute the retinoic acid-inducible gene (RIG)-l-like receptors (RLR). 
These cytosolic receptors sense intracellular viral replication through binding of viral nucleic acids. 
The adaptive immune system is characterized by pathogen specific responses mediated by B and T 
lymphocytes. The development of adaptive immune reactions takes significantly longer (4 to 7 days) 
than the initiation of the rapid innate reactions (minutes to hours). However, the adaptive immune 
system is able to build memory responses after the initial encounter with a specific pathogen, 
providing a more rapid reaction to subsequent infections. B cells are activated through recognition of 
Part 1 - Introduction & Scope
16
   
pathogen specific antigens via the B cell receptor (BCR) and subsequently differentiate into plasma 
cells, characterized by the secretion of pathogen specific antibodies (AB). The binding of pathogens 
by ABs triggers the activation of the complement system, an innate protein cascade facilitating the 
uptake of pathogens by immune cells and mediating the direct killing of pathogens. Moreover, 
binding of AB to pathogens activates mast cells, NK cells and neutrophils. The second effector cells of 
the adaptive immune system, T cells, are stimulated through their specific T cell receptor (TCR). 
Antigen presenting cells (APC), i.e. B cells, macrophages and DCs, display the TCR matching antigen in 
major histocompatibility complex (MHC) molecules on their surface, provide appropriate co-
stimulation and secrete pro-inflammatory cytokines to activate T cells. Three different subsets of T 
cells are generally distinguished: 1) CD4+ T helper (Th) cells 2) CD8+ cytotoxic T cells (CTL) and 3) 
CD4+CD25+ regulatory T cells (T reg). Naïve Th cells are activated through presentation of antigen in 
the context of MHC class II molecules on APCs and subsequently differentiate into different subsets, 
i.e. Th1, Th2, and Th17. Th1 cells mainly produce the cytokine interferon γ (IFNγ) thereby assisting 
CTL responses and macrophage activation. Th2 cells support the AB production by B cells through 
secretion of interleukins (IL) 4 and 5. Th17 cells are characterized by their secretion of IL17 and 
thought to be involved in protection from viral, bacterial and fungal infections. Naïve CTLs, the 
second T cell subset, are activated through antigen bound MHC class I molecules on the surface of 
APCs. Activated CTLs recognize and kill virally infected cells through secretion of cytotoxic substances 
like granzyme B and perforin. T regs constitute a special T cell subset as they can inhibit the functions 
of Th cells and CTLs through cell-cell contact dependent mechanisms. This suppression is further 
assisted by the secretion of the anti-inflammatory cytokines IL-10 and TGF-β. The inhibitory T regs 
are pivotal for the regulation of excessive immune responses and therewith for the prevention of 
auto-immunity. 
 
Dendritic cells 
DCs are the most potent professional APCs of the immune system which instruct innate immune cells 
and antigen-specific B and T cells to initiate adaptive immunity. DCs sample and process material 
from their microenvironment. They ingest proteins, break them down into peptides and present 
them in MHC molecules. Upon infection or inflammation, immature DCs get activated by danger 
signals (e.g., bacteria, viruses, apoptotic cells and cancer peptides) through PRR signaling and 
differentiate into mature DCs.73 After maturation, they migrate to the lymph nodes, where they 
present the peptides to T cells. Endogenous antigens (self or viral) are processed by the proteasome 
and loaded onto MHC class I molecules, whereas exogenous antigens are broken down in endosomes 
and loaded onto MHC class II molecules. Moreover, DCs have the unique ability to present 
exogenous antigen in the context of MHC class I molecules, a process referred to as cross-
presentation. The efficient cross-priming of CTLs with MHC class I bound exogenous peptides is 
crucial for the induction of immune responses against viruses which do not infect DCs and tumor 
cells. The immunological response mediated by DCs strongly depends on the integration of three 
distinct signals: the recognition of the peptide-MHC complex (signal 1), stimulation via co-stimulatory 
molecules (signal 2) and cytokines (signal 3). Immature DCs provide only signal 1, leading to immune 
tolerance via T cell anergy or the induction of T regs, whereas, fully matured DCs provide all three 
signals and induce the full-scale activation of immune-competent effector T cells. The nature of 
cytokines secreted by DCs thereby greatly determines the polarization of Th cells (Th1, Th2, Th17 or T 
reg). Recent studies have demonstrated that innate immune signals are important for the skewing of 
DCs themselves and therewith subsequently determine the polarization of Th cells.74 INFγ, e.g. 
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secreted by NK cells, was shown to enhance IL-12 production by DCs, the key cytokine for Th1 
polarization. Skewing towards Th2 differentiation is driven by the nature of the pathogen, i.e. 
helminthes, and cytokines like IL-4 and the epithelial cell secreted thymic stromal lymphopoietin 
(TSLP).75 Fungal PAMPs recognized by the c-type lectin receptor dectin-1 have been shown to induce 
a Th17 polarizing phenotype in DCs, i.e. the secretion of IL-6 and IL-23. Lastly, binding of bacterial 
products to CD11b/CD18 on DCs induces the secretion of IL-10 and subsequent induction of T reg 
differentiation. Besides these innate signals, recent data suggest that the nature of the DC subset is 
an additional important factor in the polarization of T cells. 
 
DC subsets 
Despite their indispensable role in raising an immune response, DCs are a rather rare and 
heterogeneous type of immune cell. DC subtypes differ in phenotype and function, which may also 
depend on their localization. Langerhans cells (LCs) are DCs that are predominantly found in 
epidermal layers of the skin where they are mainly involved in the uptake and presentation of 
microbial antigens. This specific tissue subset is characterized by the expression of langerin. Human 
peripheral blood comprises two more main subtypes of DCs. CD11c expressing conventional DCs 
(cDCs, also referred to as myeloid DCs) and CD11c negative (human) or low (mouse) plasmacytoid 
DCs (pDCs).76 cDCs are recognized as the classical DC subset; they rapidly and very efficiently take up 
and process antigen to subsequently prime B- and T-lymphocytes.77-79 In man, cDCs can further be 
characterized by the expression of general myeloid markers, such as CD13 and CD33. They lack 
lineage specific markers (CD3, CD14, CD19 and CD56), but express high levels of MHC class II. Blood 
residing cDCs can further be subdivided based on differential surface expression of CD1c (BDCA-1) 
and BDCA-3. Both of these cDC subsets have the capacity to produce interleukin-12 (IL-12) in 
response to microbial stimuli through TLRs.80-82 However, they clearly differ in their expression of 
surface molecules, PRRs and their potency to stimulate T cells.83-85 BDCA-1+ cDCs play a central role in 
the recruitment of other immune cells via production of IL-8, whereas BDCA-3+ cDCs were shown to 
efficiently cross-present exogenous antigen to CTLs, a process that is essential for the induction of 
anti-tumor immune responses.86 In mice, at least three cDC subsets are distinguished in the spleen: 
CD8α+/CD4-, CD8α-/CD4+ and double negative CD8α-/CD4- cDCs.87 These three murine cDC subsets 
express distinct PRR profiles and respond differently to pathogenic stimuli.88,89 CD8α+/CD4- are 
generally regarded as the most efficient cross-presenting subset, similar to the BDCA-3+ cDCs in 
human. However, recent data indicate that all DC subsets are commonly able to cross-present 
antigen, whereas the efficiency critically depends of the nature of antigens and activation signals.90 
pDCs are clearly different from cDCs in shape, physiological presence, activation pattern, migration 
and function. They play a distinctive role at the interface of innate and adaptive immunity.91 Human 
pDCs are distinctively identified by their expression of BDCA-4, BDCA-2 and CD123. In the mouse, 
pDCs express the cell specific surface molecules Siglec-H and PDCA-1 (also known as BST-2). pDCs 
comprise a highly specialized DC subset which is characterized by the rapid secretion of large 
amounts of type I IFNs in response to unmethylated CpG oligonucleotide motifs derived from 
bacterial and viral DNA/RNA. 92-95 In addition, upon activation they are able to acquire DC 
morphology, present antigen and efficiently stimulate T cells. 
The heterogeneous phenotypes of the different DC subsets endows them to distinctly respond to the 
danger signals that they encounter in their microenvironment (Figure 3). Besides the pathogen 
derived triggers, chemokines and cytokines are known to modulate DC function and thereby the 
outcome of immune responses (see also above “Dendritic cells”).96 In addition, recent data 
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demonstrate that the unique composition of a given tissue microenvironment can influence the 
function of local DCs. 
 
Hormones and vitamins in dendritic cell biology 
The important role of the tissue microenvironment on the phenotype and activation state of DCs is 
well established for mucosal organs like the gut and skin. Optimal cDC function in the 
microenvironment of the gut and in the local mesenteric lymph nodes is dependent on the VitA 
derivative retinoic acid (RA).97 The resident, tolerogenic CD103+ intestinal DCs are imprinted by RA, 
secreted by epithelial cells of the gut and stromal cells of the local MLNs.98 RA conditioned CD103+ 
DCs express the RA metabolizing enzyme retinal aldehyde dehydrogenase (RALDH) which enables 
them to produce RA themselves, a pivotal factor for the attraction of gut-homing T regs.99100,101 
Similar to the gut, optimal function of DCs in the skin is directed by sunlight induced VitD.102 DCs in 
the skin express the VitD metabolizing enzymes Cyp27A1 and Cyp27B1 and convert VitD precursors 
to the active ligand calcitriol. The secretion of calcitriol subsequently enables the infiltration of skin 
homing T cells. In addition to the important role of VitA and VitD in the imprinting of DCs to attract T 
cells, different hormones, vitamins and their NRs have been shown to direct immune responses of 
DCs, both towards tolerance and immunity (Figure 3). DC mediated immune responses can be 
enhanced by the stimulation of RAR, e.g. langerhans cells that were treated with RA have augmented 
T cell activating potential. Moreover, RA stimulated moDCs secrete increased levels of the pro-
inflammatory cytokines IL-6 and TGF-β. The suppressive effects of NR stimulation (i.e. GR, VDR, LXR 
(oxysterol receptor) and PPARγ) are particularly well studied in DCs. GR inhibits DC maturation by 
repression of co-stimulatory molecules and pro-inflammatory cytokines on the one hand, and strong 
induction of the anti-inflammatory cytokine IL-10 on the other hand.103 GR agonists (i.e. 
corticosteroids) are widely used immunosuppressive drugs for the treatment of autoimmune 
diseases, like rheumatoid arthritis systemic lupus erythematosus and transplant graft rejection.103-105 
Stimulation of VDR with VitD is well established to impair the T cell activating capacity of DCs, 
particularly moDCs. Moreover, both LXR and PPARγ have initially been shown to inhibit DC 
maturation, however, recent studies provide conflicting data showing enhanced DC activation and 
skewed DC polarization.106 The effect of LXR and PPARγ on DC function is thought to be dependent 
on the given tissue context and thus additional signals like PAMPs and cytokines, though the exact 
interplay of these factors remains elusive. 
Hormones and vitamins alter DC mediated immunity and play a critical role in tissue specific immune 
responses. Still, little is known regarding the effect on DC subsets, enhancement of DC activation, DC 
polarization and the integration of NR signaling with additional micro-environmental factors.  
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Figure 3: Dendritic cells are shaped by their microenvironment. Dendritic cells integrate pathogenic signals 
recognized by pattern recognition receptors (PRR) and microenvironemental cues recognized by nuclear 
receptors (NR). The combination of received signals will lead to the differentiation of tolerogenic or 
immunogenic DCs. The glucocorticoid receptor (GR) and vitamin D receptor (VDR) and induce tolerogenic 
responses marked by increased IL-10 and decreased IL-12, TNFα, CD86 and CD80. The retinoid acid receptor 
(RAR) enhances the immunogenic phenotype of DCs with increased IL-6, TGFβ and CD1d (important for NK cell 
activation). The peroxisome proliferator activated receptor (PPARγ) and liver x receptor (LXR) have been 
implicated in both tolerance and immunity.  
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Scope of this thesis 
 
Hormones, vitamins and their nuclear receptors control various physiological processes like 
metabolism, neurological responses, endocrine signals, cell growth and immune responses. 
Consequently, aberrant signaling via NRs is associated with corresponding diseases including cancer 
and autoimmunity. NRs are activated by hormones and vitamins, small compounds which are easy to 
synthesize and NRs therefore represent ideal drug targets. Profound knowledge of the effects of NR 
signaling on distinct cell types is a pre-requisite for the rationale design and application of NR based 
treatment modalities. The scope of this thesis was to further elucidate the role of hormones and 
vitamins in dendritic cell and cancer biology. 
Part II Despite the importance of both NRs and DCs within the immune system, still little is known 
regarding the NR expression profile in DC subsets in general and in pDCs in particular. In chapter 2 
we assessed and compared the NR expression profile of murine cDCs and pDCs. We show that both 
subsets express the same repertoire of NRs in vitro and ex vivo from different lymphoid organs. 
mRNA expression levels of distinct receptors however, differed between pDCs and cDCs especially 
upon maturation. Chapter 3 investigates the effect of VitD treatment on murine and human pDCs. 
VitD is known to have immunosuppressive functions and applied in the clinics for the treatment of 
autoimmune diseases. We show that in addition to cDCs, VitD also impairs pDCs in their ability to 
activate T cells in a VDR dependent manner. 
Part III The transcriptional activity of NRs is critically dependent on the presence of coregulatory 
proteins. Most coregulators either enhance (coactivators) or inhibit (corepressors) NR mediated 
transcription. DC-SCRIPT is a versatile NR coregulator which exerts both of these functions. In 
chapter 4 we studied the role of DC-SCRIPT in DC biology. We show that DC-SCRIPT is expressed early 
upon differentiation of monocytes to DCs and also in different circulating DC subsets. Functionally, 
knockdown of DC-SCRIPT in moDCs results in increased production of IL-10 and decreased levels of 
IL-12. Chapter 5 deals with the interplay of DC-SCRIPT with the glucocorticoid receptor in DCs. DC-
SCRIPT interacts with GR and inhibits GR mediated transcription. Furthermore, knockdown of DC-
SCRIPT leads to the enhanced expression of the GR target gene GILZ in DCs, a known hallmark of 
tolerogenic DCs. 
DC-SCRIPT has been shown to be an independent prognostic marker in breast cancer. In chapter 6 
we further extend the role of DC-SCRIPT in cancer biology and address its function in prostate cancer. 
Early malignant transformation of normal prostate epithelial cells is characterized by the loss of DC-
SCRIPT expression. Moreover, we show that DC-SCRIPT represses the function of AR and enhances 
transcription mediated by VDR, two important NRs in prostate carcinoma. 
Part IV Finally, in chapter 7, I summarize the results of this thesis and further discuss the implications 
and future perspectives of hormones and vitamins as orchestrators of dendritic cells and cancer.  
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Abstract 
Dendritic cells (DC) play a central role in the immune system. They can either induce immunity or 
promote tolerance. The DC family is generally comprised of two functionally distinct DC subsets. 
Conventional dendritic cells (cDC) are the classical antigen presenting cells; plasmacytoid dendritic 
cells (pDC) are the main producers of type I interferons thereby serving innate immunity. Upon 
activation DCs are able to present antigen and stimulate T cells. The immune modulatory functions of 
DCs largely depend on the recognition of soluble cues. Besides pathogen derived cues, recent data 
indicate that the tissue micro-environment i.e. of the gut and skin affects cDC function. Many of 
these micro-environmental factors are ligands for the nuclear receptor (NR) family of transcription 
regulators known to affect immunity and tolerance. Whether pDC function is also influenced by 
tissue derived cues, like hormones, vitamins and metabolic products, is largely unknown. Here, we 
investigated the NR expression profile of murine pDCs and cDCs. We assessed the mRNA levels of 19 
NRs of in vitro derived as well as ex vivo isolated DCs from four different lymphoid tissues. We 
observed that cDCs and pDCs expressed the same repertoire of NRs. Expression levels, however, 
differed between the two subsets, especially upon maturation of DCs. These data imply that NR 
ligands do impact pDC function and that their activity might be regulated in a DC-specific manner. 
 
Keywords: Nuclear Receptor, Dendritic cell, Dendritic cell subset, plasmacytoid dendritic cell 
 
 
Introduction 
Dendritic cells (DCs) are the most powerful professional antigen presenting cells of the immune 
system. DCs are generally divided into conventional DCs (cDCs) and plasmacytoid DCs (pDCs). cDCs 
form the classical DC subset, they are key regulators in the balance of immunity and tolerance due to 
their ability to prime B- and T-lymphocytes, the effector cells of an immune response (1-3). pDCs are 
clearly different from cDCs in shape, physiological presence, activation pattern, migration and 
function. They play a distinctive role at the interface of innate and adaptive immunity (4). pDCs are 
the main producers of type I interferons thereby inducing efficient anti-viral responses (5, 6). In 
addition, upon activation they are able to present antigen and stimulate T cells thereby inducing 
specific immune responses (4, 5).  
DCs constantly scan their environment for possible threads, like bacteria or viruses. Upon encounter 
of pathogens they recognize specific molecular patterns via binding to their pattern recognition 
receptors (PRRs), like toll like receptors (TLRs). The cells then become activated and initiate an 
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immune response. DCs are present in essentially every tissue. Besides the pathogen derived triggers, 
chemokines and cytokines are known to modulate DC function (7). In addition, recent data 
demonstrate that the unique composition of a given tissue microenvironment can influence the 
function of tissue-resident cDCs. Various studies indicate that hormones, vitamins and metabolic 
products are part of the tissue-derived signals that affect DC function (8-11). These factors are all 
ligands for the nuclear receptor (NR) family of transcription regulators (12, 13). Nuclear receptors are 
key-regulators in a diversity of physiological functions including reproduction, development, 
homeostasis, metabolism, cell differentiation and immune responses (14). Several NR agonists are 
known to modulate the immune system in general and to alter cDC phenotype and function in 
particular (8, 11, 15). The retinoid all-trans-retinol i.e. was shown to be necessary for optimal cDC 
function in mesenteric lymph nodes in the microenvironment of the gut (16-19). Despite the 
importance of both NRs and DCs within the immune system, still little is known regarding the NR 
expression profile in DC subsets including pDCs. Only recently, the hormone progesterone was shown 
to regulate IFNα production in pDCs (20). Furthermore, Abe et al. showed that the GR ligand 
dexamethasone inhibited differentiation of murine pDC and increased their apoptotic death 
(21).These data imply that NR ligands do impact pDC function and that their activity is regulated in a 
DC specific manner. Therefore, we compared the NR expression profiles of murine plasmacytoid and 
conventional DCs. In vitro cultured pDCs and cDCs as well as freshly isolated cells from four different 
lymphoid tissues were analyzed for mRNA levels of 28 NRs. Moreover, we assessed changes in NR 
expression upon maturation of pDCs and cDCs with TLR ligands. 
 
Materials & Methods 
In vitro and ex vivo purification of pDCs & cDCs 
Dendritic cells were generated from murine bone marrow isolated from femur/tibia of female 
C57BL/6N mice (Charles River, Germany). Mice were used at 6-12 weeks of age. Animal studies were 
approved by the Animal Ethics Committee of the Nijmegen Animal Experiments Committee. Cells 
were cultured at a density of 1.5-2*10e6/ml for 8-10 days (37°C, 10% CO2) in RPMI 1640 
supplemented with 10% FCS (Gibco-BRL Life Technologies), 0.5% antibiotic-antimycotic 
(Gibco/Invitrogen), 1% Ultra-glutamine (Lonza), 50mM β-ME (Sigma-Aldrich) and 200ng/ml human 
rFlt3L (Preprotech). 
To increase pDC and cDC cell counts in murine lymphoid organs, C57BL/6N mice were injected 
subcutaneously on their left flank (height of spleen) with 5-7.5*10e6 B16Flt3L tumor cells (22). 
Tumors were grown for 10-14 days and lymphoid organs (bone marrow, spleen, mesenteric and skin 
draining lymph nodes) were harvested subsequently. 
Single cell suspensions were labeled with anti-SiglecH-FITC (eBiosciences) and anti-CD11c-APC 
(Biolegend) antibodies for pDCs and cDCs, respectively. pDCs were positively sorted with anti-FITC 
microbeads. The negative fraction was subjected to positive selection with anti-APC microbeads 
(both Miltenyi Biotec, Germany) to obtain cDCs. 
 
Flow cytometry 
The purity of isolated DC subsets was determined by flow cytometry. The following monoclonal anti-
mouse antibodies and appropriate isotype controls were used: anti-CD11b-PE, anti-B220-PerCP, anti-
CD11c-APC, ratIgG2a-PerCp (all from Biologend), anti-PDCA1-PE, hamster IgG1-APC (all BD 
Pharmingen), rat IgG2b-PE, rat IgG2b-FITC, anti-siglecH-FITC (all from eBioscience). Samples were 
2 
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acquired on a CyAn™ ADP Analyzer (Beckman Coulter) and data were analyzed with FlowJo software 
(TreeStar). 
 
Stimulation experiments  
Purified DC subsets were cultured at a concentration of 1*10e6 cells/ml in 6 well cell culture cluster 
plates (Corning Incorporated). Cells were stimulated with 1µg/ml CpGB oligonucleotide (1668, Sigma 
Alrich), and 4µg/ml Resiquimod (R848, Axxora) for 16 hours. After O/N incubation cells were 
harvested and subjected to density gradient centrifugation (PAA) to remove dead cells. 
 
RNA isolation, RT-PCR & Quantitative PCR 
Total RNA was isolated with RNeasyTM MiniPrep Kit (Qiagen Benelux) according to manufacturer’s 
instructions. The optional on column DNAse treatment was applied. RNA was transcribed into cDNA 
with the RT2 First Strand cDNA Kit (SABiosciences, Qiagen Benelux) according to manufacturer’s 
instructions. The optional on column DNAse treatment was applied. RNA was transcribed into cDNA 
with the RT2 First Strand cDNA Kit (SABiosciences, Qiagen Benelux) according to manufacturer’s 
instructions. cDNA was subjected to Custom Mouse RT2profilerTM PCR Arrays (CAPM09438D-24, 
SABiosciences, Qiagen Benelux). Samples were read on a CFX96 Real Time System (BioRad). mRNA 
levels were normalized to the house keeping gene PBGD (detected by in house qPCR) and are 
expressed as 2-(Ct gene of interest minus Ct PBGD). mRNA levels of PBGD, TLRs (Table 1) and selected NRs (primer 
sequences from www.nursa.org) were detected by in house qPCR with FastStart SYBR Green Master 
(Roche Applied Science). Samples were read on a CFX96 Real Time System (BioRad).mRNA levels 
were normalized to the house keeping gene PBGD and are expressed as 2-(Ct gene of interest minus Ct PBGD). 
Statistical significance was tested with two tailed, paired students T-test. *= P<0.05; **= P<0.01; ***= 
P<0.001. 
 
Table 1: Primer sequences (in house qPCR)  
Target Primer sequences (fw/rev) 
mPBGD 5’CCTACCATACTACCTCCTGGCTTTAC 
 5’TTTGGGTGAAAGACAACAGCAT 
mTLR3 5’GGGGTCCAACTGGAGAACCT 
 5’CCGGGGAGAACTCTTTAAGTGG 
mTLR7 5’TCTTACCCTTACCATCAACCACA 
 5’CCCCAGTAGAACAGGTACACA 
mTLR9 5’ACTCCGACTTCGTCCACCT 
 5’GGCTCAATGGTCATGTGGCA 
 
Results 
In vitro generated pDCs and cDCs express the same repertoire of NR 
The in vitro differentiation of DC subsets from mouse BM is a widely used approach for the simple 
generation of large amounts of cells. To assess the expression of NRs in pDCs and cDCs, cells were 
differentiated in vitro from murine whole bone marrow (BM) (Experimental design, Figure 1A and 
suppl. Figure 1). Both subsets were sorted from the same culture with purities exceeding 95%. pDCs 
were detected as B220+, SiglecH+ (CD11c+, CD11blow) and cDCs were defined as CD11c+, CD11b+ (B220-
, SiglecH-) (Figure 2A) (5). To further confirm purity of the sorted subsets, TLR3, 7 and -9 mRNA 
expression levels were assessed by qPCR. In line with published data, we observed that pDCs did not 
express TLR3 but high levels of TLR7 and 9, whereas cDCs did highly express TLR3 but lower levels of 
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TLR7 and 9 (Figure 2B) (23). 
Total mRNA of the purified subsets was subjected to qPCR-array based expression analysis of 28 NRs. 
We tested the expression of selected receptors based on the availability of ligands and potential 
influence in immunobiology. Overall, we observed that in vitro cultured, bone marrow derived pDCs 
and cDCs expressed the same repertoire of 15 NRs out of 28 tested (Figure 2C). The expression 
profile of both subsets included at least one member of each NR subfamily analyzed. Strikingly, each 
subfamily was represented with the same member in pDCs as in cDCs. Both DC subsets expressed the 
type II NR’s RARα, RARγ, PPARβ/δ, PPARγ, Rev-Erbβ, RORα, VDR and CAR. mRNA levels of their 
hetero-dimeric partner RXRα could not be detected on the array. Independent qPCR analysis of all 
three RXR isotypes (NURSA consortium curated primers) did show expression of RXRα and RXRβ, but 
not RXRγ in both pDCs and cDCs (Figure 2D). The steroid type I NRs were less prominently 
represented; DCs showed expression of ERRα and GR, only two of eight analyzed receptors. 
Interestingly, mRNA of the sex hormone responsive NRs (ER, PR and AR) was not detected in 3-4 
independent samples. Individual qPCR analysis (NURSA consortium curated primers) of these 
receptors in the same samples confirmed the lack of expression (data not shown). The recently 
identified nerve growth factor IB-like receptors Nur77, NURR1 and NOR1 were all expressed by pDCs 
and cDCs. Interestingly, while the repertoire of NRs was identical in pDCs and cDCs, expression levels 
of individual receptors were significantly different. pDCs expressed significantly higher levels of the 
RXR heterodimer VDR and the orphan receptor TR4 compared to cDCs. Furthermore, pDCs had 
significantly lower mRNA levels of Nur77, a constitutively active orphan receptor. In conclusion, in 
vitro derived murine pDCs and cDCs expressed the same repertoire of NRs. However, the expression 
levels of specific NRs (TR4, VDR, Nur77) differed significantly between the two subsets. 
Figure 1. Experimental design  
(A) DCs were generated in vitro from murine BM. Subsequent to culture, cells were sorted into pDC and cDC fractions by 
MACS. mRNA expression levels of 28 NRs were analyzed in fresh cells or TLR matured cells. (B) Primary pDCs and cDCs 
were isolated from four different lymphoid tissues. The mRNA levels of 28 NRs were analyzed in these cells. 
2 
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DC Maturation affects NR expression in a subset specific manner (in vitro) 
The maturation of DCs via the TLR pathways is known to be affected by several NR ligands. 
Therefore, the effect of DC maturation on the expression of NRs was investigated. 
In vitro cultured pDCs and cDCs were sorted and matured for 16hr with a combination of the TLR7/8 
ligand R848 and the TLR9 ligand CpG. The maturation status of both cell types was confirmed by 
analysis of co-stimulatory molecule expression (CD86) and cytokine secretion (type I IFN, IL-6) (data 
not shown).  
Maturation of pDCs and cDCs augmented the mRNA levels of some NRs while expression levels of 
others remained unchanged (Figure 3 and suppl. Figure 2). The retinoic acid responsive NRs RARα 
and RARγ both were significantly downregulated in mature pDCs. In contrast, mature cDCs only 
downregulated the expression of RARα. Immature pDCs had higher expression levels of VDR 
compared to cDCs. Interestingly, maturation induced the downregulation of VDR in pDCs, whereas it 
led to increased VDR mRNA levels in cDCs. Expression of Nur77 was significantly decreased in both 
subsets upon maturation. On the contrary, NURR1 and both NURR1 and NOR1 were upregulated in 
mature pDCs and cDCs, respectively. In conclusion, the TLR induced maturation of pDCs and cDCs 
altered the expression levels of certain NRs in a subset specific manner. 
Figure 2. NR expression profiles of in vitro 
derived pDC and cDC. 
pDCs and cDCs were sorted from Flt3L BM 
cultures. The purity of both subsets was 
analyzed by (A) surface marker expression 
with FACS and (B) mRNA expression of TLR 3, 7 
and 9. (C) Expression levels of 28 selected NRs 
were readily detected by qPCR analysis (RT² 
profiler PCR array; SA Biosciences). (D) 
Expression of RXRα, β and γ in pDCs and cDCs 
as detected with NURSA curated primers. 
mRNA levels are shown relative to expression 
of mouse PBGD. Data shown are 
representative (A) or mean values (B,C,D) of at 
least three independent experiments.. *= 
P<0.05; **= P<0.01; ***= P<0.001. Mean +/- 
SEM. 
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NR mRNA levels in pDCs and cDCs vary between lymphoid organs 
To confirm that the expression profiles of the in vitro derived DCs match their in vivo counterparts, 
we isolated pDCs and cDCs from four different lymphoid organs – spleen, bone marrow (BM), skin 
draining lymph nodes (SLN) and mesenteric lymph nodes (MLN) (Experimental design: Figure 1B). 
The purity of cells isolated from spleen and BM was higher than 95% as analyzed by surface marker 
expression (Figure 4, A). DC subsets isolated from SLN and MLN were 80-90% pure. qPCR based 
expression analysis of TLRs further confirmed the purities on mRNA level (Figure 4B). pDC 
populations did not express TLR3 and TLR 13, which are expressed by CD8 positive cDCs and both 
CD8 negative and positive cDCs, respectively (23, 24). 
The NR expression profiles of pDCs and cDCs ex vivo in the BM, spleen, SLN and MLN were consistent 
with those of the in vitro, BM derived cell subsets (Figure 5 and Figure 6). DCs from both sources, the 
lymphoid tissues and in vitro BM cultures, expressed the same repertoire of NRs. Except for the 
orphan receptor RORγ, that was detected in freshly isolated cells from all four tissues, but not in the 
in vitro generated DC. Additionally, the expression levels of all NRs were highly comparable between 
in vitro and ex vivo DCs. The freshly isolated DCs from the lymphoid tissues showed the same trend 
as the in vitro differentiated pDCs and cDCs with respect to differential expression levels of TR4, VDR 
and Nur77 mRNA. Moreover, the differences in mRNA levels of all NRs between pDCs and cDCs 
presented the same pattern in all four tissues. However, significant changes varied between BM, 
spleen and LNs. pDCs from the BM expressed significantly lower levels of RARγ and RORγ than cDCs 
(Figure 5, A). Splenic pDCs had higher mRNA levels of RORα than cDCs (Figure 5B). In SLNs, cDCs 
showed higher expression levels of RARγ, Nur77 and NURR1 than pDCs (Figure 5C). MLN pDCs had 
higher mRNA levels of PPARβ/δ, while they did not express RORα compared to cDCs (Figure 5D). 
To evaluate the effect of the microenvironment on mRNA levels of NRs we compared the expression 
profiles of DCs freshly isolated from spleen, BM, SLN and MLN. pDCs and cDCs from all four analyzed 
Figure 3. Maturation of pDCs and cDCs augments NR expression levels 
pDC and cDC were sorted from Flt3L BM cultures. Purified pDCs and cDCs were stimulated for 16hrs with a combination of 
4µg/ml R848 and 1µg/ml CpG. Expression levels of RARα, RARγ, VDR, Nur77, NURR1 and NOR1 were readily detected by 
qPCR analysis (RT² profiler PCR array; SA Biosciences). mRNA levels are shown relative to expression of mouse PBGD. Data 
shown are mean values of at least three independent experiments. *= P<0.05; **= P<0.01; ***= P<0.001. Mean +/- SEM. 
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lymphoid organs expressed the same repertoire of NRs (Figure 6 and Figure 5). SLN resident pDCs 
had slightly higher mRNA levels of the retinoic acid responsive receptor RARα compared to their 
splenic and BM counterparts (Figure 6A). Splenic pDCs on the other hand had a trend towards higher 
expression levels of both PPARγ and Nur77. Yet, none of these differences in pDCs from different 
organs reached statistical significance. Expression levels in cDCs were also largely similar between 
organs (Figure 6B). However, the mRNA level of RORalpha was significantly higher in MLN cDCs 
compared to cells from BM, spleen and SLN. RXRα and β were expressed in comparable levels in 
both, pDCs and cDCs (Figure 6C). In conclusion, pDCs and cDCs in the BM, spleen, SLNs and MLNs 
expressed the same repertoire of NRs. The differences in the NR mRNA expression levels of pDCs 
compared to cDCs on the other hand varied between organs. The mRNA levels of most NRs within 
one subset were relatively stable in cells from different lymphoid tissues in steady state conditions. 
 
Discussion 
Increasing evidence shows that ligands for the NR superfamily shape the phenotype of DCs. 
Particularly activation of RAR, VDR, PPARγ, GR and more recently LXR has been shown to influence 
the immune response elicited by cDCs (8, 11). While cDCs are appreciated to be shaped by NR 
ligands, little is known about the role of NRs in pDCs. Interestingly, pDCs express the novel 
transcriptional regulator DC-SCRIPT, which modulates the activity of multiple members of the NR 
family of proteins (25-28). In the present study, we evaluated the expression of 28 NRs in murine 
pDCs and cDCs. Both cell types expressed the same repertoire of 15 receptors in vitro.  
TLR mediated maturation of DCs significantly augmented the expression levels of the retinoid acid 
receptors in immature pDCs and cDCs. In the gut, retinoid acid was shown to be important in the 
imprinting of resident CD103+ DCs. Stimulation of these cells in the lamina propria by dietary retinoid 
acids is pivotal for their tolerogenic properties (18, 19). Populations of pDCs are found in the lamina 
propria and the local mesenteric lymph nodes. Their role within the tolerogenic environment in the 
Figure 4. Purity of freshly isolated pDCs and cDCs 
from lymphoid organs. 
pDC and cDC were isolated from bone marrow 
(BM), spleen, skin draining lymph nodes (SLN) and 
mesenteric lymph nodes (MLN). The purity of both 
subsets was analyzed by (A) surface marker 
expression with FACS and (B) mRNA expression of 
TLR 3, 7, 9 and 13. mRNA levels are shown relative 
to expression of mouse PBGD. Data shown are 
representative (A) or mean values (B) of at least 
three independent experiments. Mean +/- SEM. 
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small intestine, however, has not yet been investigated. The expression of RARα and RARβ in 
immature and mature pDCs suggests a role for retinoid acid stimulation also for this DC subset.  
Expression levels of the universal heterodimeric receptor RXRα were rather low in both pDCs and 
cDCs. Despite these low mRNA levels the receptor is likely to be active as both cells types responded 
to stimulation with 1,25 dihydroxyvitamin D3, the ligand for the RXR-heterodimer VDR (data not 
shown). We found that the RXR heterodimer VDR is expressed in immature and mature pDCs and 
cDCs. VDR is well known to induce tolerogenic properties in murine and human cDCs (29, 30). In 
contrast, stimulation of human pDCs with VDR ligands did not induce a tolerogenic phenotype (31). 
Figure 5: NR expression profiles of pDCs compared to cDCs ex vivo. 
Expression levels of 28 selected NRs were readily detected by qPCR analysis (RT² profiler PCR array; SA Biosciences). NR 
expression in freshly isolated pDCs and cDCs from (A) bone marrow (BM); (B) spleen; (C) skin draining lymph nodes (SLN) 
and (D) mesenteric lymph nodes (MLN). mRNA levels are shown relative to expression of mouse PBGD. Data shown are 
mean values of three independent experiments. *= P<0.05; **= P<0.01; ***= P<0.001. Mean +/- SEM. 
2 
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However, pDC specific functional consequences, like enhanced activation or altered cytokine 
production, of VDR stimulation have not yet been thoroughly investigated. 
All three members of the NR4A family of NRs were expressed in immature and mature cDCs and in 
pDCs. Recently, the NR4A family of orphan receptors is proposed to be involved in immune 
regulation and inflammation, inlcuding immune disorders like rheumatoid arthritis, psoriasis and 
arthrosclerosis (32). Moreover, NR4A receptor genes have been shown to be rapidly induced in 
activated macrophages (33). Overexpression of Nur77 in murine RAW264.7 macrophages led to 
increased transcription of inflammatory, apoptosis and cell cycle control genes. In accordance with 
our data, Ng et al. found NOR1 upregulated and Nur77 downregulated in virally infected murine DCs 
(34). Additionally, human DCs have increased NOR1 mRNA levels upon maturation. This high 
expression was correlated to an increase in apoptosis (35). Yet, the functional role of all three NR4A 
members in DC biology, and specifically in different DC subsets, remains to be elucidated. 
pDCs and cDCs were matured with the TLR7/8 ligand R848 and TLR9 ligand CpGB as both subsets 
express significant amounts of TLR7 and TLR9. It would be interesting to assess the effect of other 
TLR ligands, i.e. for TLR2 or TLR4 which are more specific for cDCs, and their effects on NR expression.  
In addition to in vitro derived pDCs and cDCs, we investigated the NR expression pattern in primary 
DCs isolated from four different lymphoid tissues. Given the low abundance of pDCs in these tissues, 
we injected mice with Flt3l expressing B16 tumors to increase DC numbers. The B16 tumor model is 
poorly immunogenic and DCs isolated from these mice had an immature phenotype. We therefore 
consider these conditions to be steady state. pDCs and cDCs in the BM, spleen, SLNs and MLNs 
expressed the same repertoire of NRs. These results show that in vitro, Flt3L – differentiated, murine 
DCs resemble in vivo pDCs and cDCs in the lymphoid tissues with respect to their NR expression 
pattern. Therefore, they represent a very suitable system for isolated analysis of individual NR ligand 
B A 
Figure 6. NR expression profiles of pDCs and cDCs from different microenvironments 
pDC and cDC were isolated from bone marrow (BM), spleen, skin draining lymph nodes (SLN) and mesenteric lymph nodes 
(MLN). Expression levels of 28 selected NRs in (A) pDC and (B) cDC were readily detected by qPCR analysis (RT² profiler 
PCR array; SA Biosciences). (C) Expression of RXRα, β and γ in pDC and cDC from lymphoid organs as detected with NURSA 
curated primers. mRNA levels are shown relative to expression of mouse PBGD. Data shown are mean values of three 
independent experiments. *= P<0.05; **= P<0.01; ***= P<0.001. Mean +/- SEM. 
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effects. Although the NR repertoire of pDCs and cDCs was similar between organs, the mRNA 
expression levels differed. The distinct DC subsets might therefore specifically react to NR ligands 
present in different microenvironments. Interestingly, pDCs in the gut draining LNs expressed 
significantly higher levels of PPARβ/δ than cDCs whereas cDCs expressed more PPARγ. Hously et al. 
showed that PPARγ is essential for the imprinting of tolerogenic cDCs and consequently regulatory 
Tcell (Treg) induction (36). PPARβ/δ might be functionally important for pDCs in the mesenteric LNs.  
 
Conclusion 
Different DC subsets can exert specified functions due to cell-intrinsic properties, like differential 
expression of PRRs and downstream signaling proteins (37). Moreover, each DC subset can 
specifically react to microenvironmental factors, including NR ligands. Our data show that NR 
expression is regulated in a cell specific manner in pDCs and cDCs, which indicates that hormones 
and vitamins differentially affect pDC and cDC function. 
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Suppl. Figure 1: DC subset purification procedure 
Cells were labeled with anti-SiglecH-FITC and anti-CD11c-APC antibodies for pDCs 
and cDCs, respectively. pDCs were positively sorted with anti-FITC microbeads. The 
negative fraction was subsequently subjected to positive selection with anti-APC 
microbeads to obtain cDCs. 
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Suppl. Figure 2: NR expression levels in mature pDCs and cDCs 
pDCs and cDCs were sorted from Flt3L BM cultures. Purified pDCs and cDCs were stimulated for 16hrs with a combination 
of 4µg/ml R848 and 1µg/ml CpGB. Expression levels of 28 selected NRs in (A) pDCs and (B) cDCs were readily detected by 
qPCR analysis (RT² profiler PCR array; SA Biosciences). (C) Expression of RXRα, β and γ in pDCs and cDCs from lymphoid 
organs as detected with NURSA curated primers. mRNA levels are shown relative to expression of mouse PBGD. Data 
shown are mean values of at least three independent experiments. *= P<0.05; **= P<0.01; ***= P<0.001. Mean +/- SEM. 
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Abstract 
Topical application of the Vitamin D (VitD) analog calcipotriol is a highly effective standard treatment 
modality of psoriatic skin lesions. However, the immune modulatory effects of the treatment are 
incompletely understood. VitD is well known to induce tolerogenic responses in conventional DCs 
(cDC). Plasmacytoid DCs (pDCs) comprise a specialized, naturally occurring DC subset known to be 
important in autoimmune diseases including psoriasis. pDCs from the blood rapidly infiltrate psoriatic 
skin and are key to the initiation of the immune mediated pathogenesis of the disease. We now 
demonstrate that pDCs express various proteins of the VitD receptor (VDR) pathway, including the 
VitD metabolizing enzymes Cyp27B1 and Cyp24A1, and that VDR is transcriptionally active in pDCs. 
Moreover, VitD impairs the capacity of murine and human pDCs to induce T cell proliferation and 
secretion of the Th1 cytokine, IFNγ. The inhibitory effect of VitD is dependent on the expression of 
the VitD receptor in the DCs. This study demonstrates that VitD signaling can act as a natural 
inhibitory mechanism on both cDCs and pDCs which may instigate the development of VitD based 
therapeutic applications for psoriasis and other inflammatory skin diseases.   
 
 
Introduction 
Psoriasis is a common autoimmune disease of the human skin, affecting 2% of the population 
worldwide (1). Disease onset and chronic states are mediated by auto reactive T cells and secretion 
of T helper 1 (Th1) cytokines which induce the hyperproliferation of keratinocytes (1, 2). Recent 
studies have demonstrated that the early pathogenesis of psoriasis is marked by the infiltration of 
plasmacytoid dendritic cells (pDCs), a specialized subset of dendritic cells (DCs). pDCs are attracted to 
chemerin chemogradients in early psoriatic lesions, they become activated trough recognition of self 
DNA complexes and subsequently exacerbate T cell activation, thereby driving disease 
development(3-5). 
Current standard treatment modalities of psoriatic skin plaques include the topical use of the vitamin 
D (VitD) analog calcipotriol (5-7). VitD refers to a group of metabolites which exert their function 
through the VitD receptor (VDR). The active metabolite calcitriol (1,25dihydroxyvitamin D3) is 
metabolized from precursors during a multistep process starting in the skin (8). Here, UVB induces 
the conversion of 7-dehydrocholesterol into vitamin D3 (cholecalciferol). Subsequently, 
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cholecalciferol is hydroxylated in the liver by the enzymes Cyp2R1 or Cyp27A1 to calcifediol 
(25hydroxyvitamin D), the main circulating derivative of VitD. Finally, calcifediol is hydroxylated by 
the enzyme Cyp27B1 towards the active ligand calcitriol, in the kidneys. Importantly, the metabolism 
of calcitriol is not restricted to these specific tissues and can also take place in different cell types 
expressing the enzymes, including conventional dendritic cells (cDC) (9). Although VitD therapy is 
very effective in resolving skin plaques, the exact underlying mechanisms of action are not yet 
completely understood. 
In psoriatic lesions, VitD is known to inhibit the epidermic hyperproliferation and promote 
differentiation of keratinocytes. Moreover, VitD has been shown to be a potent regulator of immune 
responses in general and also in psoriatic skin (10, 11). The two main target cells of VitD in the 
immune system are T cells and DCs. Stimulation of T cells with VitD impairs their proliferation, pro-
inflammatory cytokine secretion (IFNγ, IL-17) and promotes development of Th2 and regulatory T 
cells (Treg) (12, 13). VitD treated in vitro differentiated DCs express decreased levels of co-
stimulatory molecules and increased levels of  inhibitory receptors. Moreover, they secrete lower 
amounts of pro-inflammatory and higher amounts of anti-inflammatory cytokines (14-16). 
Consequently, VitD treated DCs are less potent in their induction of T cell responses and induced the 
generation of Tregs. Few studies described a tolerogenic response of VitD treated naturally occurring 
blood DCs (17-19). The data from Penna and colleagues pointed towards a marked inhibitory effect 
of VitD on cDCs, exclusively. They showed that production of pro-inflammatory cytokines and up-
regulation of co-stimulatory molecules by pDCs was unaffected after treatment with VitD (17). 
pDCs are the main producers of type I interferon; additionally, when activated, they too are potent 
antigen presenting cells and inducers of T cell responses (20, 21). The precise effect of VitD on the 
antigen presenting capacities of pDCs has not been elucidated to date. Here, we show that 
stimulation of murine and human pDCs with VitD prior to and during maturation significantly impairs 
their T cell stimulatory capacities. The inhibitory effect of VitD was dependent on the expression of 
the vitamin D receptor (VDR). We conclude that VitD signaling acts as a natural inhibitory mechanism 
on pDCs and cDCs. 
 
Materials and Methods 
Mice 
C57BL/6n and Balb/C mice (6–12 weeks old, Charles River Wiga (Sulzfeld, Germany) were maintained 
in individually ventilated cage (IVC) units at the Central Animal Laboratory (Nijmegen, The 
Netherlands). Drinking water and standard laboratory food pellets were provided ad libitum. 
Experiments were performed according to the guidelines for animal care of the Nijmegen Animal 
Experiments Committee. 
Leuven Vdr KO mice were described elsewhere (43, 44). The animals were bred in the animal housing 
facilities of the Proefdierencentrum Katholieke Universiteit Leuven, received a normal diet (1.1% 
calcium, 0.8% phosphorus, 0% lactose (Standard; Carfil, Oud-Turnhout, Belgium), and had free access 
to tap water. The Animal Ethics Board of the KUL approved all experimental procedures. 
 
Murine pDCs and cDCs 
DCs were generated from murine BM isolated from femur/tibia. Cells were cultured at a density of 
1.5-2*10e6/ml for 8-10 days (37°C, 10% CO2) in RPMI 1640 + 10% FCS (Gibco-BRL Life Technologies), 
0.5% antibiotic-antimycotic (Gibco/Invitrogen), 1% Ultra-glutamine (Lonza), 50mM β-ME (Sigma-
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Aldrich) and 200ng/ml human rFlt3L (Preprotech). Before MACS sorting cells were harvested and 
subjected to density gradient centrifugation (PAA, Germany) to remove dead cells. 
To increase pDC and cDC counts in murine lymphoid organs, mice were injected subcutaneously on 
their left flank (height of spleen) with 5-7.5*10e6 B16Flt3L tumor cells (45). Tumors were grown for 
10-14 days and lymphoid organs were harvested subsequently. 
Single cell suspensions were labeled with anti-SiglecH-FITC (eBiosciences) and anti-CD11c-APC 
(Biolegend) antibodies for pDCs and cDCs, respectively. pDCs were positively sorted with anti-FITC 
microbeads. The negative fraction was subjected to positive selection with anti-APC microbeads 
(both Miltenyi Biotec, Germany) to obtain cDCs. 
 
Human moDCs and pDCs 
DCs were isolated from buffy coats obtained from healthy volunteers after written informed consent 
per the Declaration of Helsinki and according to institutional guidelines. Peripheral blood 
mononuclear cells (PBMCs) were purified from buffy coats via ficoll density gradient centrifugation 
(Lucron Bioproducts). moDCs were cultured as described previously (46). Plastic–adherent 
monocytes were cultured for 6 d in RPMI 1640 medium (Life Technologies, Breda, The Netherlands) 
with 1% ultra-glutamine (PAA Germany), 0.5% antibiotic–antimycotic (PAA, Germany), 10% (v/v) FCS 
(Greiner Bio-one), IL-4 (300 U/ml), and GM-CSF (450 U/ml) (both Cellgenix). IL4 and GM-CSF were 
added again at day3. 
pDCs were purified from PBLs (non-adherent fraction) by positive selection using anti–BDCA-4–
conjugated magnetic microbeads (Miltenyi Biotec). As previously described, pDC purity was assessed 
by double staining BDCA2/CD123 for pDCs (> 95%; all Miltenyi Biotec) (47). pDCs were cultured in X-
VIVO-15 medium (Lonza) with 2% human serum. 10ng/ml human rIL3 (Cellgenix) was added if 
indicated. 
 
Flow cytometry 
VDR protein was detected by intracellular antibody staining. Briefly, cells were stained with fixable 
viability dye efluor780 (eBioscience). Subsequently, murine organ suspensions and human pDCs were 
stained for appropriate membrane markers (see below). Cells were fixed/permeabilized with 
Cytofix/Cytoperm Kit (BD Bioscience), and blocked with 1% normal goat serum for mouse and 1% 
human serum for human cells. VDR was stained and samples were acquired on a CyAn™ ADP 
Analyzer (Beckman Coulter). Data were analyzed with FlowJo software (TreeStar). 
The following antibodies and isotype controls were used 1) Murine: rat-anti-CD11b-PE, rat-anti-B220-
PerCP, hamster-anti-CD11c-APC, ratIgG2a-PerCp (all from Biologend), rat-anti-PDCA1-PE, hamster 
IgG1-APC (all BD Biosciences), rat IgG2b-PE, rat IgG2b-FITC, rat-anti-SiglecH-FITC (all from 
eBioscience); 2) human: mouse-anti-BDCA2-FITC, mouse-anti-CD123-APC (both Miltenyi Biotec), 
mIgG1-FITC and mIgG1-APC (eBioscience). 
For murine and human samples VDR was detected with either m-anti-VDR or m-anti-VDR-biotin at 
4µg/ml (both clone D6, Santa Cruz Biotechnology) and secondary detection antibodies goat-anti-mIg-
PE or streptavidin-PE (both BD Biosciences), respectively. 
 
RNA isolation, RT-PCR & Quantitative PCR 
Total RNA was isolated with RNeasyTM MiniPrep Kit (Qiagen Benelux) or Quick-RNA MiniPrep 
(ZymoResearch) according to manufacturer’s instructions. RNA was transcribed into cDNA with the 
RT2 First Strand cDNA Kit (SABiosciences, Qiagen Benelux). Alternatively, RNA was treated with 
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DNase I (amplification grade; Invitrogen) and reverse-transcribed into cDNA using random hexamers 
and MMLV reverse transcriptase (Invitrogen). mRNA levels of genes of interest (see suppl. table 1) 
were detected by qPCR with FastStart SYBR Green Master (Roche Applied Science). Samples were 
read on a CFX96 Real Time System (BioRad). mRNA levels were normalized to the house keeping 
gene PBGD and are expressed as 2-(Ct gene of interest minus Ct PBGD). 
 
Western blotting 
5*10e6 murine in vitro derived cDCs and pDCs were lysed in 1% SDS and 62.5mM Tris pH 6.8. Cell 
lysates were mixed with sample buffer (5% glycerol, 6% SDS, 125mM Tris-HCL pH 6.8, 0.1mg/ml 
bromophenol blue and 10% β-ME), heated to 95°C  for 5min, resolved by 10% SDS-PAGE and 
transferred to nitrocellulose membranes (4°C, 30mA) (Schleicher and Schuell). Membranes were 
blocked with 3% BSA and 1% milk powder in PBST (1hr RT) and subsequently stained with 1µg/ml m-
anti-VDR (clone D6, Santa Cruz Biotechnology) and rb-anti-actin (Sigma Aaldrich) (both in ¼ PBST, 1hr 
RT). After 3x wash with PBST secondary Abs goat-anti-mouse IRDye 800CW and donkey-anti-rabbit 
IRDye 680RD (Li-cor Biosciences) were added (¼ PBST, 1hr RT). Membranes were washed 3x in PBST 
and scanned with an Odyssey Infrared Imaging System (Li-cor Biosciences) to visualize proteins. 
 
Stimulation experiments DCs 
Human and murine DC subsets were cultured at a concentration of 1*10e6 cells/ml. For target gene 
detection cells were stimulated with 100nM calcitriol (1,25-(OH)2D3), 100nM calcifediol (25(OH)D3) 
(both Sigma Aldrich), a combination of both or vehicle (EtOH). For the FACS staining of co-stimulatory 
molecules, human pDCs were pre-stimulated with 100nM 1,25(OH)2D3, 100nM 25(OH)D3 for two 
hours and subsequently VitD derivatives and 0.5µg/ml ODN-CpG C (M362; Axxora) were added for 
additional incubation overnight. 
Figure 1. Murine pDCs express 
VDR in vitro and ex vivo 
(A) DCs were generated in vitro 
from murine bone marrow 
(BM) or freshly isolated from 
bone marrow and spleen. Cells 
were sorted into pDC and cDC 
fractions by MACS. VDR mRNA 
was detected by qPCR and 
mRNA levels are shown 
relative to expression of 
mouse PBGD. VDR protein 
expression was detected by (B) 
western blot and (C) 
intracellular antibody staining 
and subsequent FACS on in 
vitro cultured pDCs and cDCs 
or primary cells from bone 
marrow and spleen. Geometric 
mean fluorescence intensities 
(gMFI) shown are corrected for 
isotype control staining. Data 
shown are mean values (A) or 
representative (B,C) of at least 
three independent 
experiments. *= P<0.05; **= 
P<0.01; ***= P<0.001. Mean 
+/- SEM. 
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Mixed Leukocyte reaction murine DCs 
Isolated pDCs and cDCs were pre-stimulated with vehicle or 100nM Calcifediol and 100nM Calcitrol 
for 2 h. Subsequently, additional VitD derivatives and 0.1 µg/ml CpGB (1668, Sigma Aldrich) or 0.4 
µg/ml Resiquimod (R848, Axxora) were added for additional incubation O/N. Supernatant was 
collected, DCs were washed with PBS and 504 CFSE-labeled allogeneic splenocytes (depleted for 
CD11c and B220) were added in a ratio of 1:2 and 1:6. Cells were incubated round bottom 96 well 
cluster plates (Corning).  
 
ELISA 
Human IFNγ levels were measured with the ELISA Ready-SET-Go!®RSG kit according to 
manufacturer’s instructions (eBioscience, Vienna, Austria). Murine IFNγ levels were measured by 
sandwich Elisa with rat-anti-mIFNgamma (Clone R4-6A2, BD), anti-mIFNgamma-biotin (Clone XMG 
1.2, Biolegend), streptavidin-HRP (Invitrogen) and TMB (Sigma-Aldrich) substrate. 
 
Statistics 
Data were analyzed with one or two tailed, students T-test using GraphPad Prism 5.0. *= P<0.05; **= 
P<0.01; ***= P<0.001. 
 
Results 
Murine pDCs and cDCs respond to stimulation with calcitriol and its precursor calcifediol 
In a qPCR based screen for NR expression in DC subsets, we found expression of VDR and its 
heterodimeric partner RXR in murine pDCs (22). To corroborate these findings, we assessed the 
mRNA levels of VDR in independent pDC and cDC samples freshly isolated from bone marrow (BM) 
and spleen or derived from in vitro progenitor cell cultures with Flt3L. These data confirmed that in 
vitro derived and lymphoid tissue resident pDCs expressed VDR mRNA levels (Figure 1A). In 
accordance with the mRNA levels, also VDR protein was expressed in in vitro cultured pDCs (Figure 
1B and C) and in pDCs in the BM and spleen (Figure 1C).  
Figure 2. Murine pDCs and 
cDCs react to stimulation 
with calcitriol and its 
precursor calcifediol 
pDCs and cDCs were 
sorted from Flt3L bone 
marrow cultures. 
Expression of (A) the co-
regulators Drip205, 
Hairless, (B) the vitamin D 
metabolizing enzymes 
Cyp27A1, Cyp2R1, 
Cyp27B1, and the VDR 
target genes VDR (C) and 
Cyp24A1 (D) in pDCs and 
cDCs were detected with 
qPCR. mRNA levels are 
shown relative to 
expression of mouse 
PBGD. Data shown are 
mean values of at least 
three independent 
experiments. *= P<0.05; 
**= P<0.01; ***= P<0.001. 
Mean +/- SEM. 
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The transcriptional activity of VDR is affected by the presence of the active ligand calcitriol, VitD 
metabolizing enzymes and transcriptional co-regulators. We assessed the mRNA levels of the VDR co-
activator, DRIP205, and the co-inhibitor, Hairless (23, 24). Both co-regulators were expressed at 
comparable levels in Flt3L derived pDCs and cDCs (Figure 2A). cDCs are known to be able to actively 
synthesize the active VDR ligand calcitriol from its precursors cholecalciferol and calcifediol, 
mediated by the enzymes Cyp27A1 or Cyp2R1 and Cyp27B1, respectively (9, 25). Our data show that 
both murine pDCs and cDCs express similar levels of Cyp27A1 and Cyp2R1 as well as Cyp27B1 (Figure 
2B). As pDCs and cDCs expressed co-regulators and enzymes of the VitD pathway, we investigated 
whether VDR was transcriptionally active and whether both subsets could respond to the VitD 
precursor calcifediol. To this extent, pDCs and cDCs were stimulated with calcifediol or calcitriol and 
mRNA levels of the known VDR target genes VDR itself and the enzyme Cyp24A1 were measured. 
pDCs and cDCs both rapidly up-regulated the expression of VDR two hours after stimulation with 
calcitriol (Figure 2C). VDR mRNA was back to baseline levels 16 hours after stimulation. Moreover, 
both subsets also strongly up-regulated VDR in response to calcifediol stimulation, indicating that 
calcifediol is processed into active calcitriol and thus that the enzyme Cyp27B1 is active in DCs. 
Expression of the target gene Cyp24A1 was induced 16 hours after stimulation with calcitriol, albeit 
Figure 3. Vitamin D stimulated murine pDCs and cDCs induce markedly impaired T cell proliferation 
(A) pDC and (B) cDC were sorted from Flt3L BM cultures of either WT or VDR-/- mice. Purified pDCs and cDCs were pre-
stimulated for 2 hrs with 100nM calcitriol and 100nM calcifediol. Subsequently, cells were stimulated again with 100nM 
calcitriol, 100nM calcifediol and vehicle or 100ng/ml CpG for additional 16hrs. Cells were washed and co-incubated with 
CFSE labeled splenocytes (CD11c, B220 depleted) for 5 and 6 days. T cell proliferation was measured as indicated by CFSE 
dilution. Numbers indicate the percentage of proliferation. Data shown are representative of at least three independent 
experiments. 
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at low levels (Figure 2D). Calcifediol alone induced very low expression of Cyp24A1 in pDCs only. 
Moreover, both pDCs and cDCs responded to stimulation with the clinical VitD analog calcipotriol 
(suppl. Figure 1).Taken together, these data show that both pDCs and cDCs express transcriptionally 
active VDR protein and respond to stimulation with the VitD precursor calcifediol and the active VDR 
ligand calcitriol. 
 
Vitamin D impairs the T cell stimulatory capacities of murine pDCs 
VitD is part of the standard treatment of psoriatic skin lesions and different studies suggest that VitD 
therapy modulates the immune response in skin plaques. Since pDCs are implicated in the initiation 
of psoriatic pathogenesis we investigated the T cell stimulatory capacities of VitD stimulated pDCs. 
DCs were pre-treated with calcitriol and calcifediol and subsequently stimulated with CpG. After 
stimulation, DCs were added to an allogeneic mixed leukocyte reaction (MLR). cDCs are known to be 
impaired by VitD and as expected, VitD stimulated cDCs were much less potent in the induction of T 
cell proliferation compared to vehicle treated cells (Figure 3A).  Intriguingly, also pDCs showed a 
remarkably decreased T cell 
activating capacity when treated 
with VDR ligands (Figure 3B). The 
inhibitory effect of VDR ligand 
stimulation was most 
pronounced in unstimulated DCs 
compared to CpG stimulated 
cells in both pDCs and cDCs and 
essentially absent when DCs 
were matured with the potent 
TLR ligand R848 (suppl. Figure 
2A). VDR deficient (VDR-/-) pDCs 
and cDCs were generally slightly 
less effective Tcell stimulators 
compared to wildtype (WT) DCs. 
However, upon stimulation with 
the VDR ligands VDR-/- DCs were 
Figure 4. Vitamin D impairs the capacity 
of murine pDCs and cDCs to activate T 
cells 
(A) pDC and (B) cDC were sorted from 
Flt3L BM cultures of either WT or VDR-/- 
mice. Purified pDCs and cDCs were pre-
stimulated for 2 hrs with 100nM calcitriol 
and 100nM calcifediol. Subsequently, 
cells were stimulated again with 100nM 
calcitriol, 100nM calcifediol and vehicle 
or 100ng/ml CpG for additional 16hrs. 
Cells were washed and co-incubated with 
splenocytes (CD11c, B220 depleted) for 5 
and 6 days. IFNγ levels in the supernatant 
were measured with Elisa. Data shown 
are mean values of at least three 
independent experiments. ns = non 
significant; *= P<0.05; **= P<0.01; ***= 
P<0.001. Mean +/- SEM. 
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not impaired in their T cell activating potential, indeed demonstrating that the inhibitory effect of 
VitD was dependent on the presence of VDR in DCs (Figure 3). 
Psoriasis is a Th1 driven disease; therefore we next assessed the secretion of cytokines in the 
allogeneic MLR. In line with the impaired proliferation, also levels of the Th1 cytokine IFNγ were 
significantly decreased when pDCs and cDCs were pretreated with VDR ligands (Figure 4). Moreover, 
inhibition of IFNγ production was more prominent in unstimulated pDCs compared to the CpG 
stimulated cells. Robust stimulation of pDCs and cDCs with R848 lead to small but significant 
impairment of IFNγ secretion (suppl. Figure 2B). Importantly, VDR deficient DCs were not hampered 
in their capacity to induce IFNγ in T cells when stimulated with VDR ligands confirming that the 
inhibitory effect of VitD is dependent on VDR expression (Figure 4). Furthermore, the secretion of IL5, 
IL10 and IL17 was not changed significantly between vehicle and calcitriol/calcifediol treatment (data 
not shown) indicating that VDR stimulation did not alter T cell skewing in this setting. 
In conclusion, stimulation of the VDR inhibits the T cell stimulatory capacity of both conventional and 
plasmacytoid murine dendritic cells. 
 
Human pDCs respond to stimulation with calcitriol 
Our data show that murine pDCs exhibit impaired T cell stimulatory capacities upon pretreatment 
with VDR ligands. To extrapolate these findings to men, we assessed the activity of VDR in human 
pDCs (hPDC). Freshly isolated pDCs from human buffy coats expressed high levels of VDR protein 
(Figure 5A). Moreover, in line with the murine data both human moDCs and hPDCs expressed 
considerable mRNA levels of the VitD metabolizing enzymes Cyp27A1, Cyp2R1 and Cyp27B1 (Figure 
5B). To address the functionality of VDR, moDCs and hPDCs were stimulated with either calcifediol 
alone or the combination of calcitriol and calcifediol. Subsequently, mRNA levels of the VDR target 
gene Cyp24A1 were measured. mRNA levels of Cyp24A1 were significantly induced in moDCs and 
hPDCs upon stimulation with calcitriol/calcifediol (Figure 5C). Treatment with calcifediol alone led to 
significant expression of Cyp24A1 in moDCs after 16hrs, indicating that the cells metabolize the 
precursor. hPDCs did not express Cyp24A1 when stimulated with calcifediol alone (data not shown).  
These data show that human moDCs and PDCs express a functionally active VDR. 
Figure 5. Human PDCs and moDCs 
react to stimulation with calcitriol 
Human PDCs were sorted from PBLs. 
moDCs were cultured from 
monocytes for 6 days  in the 
presence of IL-4 (300 U/ml) and GM-
CSF (450 U/ml). Expression of (A) VDR 
protein was detected by intracellular 
antibody staining. (B) The VitD 
metabolizing enzymes Cyp27A1, 
Cyp2R1, Cyp27B1 and (C) the VDR 
target gene Cyp24A1 in hPDCs and 
moDCs were detected with qPCR. (C) 
moDCs and hPDCs were stimulated 
with 100nM calcitriol and 100nM 
calcifediol for indicated timepoints. 
mRNA levels are shown relative to 
expression of human PBGD. Data 
shown are (A) representative or (B,C) 
mean values of at least three 
independent experiments. *= P<0.05; 
**= P<0.01; ***= P<0.001. Mean +/- 
SEM. 
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Vitamin D stimulated human pDCs have impaired T cell stimulatory capacities 
As VDR was transcriptionally active in hPDCs we next looked at the effect of VDR ligand stimulation 
on their T cell activating capacity. hPDCs were pre-stimulated with calcifediol and calcitriol, 
subsequently, CpG was added or not. hPDCs were washed extensively and incubated with allogeneic 
peripheral blood leukocytes for different days. In line with the murine pDCs, also human PDCs were 
markedly impaired in their ability to induce T cell proliferation when pretreated with 
calcitriol/calcifediol, both without stimulation and upon CpG activation (Figure 6A). 
Moreover, also production of the Th1 cytokine IFNγ was significantly decreased when hPDCs were 
stimulated with VDR ligands (Figure 6B). These data indicate that VitD is able to modulate the 
function of  hPDCs and acts to decrease their capacity to induce T cell activation. 
 
Discussion 
Topical application of the VitD analog calcipotriol is a highly effective standard treatment of psoriatic 
skin lesions (26). However, the underlying mechanisms of action are still incompletely understood. 
Psoriasis is a immune driven disease and VitD is thought to modulate inflammation in diseased skin 
(Reichrath et al., 1997). Within the immune system, VitD has pronounced tolerogenic effects on T 
cells and cDCs (27-29). pDCs rapidly infiltrate psoriatic skin and are at the initiation of disease 
pathogenesis (3). Here, we show that the VDR is active in and potently inhibits murine and human 
pDCs in their ability to induce T cell proliferation and activation.  
pDCs expressed various proteins of the VDR pathway, including the coactivator Drip205, the 
coinhibitor Hairless and the VitD metabolizing enzymes Cyp27A1, Cyp27B1 and Cyp24A1. VDR was 
transcriptionally active in pDCs as shown by induced target gene expression after stimulation with 
VDR ligands. Moreover, murine pDCs that were treated with calcitriol/calcifediol prior to and during 
activation with the TLR9 ligand CpG were clearly reduced in their capacity to stimulate T cell 
proliferation. Production of the Th1 cytokine IFNγ in the allogeneic MLR was also significantly 
Figure 6. Vitamin D stimulation of human PDCs reduces their ability to activate T cells 
Human PDCs were sorted from PBLs and pre-stimulated for 2 hrs with 100nM calcitriol and 100nM calcifediol. 
Subsequently, cells were stimulated again with 100nM calcitriol, 100nM calcifediol and vehicle or 100ng/ml CpG for 
additional 5hrs. Cells were washed and co-incubated with allogeneic PBLs for 7 days. IFNγ production by PBLs was 
measured by Elisa. Data shown are mean values of at least three independent experiments. *= P<0.05; **= P<0.01; ***= 
P<0.001. Mean +/- SEM. 
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reduced by VitD pre-treatment of pDCs and cDCs , whereas, secretion of the T cell cytokines IL5, IL17 
and IL10 was unaffected (data not shown). VitD stimulated DCs were previously shown to induce the 
generation of tolerogenic T cells (14, 29, 30). However, most of these studies have been performed 
with VitD treatment during the differentiation of monocytes towards DCs. These experiments also 
showed marked reduction in the expression of CD80, CD86 and diminished secretion of pro-
inflammatory cytokines IL6 and IL12. We could not detect a significant inhibition of these co-
stimulatory molecules and cytokines in pDCs and cDCs stimulated with VitD during maturation. The 
inhibitory mechanisms of VitD during DC differentiation therefore are likely to follow different 
kinetics compared to the inhibitory mechanisms during DC maturation. 
The impairment of allogeneic T cell activation was most pronounced in unstimulated pDCs and less in 
CpG treated cells. In addition, strong activation of murine pDCs and cDCs with the TLR7/8 ligand R848 
was not affected by stimulation with VitD. Consequently, VitD mediated suppression of T cell priming 
seems to be an immune regulatory mechanism that is most important during mild infections and that 
can be overcome by strong immune stimuli. VitD metabolism is a multistep process initiated in the 
skin with the photoinduced conversion of 7-dehydrocholesterol and resulting in the production of 
the active ligand calcitriol. Recent studies report an alternative VitD activation pathway that is 
dependent on Cyp11A1. This pathway comprises a range of bioactive VitD derivatives with potential 
therapeutic interest due to their low calcemic activity (31-33). The skin is a part of the first line of 
defense that harbors various dendritic cells (34, 35). In this context, VDR ligands can act as a steady 
state regulatory system that may prevent autoimmune responses while allowing immune activation 
towards severe pathogenic manifestations. This hypothesis is supported by the evident 
epidemiologic correlation of VitD deficiency with psoriasis (36) and other autoimmune disorders like 
systemic lupus erythematosus (SLE) (37, 38). Moreover, rapid skin infiltrations of pDCs are causally 
linked to the early pathogenesis of psoriasis (39) and SLE (40).  
In man, VitD is known to inhibit the differentiation and maturation of moDCs (15). Moreover, Penna 
et al. reported that calcitriol inhibits the maturation of human circulating cDCs, whereas hPDCs were 
not affected (17). In line, we also observed that stimulation of hPDCs with calcitriol did not impair the 
production of IFNα (data not shown) or the expression of CD80, CD86, MHC-II and ILT3 (suppl. Figure 
3). However, stimulation with VitD clearly impaired the ability of hPDCs to induce T cell proliferation 
and secretion of the Th1 cytokine IFNγ. 
The tolerogenic agent VitD has been studied and exploited for the treatment of psoriasis and other 
cutaneous diseases (39) but the underlying molecular mechanisms are only partly understood. 
Recent data demonstrate that VitD analogs alter the expression of antimicrobial alarmins, i.e. 
decreased HBD2, HBD3 and increased cathelicidin, in psoriatic skin (41). Interestingly, the cathelicidin 
peptide LL-37 has been shown to induce pDC activation when complexed with self DNA, suggesting 
increased inflammatory responses upon VitD treatment (42). However, VitD analogs did not result in 
increased IFNα levels in psoriatic skin. The diverse functions of LL-37 in psoriasis are still incompletely 
understood and future studies will further clarify its seemingly paradoxical effects. 
pDCs are important players within the immune system; while they are absent in the skin during 
steady state, they rapidly infiltrate upon skin injury and during pathologic skin conditions (39). We 
now demonstrate that VitD potently inhibits the ability of pDCs to induce T cell activation in mouse 
and man. Exploitation of the tolerogenic properties of pDCs in therapeutic applications may 
therefore benefit from the clinical applicability of VitD for psoriasis and other skin pathologies. 
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Supplementary Figure 1. pDCs and cDCs were sorted from Flt3L bone marrow 
cultures. Cells were stimulated with 100nM calcipotriol for 4hrs. Expression of 
the VDR target genes mVDR itself was detected with qPCR. mRNA levels are 
shown relative to expression of mouse PBGD. Data shown are mean values of 
at least three independent experiments. *= P<0.05; Mean +/- SEM.  
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Supplementary Figure 3. Human PDCs were sorted from PBLs. Expression of (A) CD80, CD86 and HLA-DR was detected by 
antibody staining. (B) Expression of hILT3 was detected with qPCR. mRNA levels are shown relative to expression of human 
PBGD. Data shown are (A) representative or (B) mean values +/- SEM of at least three independent experiments. *= 
P<0.05; **= P<0.01; ***= P<0.001. 
Supplementary Figure 2. pDC and cDC were sorted from Flt3L BM cultures of either WT or VDR-/- mice. Purified pDCs 
and cDCs were pre-stimulated for 2 hrs with 100nM calcitriol and 100nM calcifediol. Subsequently, cells were stimulated 
again with 100nM calcitriol, 100nM calcifediol and vehicle or 400ng/ml R848 for additional 16hrs. Cells were washed and 
co-incubated with CFSE labeled splenocytes (CD11c, B220 depleted) for 5 and 6 days. (A) T cell proliferation was 
measured as indicated by CFSE dilution. Numbers indicate the percentage of proliferation.(B) IFNγ levels in the 
supernatant were measured by Elisa. Data shown are (A) representative or (B) mean values +/- SEM of at least three 
independent experiments. *= P<0.05; **= P<0.01; ***= P<0.001.  
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Abstract 
Dendritic cells (DCs) are the professional antigen presenting cells of the immune system that dictate 
the type and course of an immune response. Molecular understanding of DC biology is important for 
the design of DC based immunotherapies and optimal clinical applications in vaccination settings. 
Previously, we isolated and characterized the cDNA encoding DC-SCRIPT (dendritic cell–specific 
transcript, also known as ZNF366). DC-SCRIPT mRNA expression in the immune system was confined 
to DCs and was reported to be an early hallmark of DC differentiation. Here, we demonstrate IL-4 to 
be the dominant factor for DC-SCRIPT expression in human monocyte derived DCs (moDCs). In 
addition we show, for the first time, endogenous DC-SCRIPT protein expression in human DCs both in 
vitro and in situ. DC-SCRIPT protein is detected early upon differentiation of monocytes into DCs and 
is also present in multiple freshly isolated DC subsets. Maturation of DCs with TLR ligands further 
increased DC-SCRIPT mRNA expression, suggesting a role in DC maturation. Indeed, siRNA mediated 
knock-down of DC-SCRIPT affected the cytokine response upon TLR stimulation. These DCs displayed 
enhanced IL-10 and decreased IL-12 production, compared to wild-type DCs. Silencing of IL-10 in DC-
SCRIPT knock-down DCs rescued IL-12 expression, suggesting a primary role for DC-SCRIPT in the 
regulation of IL-10 production. 
 
 
Introduction 
Dendritic cells (DCs) are the professional antigen presenting cells of the immune system and play an 
essential role in the initiation and modulation of immune responses. DCs reside in the tissue in an 
immature state, and are capable of recognizing and capturing microbial antigens through specific 
receptors. Upon infection or inflammation, they undergo a complex process of maturation, where 
they change from antigen-capturing cells into antigen-presenting cells(1). With the expression of co-
stimulatory or co-inhibitory molecules and the secretion of pro- or anti-inflammatory cytokines, DCs 
generate either immunity or tolerance through T-lymphocyte stimulation(2). The type of molecules 
that are expressed greatly depends on the activation status of the DC, and is affected by 
environmental stimuli(3-5). 
A broad range of DC subsets have been described, including the in vitro monocyte derived DCs 
(moDCs) and the in vivo blood derived myeloid and plasmacytoid DCs (mDCs and pDCs, respectively). 
Myeloid DCs act as sentinels in the periphery and have a specialized function depending on their 
location and Pattern Recognition Receptors (PRRs) expression profile. The cellular cues present at 
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different locations, e.g. gut, skin or other organs, inflicted by local invading pathogens direct the 
mDCs towards a specific response. Plasmacytoid DCs are considered the front line of defense in anti-
viral immunity as they rapidly produce massive amounts of type I interferon in response to viral 
infection and prime T cells against viral antigens(6-8). In vitro, DCs can be generated from monocytes 
through stimulation with IL-4 and GM-CSF(9). These cytokines trigger DC differentiation while 
inhibiting macrophage and osteoclast differentiation(10-12).  
The differentiation of the DC subsets from their precursors is a highly complex process. Genetic 
analyses have identified different transcription factors, including IRF4, RelB and PU.1, to be crucial in 
the development of specific DC subsets in lymphoid organs(13-17). DC differentiation and maturation 
requires a complete change in the DC gene expression profile, mediated by the combinatorial effect 
of a few key transcription factors and chromatin re-organization(18).  
In 2006 we identified and characterized a new DC expressed transcription factor, termed dendritic 
cell–specific transcript (DC-SCRIPT; also known as ZNF366). DC-SCRIPT mRNA is present in all DC 
subsets tested so far, including moDCs, mDCs, pDCs and LCs (Langerhans cells). Interestingly, 
expression was not detected among other leukocyte populations(19), suggesting an essential role of 
DC-SCRIPT in DC biology. Outside the immune system, DC-SCRIPT has also been detected in epithelial 
cells in the breast and in tumors derived thereof(20, 21). DC-SCRIPT is located on human 
chromosomes 5q13.2(22) and is encoded by an 8 kb messenger RNA. It is well conserved in 
evolution, with the human and mouse genes both located in syntenic chromosomal regions, sharing 
80% amino acid sequence homology(23). The protein consists of a proline rich region, 11 C2H2-type 
zinc fingers and an acidic region. In addition, it bears a functional CtBP1 motif and an LxxLL Nuclear 
Receptor (NR) interaction motif(19, 24). NRs are ligand-inducible transcription factors that bind 
specific DNA-regulatory response elements. NRs and their co-regulators have been described to play 
an important role in a wide variety of biological processes including immunobiology and cancer 
biology(25-29). Moreover, we demonstrated that DC-SCRIPT is a unique modulator of NR function 
and a strong and independent prognostic marker in breast carcinoma(20). 
Thus far, the expression and function of DC-SCRIPT in DCs remains largely unknown. Here, we 
characterized the endogenous DC-SCRIPT protein expression dynamics in the in vitro monocyte 
derived DCs as well as in primary blood derived DCs and studied its functional role in DC maturation. 
 
Material & Methods 
Generation of human DCs 
Human monocyte derived Dendritic Cells (moDCs) were generated from PBMCs as described 
previously(30). Monocytes were derived from buffy coats. Plastic-adherent monocytes were cultured 
for 6 days in Phenol red free RPMI-1640 medium (Life Technologies, Breda, The Netherlands) 
supplemented with 1% ultra-glutamine (Cambrex, Wiesbaden, Germany), 0,5% antibiotic-antimycotic 
(Invitrogen, Breda, The Netherlands), 10% (v/v) FCS (Greiner, Kremsmuenster, Austria), IL-4 (300 
U/ml), and GM-CSF (450 U/ml) both from cellgenix. During day 3 moDCs were supplemented with 
new IL-4 (300 U/ml) and GM-CSF (450 U/ml). Mature moDCs were generated from day 6 immature 
moDCs through 48 hour stimulation with 200 ng/ml LPS (InvivoGen, Toulouse, France). Human 
Myeloid Dendritic Cells (mDCs) were isolated from PBMCs using the CD1c (BDCA-1)+ Dendritic Cell 
Isolation Kit (Miltenyi Biotec, Leiden, The Netherlands). Human Plasmacytoid Dendritic Cells (pDCs) 
were isolated from PBMCs using the CD304 (BDCA-4/Neuropilin-1)+ MicroBead Kit (Miltenyi Biotec, 
Leiden, The Netherlands). Purity (>90%) of the freshly isolated mDCs and pDCs were ensured by FACS 
staining. 
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RNA isolation and quantitative PCR 
Total RNA was isolated from cells using an RNA isolation kit (Zymo research). RNA quantity and purity 
were determined on a NanoDrop spectrophotometer. RNA was treated with DNase I (amplification 
grade; Invitrogen) and reverse-transcribed into cDNA by using random hexamers and Moloney 
murine leukemia virus reverse transcriptase (Invitrogen). mRNA levels for the genes of interest were 
determined with a CFX96 sequence detection system (Bio-Rad, Veenendaal, The Netherlands) with 
SYBR Green (Roche, Woerden, The Netherlands) as the fluorophore and gene specific oligonucleotide 
primers. The primers for DC-SCRIPT and PBGD were described previously(20) Other used primers 
(forward, reverse): IL-12 (5'-ATGGCCCTGTGCCTTAGTAGT-3', 5'-CGGTTCTTCAAGGGAGGATTTT-3'), IL-6 
(5'-GCTATGAACTCCTTCTCCACAAGCG-3', 5'-ATCCATCTTTTTCAGCCATCTTTGG-3'), TNF (5'-
ATGAGCACTGAAAGCATGATCC-3', 5'-GAGGGCTGATTAGAGAGAGGTC-3'), IL10 (5'-
TCAAGGCGCATGTGAACTCC-3', 5'-GATGTCAAACTCACTCATGGCT-3'). Reaction mixtures and program 
conditions were used that were recommended by the manufacturer (Bio-Rad). Quantitative PCR data 
were analyzed with the CFX Manager V1.6.541.1028 software (Bio-Rad) and checked for correct 
amplification and dissociation of the products. mRNA levels of the genes of interest were normalized 
to mRNA levels of the housekeeping gene porphobilinogen deaminase (PBGD) and were calculated 
according to the cycle threshold method(31). 
 
Immunohistochemistry 
Snap-frozen tonsil specimens were obtained from the Department of Pathology, RUNMC St, Radboud 
and approved by the institutional ethics committee of the RUNMC. The specimens were embedded 
in OCT embedding matrix (CellPath, Newtown, UK) and sectioned in 5 μM thick tissue sections. The 
sections were placed on Superfrost slides (Thermo Scientific, Etten-Leur , the Netherlands), fixed with 
acetone, and incubated with 4 μg/mL goat anti-human DC-SCRIPT antibody (R&D Systems, Abingdon, 
UK), 4 μg/mL mouse anti-human DC-SIGN (AZN-D1), followed by incubation with a biotinylated horse 
anti-goat IgG or horse anti-mouse (Vector Laboratories), and signal development was performed 
using a Vectastain ABC-HRP Kit (Vector Laboratories, Burlingame, CA) and DAB (Sigma Aldrich, 
Zwijndrecht, the Netherlands). Isotype-matched goat IgG (R&D Systems) and mouse IgG1 (BD 
Bioscience) were used as controls. Sections were counterstained with hematoxylin to visualize the 
cell nuclei and analyzed by using a Leica DM LB microscope (Leica Microsystems B.V., Rijswijk, the 
Netherlands). 
 
Western blotting 
Cells were lysed in 1% SDS and 62,5mM Tris pH 6.8 and the protease inhibitors 2 μg/mL leupeptin 
(Sigma Aldrich), 2 μg/mL aprotinin (Roche), and 1 mM phenylmethylsulfonyl fluoride (Sigma Aldrich). 
Cell lysates were mixed with sample buffer containing 5% glycerol, 6% sodium dodecyl sulfate, 125 
mM Tris–HCl (pH 6.8), 0.1 mg/mL bromophenol blue (Gebr . Schmid GmbH + Co, Freudenstadt, 
Germany), and 10%-mercaptoethanol (Sigma Aldrich); heated at 95°C for 5 minutes; and then cooled 
on ice. The proteins were resolved by electrophoresis on an 8% polyacrylamide gel (ratio of 
acrylamide to bisacrylamide, 37.5:1) and transferred overnight to Protran nitrocellulose transfer 
membranes (Schleicher and Schuell, ‘s-Hertogenbosch, the Netherlands) at 30 mA and 4°C. To block 
nonspecific protein binding, the membranes were incubated in 1% skimmed milk powder and 3% 
bovine serum albumin in PBST. The membranes were then incubated for 1 hr with 2,5 μg/ml goat 
anti-human DC-SCRIPT antibody (R&D Systems, Abingdon, UK), washed three times in PBST, and 
subsequently incubated for 1 hour with the secondary antibody IRDye 800CW donkey anti goat IgG 
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(1:5000 dilution; Li-cor Biosciences, Bad Homburg, Germany ) to detect DC-SCRIPT. To detect actin, 
the membranes were incubated with a mouse anti-actin (1:20.000 dilution, Sigma clone AC-40), 
washed three times in PBST, and incubated for 1 hour with the secondary antibody Alexa Fluor 680 – 
conjugated Donkey-anti-mouse IgG (1:5000 dilution; Invitrogen). All membranes were then washed 
three times in PBST. After staining, the membranes were scanned by using an Odyssey Infrared 
Imaging System (Li-cor Biosciences) to visualize the proteins. 
 
Confocal Laser Scanning Microscopy 
Round ø 12 mm cover slides (Thermo Scientific, Braunschweig, Germany) were coated with Poly-L-
Lysine (Sigma Aldrich). Immature and mature moDCs (day 6), mDCs and pDCs were seeded on cover 
slides (50.000 cell/slide) and adhered for 2 hours in serum free, phenol red free RPMI-1640 
supplemented with 1% ultra-glutamine, 0,5% antibiotic-antimycotic, IL-4 (300 U/ml) and GM-CSF 
(450 U/ml). DCs were fixed using 1% paraformaldehyde extra pure DAC 1 (Merck, Haarlem, The 
Netherlands) in PBS for 15 min at RT. DCs were permeabilized with 100% ice cold Methanol (Boom, 
Meppel, The Netherlands) for 5 minutes at 4oC, washed with PBS, blocked for 1 hour with 3% BSA 
(Roche) and 1% Normal Donkey Serum (Sigma Aldrich) in PBS, stained 1 hour with 2,5 μg/ml Goat-
anti-human DC-SCRIPT (R&D Systems, Abingdon, UK) and 1 hour with 1/400 Alexa Fluor 488 Donkey 
anti-Goat IgG (Invitrogen). The nucleus was stained for 5 minutes with 0,3 μg/ml DAPI (Sigma Aldrich) 
or 1 μg/μl Propidium Iodide (ITK, Uithoorn, The Netherlands), washed with PBS and mounted on 76 x 
26 mm microscope slide (Thermo Scientific) with mowiol + 2,5% azide (Calbiochem, San Diego, US). 
Confocal laser scanning microscopy (CLSM) was carried out with an Olympus FV1000 Confocal Laser 
Scanning Microscope with an Argon (457, 488, 515nm), and 405, 559 and 635 diode lasers at the 
Microscopic Imaging Facility of the Department of Cell Biology, Nijmegen Centre for Molecular Life 
Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. The N/C ratio 
(mean Nuclear values/mean Cytoplasmic values) of DC-SCRIPT expression was calculated using a 
custom written quantitative image analysis algorithm in Fiji/ImageJ software (http://fiji.sc/). 
 
Goat-anti-DC-SCRIPT validation 
Immature moDCs were stained with 2,5 μg/ml goat-anti-human DC-SCRIPT or mouse-anti-human GR 
(Abcam, Cambridge, UK) for 40 minutes and 1 hour with 1/400 Alexa Fluor 488 Donkey-anti-goat or 
Goat-anti-mouse. Prior to staining the primary antibodies were supplemented with vehicle (2,9 μl 10 
mM HCl + 2,9 μl 10mM NaOH) or 9,96 μg/ml recombinant human DC-SCRIPT (R&D Systems, 
Abingdon, UK).  
 
siRNA mediated knock-down 
For DC-SCRIPT silencing a 23 nucleotide Custom ZNF366 siRNA termed SC38 targeting the DC-SCRIPT 
gene at position 2349-2369 was used (Dharmacon, Lafayette, Colorado, US). For IL-10 silencing the 
ON-TARGETplus SMARTpool IL10 (Dharmacon) containing 4 different IL-10 targeting siRNA oligos 
each 21 nucleotides long was used. The irrelevant siRNA ON-TARGETplus Non-Targeting siRNA#1 
(Dharmacon) was used as control. Cells were washed twice in PBS and once in OptiMEM without 
phenol red (Invitrogen). A total of 10 μg of siRNA was transferred to a 4-mm cuvette (Bio-Rad), and 
10 × 106 DCs were added in 200 μL of OptiMEM and incubated for 3 minutes before being pulsed 
with an exponential decay pulse at 300 V, 150 μF in a Genepulser Xcell (Bio-Rad) as described 
previously(32). Immediately after electroporation, the cells were transferred to warm (37°C) DC 
culture medium without AA and supplemented with 1% ultra-glutamine, 0,5% antibiotic-antimycotic, 
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10% (v/v) FCS, IL-4 (300 U/ml), and GM-CSF (450 U/ml). Day 6 (72 hours after transfection) DCs were 
stimulated with vehicle, 200 ng/ml LPS, 4 μg/ml R848 (Axxora, Raamsdonkveer, The Netherlands) or 
20 μg/ml PolyI:C (Sigma Aldrich) for 24 hours. RNA was isolated with the Quick-RNA MiniPrep kit 
(Zymoresearch). Total lysates were prepared 72 hours after transfection, lysing 50.000 cells in 50 μl 
1% SDS lysis buffer containing 1% SDS and 62,5 mM TRIS pH 6,8 plus the protease inhibitors 2 μ g/mL 
leupeptin, 2 μg/mL aprotinin, and 1 mM phenylmethylsulfonyl fluoride.  
 
ELISA 
Cytokines were measured in the supernatants 24 hours after induction of maturation. IL-12p70 
production was measured using a standard sandwich enzyme-linked immunosorbent assay (ELISA; 
Pierce Biotechnology, Etten-Leur, The Netherlands). IL-6 was measured using PeliPair human IL-6 
ELISA kit (Sanquin, Amsterdam, The Netherlands), TNF was measured using Human TNF ELISA Set (BD 
Biosciences, Breda, The Netherlands), IL-10 was measured using Human IL-10 Module Set (Bender 
MedSystems, Vienna, Austria). Differences in cytokine production were assessed using t tests. Two-
sided P values less than .05 were a priori considered to be statistically significant. 
 
Mixed Leukocyte Reaction 
DCs were electroporated at day 4 of differentiation with siSC or control siRNA and seeded in a 96-
well plate (50000 cells/well). At day 7 DCs were stimulated with vehicle or 4 μg/ml R848 for 8 hours, 
after which the medium was replaced with fresh DC-medium. At day 8, 24 hours after R848 
stimulation, PBLs were added to the DCs, in a ratio of 1:1, and co-cultured for 120 hours. After 4 days 
of co-culture cells were pulsed with [3H]-thymidine for 15 hours, harvested, and [3H]-thymidine 
incorporation was determined as a measure for T-cell proliferation. To analyze the T helper cell 
profile, supernatants were collected after 2 days of DC-PBLs coculture. Cytokine production  in the 
supernatant were analyzed with a human Th1/Th2 Multiplex kit (eBioscience, Vienna, Austria) 
according to manufacturer’s instructions.  
Figure 1. DC-SCRIPT mRNA expression in moDCs  
(A and B) DC-SCRIPT mRNA expression relative to PBGD mRNA in monocytes as determined by quantitative polymerase 
chain reaction. Monocytes were cultured in the presence of vehicle (white bars), IL-4 (light grey bars), GM-CSF (dark grey 
bars) or IL-4 and GM-CSF (black bars) and harvested at the indicated time points. Day 6 DCs were stimulated with vehicle 
or LPS for 48 hours to obtain immature and mature day 8 DCs, respectively. Representative data from 1 out of 3 donors. 
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Results 
IL-4 induces DC-SCRIPT mRNA expression in monocytes 
Within the immune system, human DC-SCRIPT mRNA has been found to be preferentially expressed 
by DCs(19) To obtain more insight into the expression characteristics of DC-SCRIPT, we investigated 
DC-SCRIPT mRNA expression during differentiation of monocytes into DCs. Hereto, adherent 
monocytes were cultured in the presence of IL-4(33, 34) GM-CSF or the combination of both 
cytokines. Cells were analyzed at different time points after start of differentiation. In the absence of 
cytokines (vehicle) essentially no DC-SCRIPT mRNA expression could be detected. In the presence of 
GM-CSF alone, only small amounts of DC-SCRIPT mRNA were discerned. Incubation with IL-4 and 
GM-CSF or IL-4 alone resulted in DC-SCRIPT mRNA expression within 2 hours after the start of 
stimulation, indicating IL-4 as the dominant factor for DC-SCRIPT induction. An increase in DC-SCRIPT 
mRNA levels was observed up to 8 hours after stimulation (figure 1A). At later time points, DC-SCRIPT 
mRNA levels decreased somewhat but remained stable from day 3 to day 8. DCs matured with LPS 
demonstrated an increase in mRNA expression levels (figure 1B), suggesting a role for DC-SCRIPT in 
DC maturation. 
 
DC-SCRIPT protein is expressed in different DC subsets  
To confirm endogenous DC-SCRIPT protein expression, cell lysates were prepared from monocytes at 
different time points after the onset of differentiation towards DCs. Within 4 hours, DC-SCRIPT 
protein expression could be observed. Protein levels steadily increased during differentiation to DCs 
and remained constant from day 6 onwards (Figure 2A). In line with its mRNA expression, DC-SCRIPT 
protein expression is also dependent on IL-4 (data not shown). 
To prove that DC-SCRIPT protein is also present in freshly isolated blood mDCs and pDCs, cell lysates 
were prepared from purified mDCs and compared to total PBMC (peripheral blood mononuclear 
cells). DC-SCRIPT protein could not be detected in total PBMCs (figure 2B, lane 1), nor could it be 
detected in the mDC negative fraction (figure 2B, lane 2). However, in the mDC fraction DC-SCRIPT 
protein expression was readily observed (figure 2B, lane 3). Similarly, DC-SCRIPT protein was present 
in pDCs, albeit at lower levels compared to moDCs and mDCs (figure 2C, lane 3). No DC-SCRIPT 
expression could be detected in the total PBL (peripheral blood leukocyte) fraction (figure 2C, lane 1) 
and the pDC negative fraction (figure 2C, lane 2). These data show for the first time that DC-SCRIPT is 
endogenously expressed at protein level in freshly isolated mDCs and pDCs. 
 
DC-SCRIPT sub-cellular distribution varies among DC subsets 
The localization of endogenous DC-SCRIPT protein in the different subsets of DCs was investigated 
with confocal laser scanning microscopy (CLSM). Hereto, DCs were stained with anti-DC-SCRIPT 
antibodies recognizing the C-terminal part of DC-SCRIPT. The specificity of the antibody was validated 
by DC-SCRIPT peptide blocking experiments (supplemental figure S1). Our data show that DC-SCRIPT 
is predominantly localized in the nucleus of moDCs, and reveal that localization does not change 
upon maturation of the cells with LPS (figure 3A). Some DC-SCRIPT expression could be discerned in 
the cytoplasm. In fresh mDCs, DC-SCRIPT localization is also most pronounced in the nucleus of the 
cells. In pDCs, expression levels of DC-SCRIPT were apparently lower compared to mDC and moDC 
subsets. DC-SCRIPT staining could be found in both the cytoplasm and nucleus of pDCs, depending on 
the donor. Quantification of DC-SCRIPT expression in the nucleus and the cytoplasm was used to 
confirm localization differences between pDC donors, and between mDCs and pDCs. Between pDC 
donors the nucleus to cytoplasm (N/C) ratio varied between 1,1 and 2,4 (mean: 1,5 +/- 0,59) In 
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contrast, mDCs displayed a N/C ratio of 2,5, whereas moDCs showed an average ratio of 3. The 
variation in N/C ratio within pDCs and mDCs from a single donor was minimal. These data show that 
the DC-SCRIPT localization is predominantly nuclear in moDCs and mDCs, while in pDCs a more 
pronounced cytoplasmic DC-SCRIPT staining is observed that varies between different pDC donors.  
 
To further confirm DC-SCRIPT protein expression in DCs in immunological tissue, frozen tonsil 
sections were analyzed for DC-SCRIPT expression. The presence of DCs was confirmed by staining the 
consecutive section with the DC marker DC-SIGN (figure 3B). As expected, DCs with myeloid 
appearance were mainly present in the T-cell area in between the germinal centers, as shown by the 
DC-SIGN staining. The area in which DC-SCRIPT positive cells were found overlapped with the area 
containing DC-SIGN, a previously defined marker for myeloid DCs(35). Furthermore, also DC-SCRIPT 
expression was observed in cells with myeloid DC morphology located in the T-cell area, further 
substantiating its protein expression in mDCs. In situ, DC-SCRIPT expression in the observed myeloid 
DCs appeared to be mostly confined to the nucleus. The low expression levels of DC-SCRIPT in pDCs, 
and their low abundance in lymph nodes, did not allow proper assessment of pDCs with this 
approach.  
 
DC-SCRIPT knock-down affects IL-10 secretion by moDCs 
DC-SCRIPT mRNA and protein is expressed during the complete lifecycle of moDCs, including in 
mature DCs. To investigate its function in DC maturation, DC-SCRIPT was silenced using a siRNA oligo 
(siSC) targeting the acidic region of the DC-SCRIPT gene at position 2349-2369. DCs treated with non-
targeting siRNA oligos as well as non-treated DCs were used for comparison. Subsequently, immature 
DCs were stimulated for 24 hours with ligands for TLR4, -7/8 and -3, respectively LPS, R848 and 
PolyI:C. Our data demonstrate an efficient knock-down of DC-SCRIPT protein expression in siSC 
treated DCs at day 6 of differentiation prior to stimulation, but not control siRNA-treated and non-
treated DCs (figure 4A).  
The effect of DC-SCRIPT knock-down on DC maturation was examined by investigating cell surface 
maturation marker expression and cytokine secretion in the supernatant, at respectively 48 hours 
and 24 hours after stimulation. As expected, non-electroporated DCs markedly increased expression 
Figure 2. DC-SCRIPT protein expression in 
moDCs, mDCs and pDCs 
Proteins from cell lysates of the indicated cell 
fractions were subjected to immunoblotting 
with anti-DC-SCRIPT antibodies and anti-actin 
as loading control. (A) Cell lysates of moDCs 
harvested at the indicated time points. Day 6 
DCs were stimulated with vehicle or LPS for 
48 hours resulting in immature and mature 
day 8 DCs, respectively. (B and C) Cell lysates 
of the indicated fractions of an mDC (B) and 
pDC (C) isolation procedure. 
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Figure 3. DC-SCRIPT localization in different DC subsets 
CLSM analysis of DC-SCRIPT expression in different DC subsets. DC-SCRIPT in immature and mature DCs (A) or pDCs was 
stained with a goat-anti-DC-SCRIPT (green), the nucleus was visualized by staining with DAPI (blue). DC-SCRIPT in myeloid 
DCs was stained with a goat-anti-DC-SCRIPT (green), the nucleus was visualized by staining with PI (red) The scale bar 
represents 10 µm. (B) Immunohistochemistry staining of DC-SIGN and DC-SCRIPT in frozen tonsil sections. Cells were 
counterstained with hematoxiline to visualize the nuclei. 
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 of both maturation markers CD80 and CD83 upon TLR stimulation (figure 4B). DCs electroporated 
with siSC or irrelevant siRNA (control) also enhanced CD80 and CD83 expression upon activation, at 
equal intensities. Relative to untreated DCs, electroporated DCs showed some disparity in CD83 
expression upon LPS stimulation, possibly due to the variable maturation effects by LPS.  
DC maturation was also qualified by analyzing cytokine secretion (figure 4C). Secretion of the pro-
inflammatory cytokines IL-6 and TNF by non-stimulated DCs electroporated or not, could not be 
detected, in agreement with their immature status. Stimulation with TLR ligands differentially 
induced IL-6 and TNF secretion, with highest levels found upon R848 treatment, and lowest levels 
after PolyI:C stimulation. Both electroporated and not electroporated DCs secreted equal amounts of 
IL-6 and TNF. No significant effect of DC-SCRIPT silencing was detected relative to control siRNA 
treated and non-treated DCs. Variation after LPS treatment, was again detected between donors. In 
line with the absence of pro-inflammatory cytokine expression, also secretion of the anti-
inflammatory cytokine IL-10 was minimal in all conditions in immature DCs. As expected, TLR 
Figure 4. Cytokine secretion by DC-SCRIPT knock-down moDCs 
Day 4 moDCs were not electroporated (non-treated), or electroporated with control siRNA or siSC oligos.  At day 6, vehicle, 
LPS, R848 or PolyI:C were used to mature the DCs. (A) DC-SCRIPT expression at day 6, prior to stimulation, was analyzed by 
western blot analysis. DC-SCRIPT was visualized by immunoblotting with anti-DC-SCRIPT and anti-actin as a loading 
control. Maturation of non-treated DCs (white bars), control siRNA treated DCs (grey bars) and siSC treated DCs (black 
bars) was analyzed by measuring maturation markers CD80 and CD83 by means of FACS (B) and secretion of IL-6, TNF and 
IL-10 in the supernatant by means of ELISA (C), respectively 48 hours and 24 hours after stimulation. Data from at least 3 
donors. Error bars correspond to +/- SEM. 
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mediated maturation did induce only a minimal amount of IL-10 expression in both siRNA control 
DCs and non-treated DCs. Surprisingly, DCs electroporated with siSC displayed a significant increase 
in IL-10 secretion after treatment with LPS or R848. Little or no effect of DC-SCRIPT silencing could be 
detected upon PolyI:C stimulation. Hence, these data demonstrate that DC-SCRIPT expression in DCs 
is important for repression of IL-10 secretion during TLR4 and -7/8 induced maturation.  
 
Increased IL-10 secretion in siSC DCs impairs IL-12 secretion 
The anti-inflammatory cytokine IL-10 is known to impair DC maturation, including IL-12production(2). 
To gain more insight into the kinetics of cytokine production in siRNA control and DC-SCRIPT knock-
down DCs, cytokine mRNA and protein levels were monitored in time. To this end, IL-6, TNF, IL-12 
and IL-10 mRNA and protein expression of control siRNA or siSC electroporated DCs was measured at 
0-, 2-, 4-, 8-, 16- and 24 hours after R848 stimulation (figure 5). Both siSC and control siRNA treated 
cells demonstrated maximum mRNA expression between 2 and 16 hours for all cytokines, which 
decreased at later time points. Maximum levels of IL-6 and TNF expression were detected 4 hours 
after stimulation, whereas IL-12p35 and IL-10 mRNA expression peaked at 8 hours. The protein 
expression of IL-6, TNF and IL-10 followed the mRNA expression kinetics, reaching maximum levels at 
later time points, after which expression remained relatively stable. When comparing control siRNA 
and siSC treated DCs, no effect was found for IL-6 or TNF secretion. In contrast, siSC and control 
siRNA DCs differed greatly in the expression of IL-10 and IL-12. In addition to the increase in IL-10 
production, IL-12 production was significantly impaired at both the mRNA and the protein level in 
siSC DCs. The impaired IL-12 expression observed in siSC DCs was preceded by the increased IL-10 
secretion, suggesting a role for IL-10 in reducing IL-12 levels in siSC DCs.  
 
IL-10 silencing rescues IL-12 secretion in DC-SCRIPT knock-down DCs 
In order to confirm the role of enhanced IL-10 secretion on the expression of IL-12, both DC-SCRIPT 
and IL-10 expression were silenced. To this end, DCs were electroporated with either control siRNA, 
siSC with control siRNA or siSC with IL-10 targeting siRNA (siIL-10). Day 6 DCs were stimulated with 
R848 for 24h after which cytokine production was measured in the supernatant. As an additional 
Figure 5. Kinetics of cytokine expression 
Day 4 moDCs were electroporated with control siRNA (black) or siSC oligos (grey). At day 6 DCs were stimulated with vehicle 
or R848. Messenger RNA and protein were measured at the indicated time points for IL-10, IL-12, IL-6 and TNF expression by 
means of Q-PCR and ELISA, respectively. Representative data from 1 out of 3 donors. 
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control, untreated DCs stimulated with R848 received 106 U/ml IL-10 or vehicle 4 hours after R848 
stimulation, in order to mimic the enhanced IL-10 secretion in siSC DCs. 
Again, efficient knock-down of DC-SCRIPT protein expression was detected in all conditions 
electroporated with siSC prior to stimulation (figure 6A). IL-10 protein expression in the supernatant 
was measured at both 8 hours (data not shown) and 24 hours after stimulation and demonstrated 
efficient IL-10 silencing at both time points. DC-SCRIPT knock-down DC again showed decreased IL-12 
secretion upon R848 simulation. Likewise, addition of recombinant IL-10 to untreated DCs stimulated 
with R848 resulted in a significant (p=.011) reduction in IL-12 secretion (figure 6B). Silencing of both 
DC-SCRIPT and IL-10, however, resulted in normal IL-12 protein levels, confirming that IL-10 signaling 
mediates down-regulation of IL-12 secretion in siSC DCs (figure 6C). In line with previous results, no 
effect was detected on IL-6 and TNF secretion, suggesting that the enhanced IL-10 production 
specifically affects IL-12 expression in these cells.  
 
DC-SCRIPT knock-down impairs T-cell responses 
Next, we investigated the biological consequences of DC-SCRIPT silencing on DC-mediated T-cell 
responses in an allogeneic Mixed Leukocyte Reaction (MLR). SiSC or control siRNA electroporated 
DCs were stimulated at day 7 with vehicle or R848 for 8 hours, after which the medium was replaced 
with fresh DC-medium. Twenty-four hours after stimulation, PBLs were added and both T-cell 
proliferation and cytokine secretion were determined as a measure of T-cell activation. As shown 
(figure 7A), T-cell proliferation was readily detected upon stimulation with control siRNA treated DCs 
and was significantly impaired after stimulation with siSC treated DCs. The effect of R848 stimulation 
on T cell proliferation was limited, possibly reflecting the overall immune activation at these 
allogeneic conditions. In contrast to T cell proliferation, IFNγ secretion by T-cells in these co-cultures 
was largely dependent on the presence of R848 (figure 7B). Strikingly, DC-SCRIPT silenced DCs 
showed an impaired capacity to induce IFNγ secretion by T-cells relative to control siRNA silenced 
DCs. No significant differences were detected for the pro-inflammatory cytokine levels of IL-6 and 
Figure 6. Cytokine secretion by moDCs with silenced DC-SCRIPT and IL-10 expression 
Day 4 moDCs were electroporated with control siRNA, siSC + control siRNA or siSC + siIL-10 oligos. At day 6 DCs were 
stimulated with vehicle or R848. (A) Western blot analysis of DC-SCRIPT expression at day 6, prior to stimulation. DC-SCRIPT 
was visualized by immunoblotting with anti-DC-SCRIPT and anti-actin as a loading control. (B) Day 6 immature DCs were 
stimulated with R848, or not, and treated with vehicle or IL-10 4 hours after R848. IL-12, IL-6 and TNF secretion in the 
supernatant was measured 24 hours after R848 by means of ELISA. Data from 5 donors. Error bars correspond to +/- SEM. 
(C) Analysis of IL-10, IL-12, IL-6 and TNF secretion in the supernatant of control siRNA DCs (white bars), siSC + control siRNA 
DCs (grey bars) and siSC + siIL-10 DCs (black bars), 24 hours after stimulation, by means of ELISA. Data from at least 3 
donors. Error bars correspond to +/- SEM. 
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TNF between control and siSC treated DCs in 
these co-cultures (supplemental figure S2). 
Collectively, these data strengthen the finding 
that DC-SCRIPT plays an important role during 
DC maturation and the induction of T cell 
responses. 
 
Discussion 
Previously, we have isolated and characterized 
the cDNA encoding the transcription regulator 
DC-SCRIPT(19, 23) that is preferentially 
expressed in DCs within the immune system. In 
the present study, DC-SCRIPT mRNA and protein 
expression were found to be induced early in DC 
differentiation and were dependent on IL-4. 
Silencing of DC-SCRIPT expression affected DC 
maturation and induced IL-10 secretion in 
mature DCs, whichconsequently impaired IL-12 secretion by these cells. Furthermore, DC-SCRIPT 
silenced DCs were shown to have a significantly impaired capacity to induce T-cell proliferation and 
IFNγ responses. Hence, DC-SCRIPT appears to be an important factor in regulating DC maturation. 
In human moDCs, DC-SCRIPT expression was dependent on the presence of IL-4. Control experiments 
demonstrated no DC-SCRIPT expression in PBLs upon IL-4 stimulation (data not shown). In addition, 
although in vivo studies previously demonstrated DC-SCRIPT expression in breast epithelial cells(20), 
IL-4 stimulation of the DC-SCRIPT negative MCF-7 breast carcinoma cells did not induce DC-SCRIPT 
expression (data not shown). These data therefore suggest that the IL-4 mediated induction of DC-
SCRIPT is related to the differentiation of monocytes to DCs. It is therefore important to further 
deduce the expression and function of DC-SCRIPT in the DC differentiation process itself. 
Next to moDCs, DC-SCRIPT expression was readily detected in mDCs and pDCs. Previous reports 
demonstrated DC-SCRIPT mRNA expression in all DC subsets tested, including LCs, mDCs and 
pDCs(19). Here we show, for the first time, endogenous DC-SCRIPT protein expression in both mDCs 
and pDCs. Moreover, in vivo DC-SCRIPT expression was observed in DCs present in T-cell areas of 
tonsil tissue. In IHC- and CLSM slides DC-SCRIPT is predominantly localized in the nucleus of moDCs 
and mDCs, concomitant with the presence of a nuclear localization motif. Interestingly, some 
expression was also detected in the cytoplasm of moDCs and mDCs. This was even more pronounced 
in pDCs, however, it must be noted that expression is lower and that variations between donors were 
Figure 7. DC-SCRIPT knock-down affects T-cell activation 
Effect of DC-SCRIPT silencing on T-cell proliferation (A) 
and IFNγ secretion (B) in an allogeneic mixed leukocyte 
reaction (MLR). Day 4 moDCs were electroporated with 
control siRNA or siSC oligos. At day 7 DCs were stimulated 
with vehicle or R848 for 8 hours. Day 8 DCs were co-
cultured with PBLs in a ratio of 1:1. Data from at least 3 
donors. Error bars correspond to +/- SEM. Data indicated 
with N.D. (not detected) were below the detection limit. 
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observed for this subset. In addition, our recent work demonstrated a predominant cytoplasmic 
expression of DC-SCRIPT in breast epithelial cells(20). This suggests that DC-SCRIPT might also have 
important functions outside the nucleus. 
Further insight into the cytoplasmic expression of DC-SCRIPT might be gained from the NR biology. In 
a previous publication we have characterized DC-SCRIPT as a NR co-regulator(20). NRs and many of 
their co-regulators are found both in the nucleus as well as in the cytoplasm. The type I NRs are 
classically sequestered in the cytoplasm, and translocate to the nucleus upon ligand binding, where 
they bind to specific DNA sequences(26, 36-39). NR function is controlled by NR co-regulators, such 
as N-CoR and SMRT. Recent evidence suggests shuttling of these co-regulators between the nucleus 
and cytoplasm, triggered by changes in signaling at the cell surface(40). Further research is necessary 
to fully elucidate the pattern and dynamics of DC-SCRIPT expression in different DC subsets. 
Investigating the effects of various extracellular signals, such as NR ligands, will provide more insight 
into the DC-SCRIPT localization characteristics in DCs. 
In addition, our data uncovered an important role for DC-SCRIPT in DC maturation. DCs with silenced 
DC-SCRIPT expression displayed enhanced IL-10 and decreased IL-12 cytokine production upon 
maturation. Silencing IL-10 expression rescued the IL-12 secretion in DC-SCRIPT knock-down DCs, 
suggesting that DC-SCRIPT primarily affects the expression of IL-10. No effect was detected on IL-6 
and TNF secretion, or after PolyI:C maturation. Interestingly, TLR4 and -7/8 signal via the adaptor 
protein MyD88, whereas TLR3 activates TRIF mediated signaling(41), suggesting that DC-SCRIPT 
primarily functions in the MyD88 pathway. Functionally, DC-SCRIPT silenced DCs are less capable of 
inducing T-cell proliferation and IFNγ secretion in a co-culture with allogeneic PBLs.  
Unraveling the underlying molecular mechanisms by which DC-SCRIPT can regulate IL-10 expression 
in DCs will be an important next step. In DCs, IL-10 transcription is induced through NF-κB 
activation(42). One way of enhanced and prolonged IL-10 transcription is NF-κB acetylation(43). It 
would therefore be of great interest to see whether, and how DC-SCRIPT is involved in NF-κB 
acytylation. Furthermore, besides immunostimulatory DCs, future studies on DC-SCRIPT expression 
and function should also include tolerogenic DCs (tolDCs). These immunosuppressive DCs are known 
to secrete elevated levels of IL-10, while having diminished IL-12 secretion, thereby preventing T-cell 
proliferation(44). Studying tolDCs is even more interesting as we have recently found that DC-SCRIPT 
also affects the function of the Glucocorticoid Receptor (GR) (Hontelez et al., submitted). GR is well 
known for its central role in the generation of tolerogenic DCs, and known to induce IL-10 
production. Moreover, the IL-10 promoter contains a Glucocorticoid Responsive Element (GRE), that 
could serve as a binding site for GR to stimulate IL-10 transcription(45, 46).  
DCs are in the centre of the immune system, controlling the type and course of an immune response. 
They regulate both innate and adaptive immunity and serve as a bridge between both systems. 
Therefore, DCs are regularly used in immunotherapy. Detailed understanding of DC differentiation 
and maturation will allow for the generation of the best suitable DC for these therapies. Collectively, 
our data provide important insight in the DC biology, highlighting DC-SCRIPT as an essential factor in 
DC maturation. 
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Figure S1. Validation of the goat-anti-DC-SCRIPT antibody 
CLSM validation of the anti-DC-SCRIPT antibody using a recombinant human DC-
SCRIPT peptide (rh-DC-SCRIPT). This peptide represents the epitope for the anti-
DC-SCRIPT antibody. Mouse-anti-GR antibody was used as control. Cells were 
stained with goat-anti-DC-SCRIPT or mouse-anti-GR pre-incubated with vehicle or 
rh-DC-SCRIPT. 
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Figure S2. DC-SCRIPT knock-down does not affect IL-6 and TNF secretion in a MLR 
Effect of DC-SCRIPT silencing on IL-6 and TNF secretion in an allogeneic mixed leukocyte 
reaction (MLR). Day 4 moDCs were electroporated with control siRNA or siSC oligos. At 
day 7 DCs were stimulated with vehicle (not shown) or R848 for 8 hours. Day 8 DCs were 
co-cultured with PBLs in a ratio of 1:1. Data from 3 donors. Error bars correspond to +/- 
SEM. Data indicated with N.S. (not significant) did not meet the criteria in the t test to be 
considered statistically significant. 
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Abstract 
Dendritic cells (DCs) play a central role in the immune system; they can induce immunity or tolerance 
depending on diverse factors in the DC environment. Pathogens, but also tissue damage, hormones 
and vitamins affect DC activation and maturation. In particular glucocorticoids (GCs) are known for 
their immunosuppressive effect on DCs, creating tolerogenic DCs (tolDCs). GCs activate the Type I 
Nuclear Receptor (NR) Glucocorticoid Receptor (GR), followed by induced expression of the 
transcription factor GILZ (Glucocorticoid Inducible Leucine Zipper). GILZ has been shown to be 
necessary and sufficient for GC induced tolDC generation. Recently, we have identified the dendritic 
cell specific transcript (DC-SCRIPT) as a NR co-regulator, suppressing type I steroid NRs ER (estrogen 
receptor) and PR (progesterone receptor). Here, we analyzed the effect of DC-SCRIPT on GR activity. 
We demonstrate that DC-SCRIPT co-exists with GR in protein complexes, and functions as a co-
repressor of GR mediated transcription. Co-expression of DC-SCRIPT and GR is shown in human 
monocyte derived DCs, and DC-SCRIPT knock-down enhances GR dependent up-regulation of GILZ 
mRNA expression in DCs. This demonstrates that DC-SCRIPT serves an important role in regulating GR 
function in DCs, co-repressing GR dependent up-regulation of the tolerance inducing transcription 
factor GILZ. These data imply that by controlling GR function and GILZ expression, DC-SCRIPT is 
potentially involved in the balance between tolerance and immunity. 
 
 
Introduction 
Dendritic cell (DC) maturation occurs upon pathogen recognition and inflammation in the peripheral 
tissue, and involves up-regulation of co-stimulatory molecules and inflammatory cytokine secretion. 
Fully matured DCs migrate to T-cell areas in the lymph nodes, inducing T-cell activation (1). In 
addition, DCs can also be activated to become tolerogenic, suppressing inflammation. Both human 
and murine studies demonstrated that this process involves impaired DC activation, which can be 
triggered by ligand dependent activation of the Glucocorticoid Receptor (GR) prior to pathogen 
recognition (2). Within DCs, GR activation impairs STAT, NF-κB, AP-1, 14-3-3, Raf-1 and Ras signalling, 
thereby preventing up-regulation of co-stimulatory molecules upon DC maturation. Expression of the 
GR target gene GILZ is induced upon glucocorticoid (GC) stimulation, and serves an important role in 
mediating the immunosuppressive effects by GR. In fact, expression of GILZ in the absence of GR 
activation was demonstrated to be sufficient for the generation of tolDCs, whereas silencing GILZ 
expression prevented tolerance (3). GC treated DCs displayed suppressed MHC-I restricted antigen 
presentation (4, 5), impaired up-regulation of co-stimulatory molecules (6, 7) and reduced secretion 
of pro-inflammatory cytokines. Secretion of immunosuppressive cytokines was enhanced in these 
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cells (7-9). Collectively, these effects result in altered DC mediated T-cell activation, with reduced Th1 
responses and selective expansion of T regulatory cells (10, 11). This does not only apply to monocyte 
derived DCs (moDCs), also myeloid DCs (MDCs) (12) and plasmacytoid DCs (PDCs) (13) have been 
shown to become tolerogenic following GC exposure.  
The immunosuppressive effects of GCs are typically mediated by GR, a Type I Nuclear Receptor. The 
ligand-free form of GR predominantly resides in the cytoplasm, complexed to chaperone proteins. 
Conformational changes through ligand binding release GR from the chaperone complex, allowing for 
nuclear translocation and transcription initiation (14). 
The human GR is encoded by a single gene, and is expressed in virtually all cell types. Various GR 
isoforms have been described, and tissue specific effects are currently attributed to variation in GR 
isoform expression (15-17). GR pre-mRNA can be alternatively spliced generating the transcriptional 
active GRα and the repressor GRβ, differing in sequence only at the C-terminus ligand binding 
domain (LBD). In contrast to GRα, GRβ expression is confined to the nucleus, where it antagonizes 
GRα dependent gene transcription (18). Additionally, translation reinitiation occurs at seven AUG-
start sites at the mRNA 5'-end, generating 8 different GR polypeptides. These isoforms, termed GR-A, 
-B, -C1, -C2, -C3, -D1, -D2 and -D3, differ in length at the N-terminus and in glucocorticoid 
responsiveness, differentially affecting target gene expression. The GR-A, -B and -C isoforms are 
localized in the cytoplasm, translocating to the nucleus upon ligand binding where they initiate target 
gene transcription. In contrast, GR-D isoforms are, independent of ligand binding, confined to the 
nucleus, and have markedly lower transcriptional activity (16).  
Recently, we have identified DC-SCRIPT (DC-Specific transCRIPT) as a transcription factor and a NR 
co-regulator in human breast and prostate carcinoma tissue. DC-SCRIPT was found to be present in 
Type I and Type II NR protein complexes, repressing Type I NRs ER, PR or AR (androgen receptor) 
mediated transcription, while enhancing Type II NRs RARα/RXR, VDR/RXR or PPARγ/RXR function (19-
22). In the immune system DC-SCRIPT is specifically expressed in DCs, and in contrast to other DC 
markers, identifies all DC-subsets tested to date (23, 24). Interestingly, we have demonstrated an 
important role for DC-SCRIPT in TLR4 and TLR7/8 mediated DC maturation. DC-SCRIPT knock-down in 
moDCs increased secretion of the anti-inflammatory cytokine IL-10, which subsequently impaired 
both the production of the pro-inflammatory cytokine IL-12, as well as T-cell proliferation (25). Here, 
we investigated the putative role of DC-SCRIPT in controlling the anti-inflammatory function of GR in 
moDCs. Our data show the presence of DC-SCRIPT in GR protein complexes, and demonstrate altered 
GR mediated transcription in the presence and absence of DC-SCRIPT. Our findings therefore suggest 
active regulation of GR function by DC-SCRIPT in DCs. 
 
Material and Methods 
Cell lines 
Human embryonic kidney 293 (HEK293) cells were cultured in DMEM containing GlutaMAX 
(Invitrogen, Breda, the Netherlands) supplemented with 10% heat-inactivated FCS (Greiner Bio-one, 
Alphen a/d Rijn, the Netherlands), 1% nonessential amino acids (Invitrogen), and 0.5% antibiotic – 
antimycotic (Invitrogen). Human hepatocellular carcinoma Hep3B cells were cultured in IMDM 
(Invitrogen) supplemented with 10% heat-inactivated FCS and 0,5% antibiotic-antimycotic 
(Invitrogen). 
 
Generation of human Dendritic Cells 
Human  moDCs were generated from PBMCs as  described previously (26). Monocytes  were  derived  
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from buffy coats from healthy donors (Sanquin, Nijmegen, The Netherlands). Buffy coats were 
obtained from healthy volunteers after informed consent and according to institutional guidelines. 
Plastic-adherent monocytes were cultured for 6 days in DCs culture medium (Phenolred free RPMI-
1640 medium (Life Technologies, Breda, The Netherlands) supplemented with 1% ultra-glutamine 
(Cambrex, Wiesbaden, Germany), 0,5% antibiotic-antimycotic (Invitrogen, Breda, The Netherlands), 
10% (v/v) FCS (Greiner Bio-one, Alphen a/d Rijn, the Netherlands), IL-4 (300 U/ml), and GM-CSF (450 
U/ml) both from cellgenix). During day 3 moDCs were supplemented with new IL-4 (300 U/ml) and 
GM-CSF (450 U/ml). Mature moDCs were generated from day 6 immature moDCs through 24 hr 
stimulation with vehicle (0,1% EtOH) followed by 24 hour stimulation with 200 ng/ml LPS (InvivoGen, 
Toulouse, France). Tolerogenic moDCs were generated from day 6 immature moDCs through 24 hour 
stimulation with 100 nM dexamethasone and subsequent 24 hours with 200 ng/ml LPS. DC 
maturation was ensured by FACS staining. 
 
Confocal Laser Scanning Microscopy 
Round ø 12 mm cover slides (Thermo Scientific, Braunschweig, Germany) were coated with Poly-L-
Lysine (Sigma Aldrich, Zwijndrecht, the Netherlands). Immature, mature and tolerogenic moDCs were 
seeded on cover slides (50.000 cell/slide) and adhered for 2 hours in serum free, phenolred free 
RPMI-1640 supplemented with 1% ultra-glutamine, 0,5% antibiotic-antimycotic, IL-4 (300 U/ml) and 
GM-CSF (450 U/ml). DCs were stimulated for 1 hour with 100 nM dexamethasone or vehicle (0,1% 
EtOH). DCs were fixed using 1% paraformaldehyde extra pure DAC 1 (Merck, Haarlem, The 
Netherlands) in phosphate-buffered saline (PBS)  for 15 min at RT. DCs were permeabilized with 
100% ice cold Methanol (Boom, Meppel, The Netherlands) for 5 minutes at 4oC, washed with PBS, 
blocked for 1 hour with 3% BSA (Roche, Woerden, The Netherlands) and 1% Normal Donkey Serum 
(Sigma Aldrich) in PBS, stained 1 hour with 2,5 μg/ml (moDCs) Goat-anti-human DC-SCRIPT (R&D 
Systems, Abingdon, UK) and 2,5 μg/ml (moDCs) Mouse-anti-human GR (Abcam, Cambridge, UK) and 
1 hour with 1/400 Alexa Fluor 488 Donkey-anti-Goat IgG and 1/400 Alexa Fluor 647 Rabbit-anti-
Mouse IgG (Invitrogen). The nucleus was stained 5 minutes with 0,3 μg/ml DAPI (Sigma Aldrich), 
washed with PBS and mounted on 76 x 26 mm microscope slide (Thermo Scientific) with mowiol + 
2,5% azide (Calbiochem, San Diego, US). Confocal laser scanning microscopy (CLSM) was carried out 
with an Olympus FV1000 Confocal Laser Scanning Microscope with an Argon (457, 488, 515nm), and 
405, 559 and 635 diode lasers at the Microscopic Imaging Facility of the Department of Cell Biology, 
Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands. 
 
Plasmids 
The nuclear receptor isoforms GR,  GR-C3 and GR-D3 (National Center for Biotechnology 
Information accession number) (NM_001018077) were isolated and cloned into pHA-n3 (described 
previously in (20) generating pHA-n3/GR, pHA-n3/GR-C3, pHA-n3/GR-D3). The vectors pCATCH and 
pCATCH-DCSCRIPT were described previously (24). pCATCH-DCSCRIPT was used to generate pCATCH-
DCSCRIPTΔCtBPdm and pCATCH-DCSCRIPTΔLxxLL. The transcription reporter plasmid pMMTV-luc 
containing the mouse mammary tumor virus (MMTV) promoter was kindly provided by Prof. Dr. H. 
Stunnenberg (Department of Molecular Biology, Nijmegen Centre for Molecular Life Sciences, 
Radboud University Nijmegen, Nijmegen, the Netherlands). pMMTV-luc was used to generate 
pMMTVΔ-luc and pMMTVΔNF-I/Oct1-luc. pGRE-luc (Stratagene, La Jolla, United States) was used to 
generate pHRE1-luc, pHRE2-luc, pHRE3-luc and pHRE4-luc. 
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Co-Immunoprecipitation assay 
HEK293 cells were seeded in 10 cm culture dish (6.106 cells per dish) 24 prior to transfection. Cells 
were cotransfected with 5 μg pCATCH-DCSCRIPT or pCATCH (control) and 5μg pHA-n3/GRα or pHA-
n3 (control) by using Metafectene transfection reagent (Biontex, Martinsried/Planegg, Germany) 
according to the manufacturer’s protocol. Cells were lysed 24 hours after transfection, in 
immunoprecipitation assay buffer (50 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 50 
mM Tris – HCl [pH 7.5], 5 mM EDTA, and 0.5% sodium-deoxycholate) containing the protease 
inhibitors 2 μg/mL leupeptin (Sigma Aldrich), 2 μg/mL aprotinin (Roche, Woerden, the Netherlands), 
and 1 mM phenylmethylsulfonyl fluoride (Sigma Aldrich).  Cell lysates were used for 
immunoprecipitation (IP) of DC-SCRIPT using anti-DC-SCRIPT-coupled dynabeads (GE Healthcare, 
Hoevelaken, The Netherlands) according to the manufacturer’s protocol. Isotype-coupled-dyna-
beads were used as a control. 
 
Western Blotting 
Proteins were subjected to electrophoresis on an 8% 37.5:1 acryl/Bisacrylamide gel and transferred 
onto Protran nitrocellulose transfer membranes (Schleicher and Schuell) for 1 hour at 100 V at 4°C. 
Blots were blocked in 1%Elk/3%BSA in Phosphate-buffered saline with 0.01% Tween (PBST). DC-
SCRIPT was detected with anti-DC-SCRIPT (R&D, 1,2 μg/ml) and IRDye 680CW donkey-anti-goat IgG 
(1:5000 Li-cor biosciences) as secondary antibody.  GR was detected with a rat anti-HA (1:1000, 3F10, 
Roche) and IRDye 800CW goat-anti-rat IgG (1:5000 Li-cor biosciences), or Anti-Glucocorticoid 
Receptor antibody [3D5] (Abcam, 200 μg/μl, 1:80) and IRDye 680CW goat-anti-mouse IgG (1:5000 Li-
cor biosciences) as secondary antibody. Blots were probed with a mouse-anti-β-actin (1:20.000, 
Roche Applied Science) or rabbit-anti-actin (Sigma Aldrich) and IRDye 680CW donkey-anti-mouse IgG 
or goat-anti-rabbit (1:5000 Li-cor biosciences) as secondary antibody, as loading control. Both actin 
and DC-SCRIPT or actin and GR were visualized on the same blot using 2 different secondary 
detection antibodies conjugated with fluorescent molecules detected at 800 and 680 nm. After 
staining, the membranes were scanned using the Odyssey™ Infrared Imaging system to visualize the 
labeled proteins. 
 
Luciferase transcription assay 
Hep3b cells were plated (6.104) in 24-wells plates 8 hours before transfection and transfected using 
the Calcium Phosphate precipitation method (Invitrogen). HEK293 cells were plated at (1.105) in 24-
wells plates 24 hours before transfection and transfected using metafectene. Transfected cells were 
stimulated with 100 nM dexamethasone, 100 nM prednisolone or vehicle (0,1% EtOH) for 24 h. Cells 
were harvested 24 hours after stimulation and cell lysates were analyzed for luminescence according 
to manufacturer’s protocol (Dual-Luciferase® Reporter assay, Promega) using a Victor3 luminometer 
(PerkinElmer). Relative light units (RLU) were calculated after correction for transfection efficiency 
based on the activity of the co-transfected pRL-SV40 (Promega). The data are expressed as the mean 
activity of at least four independent experiments +/-s.e. 
 
DC-SCRIPT knock-down 
Human moDCs day 4 were electroporated with a 23 nucleotide Custom ZNF366 siRNA termed siSC 
targeting the DC-SCRIPT gene at position 2349-2369 (Dharmacon, Lafayette, Colorado, US) or the 
irrelevant siRNA ON-TARGETplus Non-Targeting siRNA#1 (Dharmacon) termed control. Cells were 
washed twice in PBS and once in OptiMEM  without phenol red (Invitrogen). A total of 10 μg of siRNA 
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 was transferred to a 4-mm cuvette (Bio-Rad), and 10 × 106 DCs were added in 200 μL of OptiMEM 
and incubated for 3 minutes before being pulsed with an exponential decay pulse at 300 V, 150 μF in 
a Genepulser Xcell (Bio-Rad) as described previously (27). Immediately after electroporation, the cells 
were transferred to warm (37°C) DC culture medium without AA and supplemented with 1% ultra-
glutamine, 0,5% antibiotic-antimycotic, 10% (v/v) FCS, IL-4 (300 U/ml), and GM-CSF (450 U/ml). Day 6 
(72 hours after transfection) DCs were stimulated with vehicle (0,1% EtOH) or 100 nM RU-486 (Sigma 
Aldrich), for 1 hour and subsequently with vehicle (0,1% EtOH) or 100 nM prednisolone for 24 hours. 
RNA was isolated with the Quick-RNA MiniPrep kit (Zymoresearch). Total lysates were prepared 72 
hours after transfection, lysing 50.000 cells in 50 μl 1% SDS lysis buffer containing 1% SDS and 62,5 
mM TRIS pH 6,8 plus the protease inhibitors 2 μ g/mL leupeptin, 2 μ g/mL aprotinin, and 1 mM 
phenylmethylsulfonyl fluoride. 
 
RNA isolation and quantitative PCR 
Total RNA was isolated from cells using an RNA isolation kit (Zymo research).RNA quantity and purity 
were determined on a NanoDrop spectrophotometer. Total RNA was DNase-I (amplification grade; 
Invitrogen) treated and cDNA was synthesized using random hexamers and Moloney murine 
leukemia virus reverse transcriptase (Invitrogen). mRNA levels for the genes of interest were 
determined with a CFX96 sequence detection system (Bio-Rad, Veenendaal, The Netherlands) with 
SYBR Green (Roche, Woerden, The Netherlands) as the fluorophore and gene specific oligonucleotide 
primers. The primers for DC-SCRIPT and PBGD were described previously (20). Other used primers 
(forward, reverse): GR (5'- CCATTGTCAAGAGGGAAGGAAAC-'3, 5'- ATGATTTCAGCTAACATCTCGGG-'3), 
GILZ (5'-AGAACCTCAATACCGACAAG-'3, 5'- CATCAGATGATTCTTCACCA-'3). Reaction mixtures and 
program conditions were used that were recommended by the manufacturer (Bio-rad). Quantitative 
PCR data were analyzed with CFX Manager V1.6.541.1028 software (Biorad) and checked for correct 
amplification and dissociation of the products. As a reference gene the housekeeping gene 
porphobilinogen deaminase (PBGD) was used. DC-SCRIPT and GILZ levels relative to PBGD were 
calculated according to the cycle threshold method, (2^- (Ct DC-SCRIPT or GILZ – Ct PBGD)) (28). Differences in 
Figure 1. Co-immunoprecipitation of GR with DC-SCRIPT 
Association of DC-SCRIPT with the Glucocorticoid Receptor. Lysates prepared from HEK293 cells co-transfected with flag 
or flag-DC-SCRIPT and HA or HA-GR were subjected to immunoprecipitation using goat-IgG or goat-anti-DC-SCRIPT 
antibody-coated beads. Immunoblotting was performed on the IP proteins with goat-anti-DC-SCRIPT to detect DC-SCRIPT 
and rat-anti-HA to detect the Glucocorticoid Receptor. Data shown are from one of three experiments that produced the 
same result. * indicates background band. 
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mRNA expression were assessed using t tests. Two-sided P values less than .05 were a priori for 
samples to be considered statistically significant. 
 
Results 
DC-SCRIPT co-immunoprecipitates GR 
DC-SCRIPT was previously shown to be present in protein complexes containing type I and/or type II 
NRs using co-immunoprecipitation (co-IP) assays (20). Whether DC-SCRIPT is also present in GR 
containing protein complexes is unknown. To investigate this, whole cell lysates were prepared from 
HEK293 cells co-transfected with expression vectors encoding DC-SCRIPT and GR or their controls. 
Immunoprecipitations (IPs) were performed on these lysates using goat-anti-DC-SCRIPT-coated beads 
or control goat-IgG-coated beads. Both the immunoprecipitated fractions and the total lysates were 
subjected to immunoblotting. The data show an effective IP of DC-SCRIPT using goat-anti-DC-SCRIPT 
antibody-coated beads, whereas unspecific binding to the control beads is minimal (Fig. 1). In 
addition, GR was effectively co-immunoprecipitated with goat-anti-DC-SCRIPT-coated beads from 
lysates of HEK-293 cells that were co-transfected with DC-SCRIPT and GR. No GR co-IP was observed 
when DC-SCRIPT was co-transfected with control HA only. These data demonstrate that in 
transfected HEK293 cells, DC-SCRIPT and GR can exist in the same protein complex. This occurs most 
likely through indirect interaction, as the co-IP of GR with DC-SCRIPT could only be demonstrated 
when using mild lysis conditions (data not shown).  
 
DC-SCRIPT represses GR function on MMTV 
Next, we investigated whether DC-SCRIPT affects transcriptional activity of GR by using luciferase 
reporter assays. Hep3B cells were co-transfected with DC-SCRIPT, GR or their controls and a reporter 
construct containing the MMTV promoter controlling luciferase expression (MMTV-luc). In the 
MMTV promoter, four hormone responsive elements (HRE) have been identified that bind ligand 
activated GR, thereby inducing transcription of the luciferase gene (29). Eighteen hours after 
transfection the cells were treated with vehicle, or the GR ligands dexamethasone (dex) or 
prednisolone (pred). Luciferase production was analyzed 24 h after stimulation. Hep3B cells lack 
endogenous GR expression, therefore only background luciferase activity was detected after GR-
ligand stimulation in the absence of ectopically expressed GR. Cells that were co-transfected with the 
GR expression vector did show luciferase activity in a GR ligand dependent manner. Both 
dexamethasone and prednisolone were able to induce luciferase production (Fig 2A). Interestingly, 
increasing expression levels of DC-SCRIPT resulted in a dose- and ligand dependent repression of GR 
activity. Previously, DC-SCRIPT has been shown to directly interact with the global t  ranscription co-
repressor CtBP1 via its CtBP1 interaction motif (24). In addition, DC-SCRIPT harbors a LxxLL motif, a 
motif known to facilitate interactions with NRs (5). Next, we examined whether the CtBP1 and the NR 
binding (LxxLL) motifs within DC-SCRIPT were important for its repressive function on GR. We 
therefore mutated both CtBP1 domains or deleted the LxxLL motif. Both mutants were tested for 
protein expression levels (data not shown), which resembled the expression levels of wild-type DC-
SCRIPT. Cellular localization was also expected to be similar, since deletion of the complete acidic 
domain does not alter its nuclear location (24). Figure 2B shows that both mutants are still able to 
strongly repress GR dependent luciferase production. Thus, DC-SCRIPT functions as a co-repressor of 
GR induced transcription on the MMTV promoter, independent of its CtBP1 binding- and LxxLL motif. 
Efficient transcription initiation via the MMTV promoter requires the presence of the most distal HRE 
site (HRE1), the regulatory element AA upstream of HRE1 (30) and binding of the transcription 
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factors NF-I and Oct1 (29, 31, 32). To assess the requirement of these regulatory elements for DC-
SCRIPT mediated co-repression, we deleted these sequence elements from the MMTV-luc reporter. 
In the MMTVΔ1-luc and MMTVΔ2-luc reporters the AA element alone, or both the HRE1 and the AA 
Figure 2. Effect of DC-SCRIPT on GR mediated transcription 
Luciferase reporter assay for GR mediated transcription. Hep3B cells were co-transfected with the firefly luciferase reporter 
plasmid MMTV-luc, the expression plasmid for GR and increasing amounts of the expression plasmid for wild-type DC-
SCRIPT (A) or with mutated CtBP- or deleted LxxLL binding sites (B). Cells were stimulated with vehicle, 100 nM 
dexamethasone or 100 nM prednisolone for 24 h. Luciferase activity is displayed relative to luciferase production upon 
dexamethasone stimulation in the presence of GR and absence of DC-SCRIPT. (C) Schematic representation of firefly 
luciferase reporters. Reporters consist of the MMTV promoter with 4 hormone responsive elements (HRE) in front of a 
TATA-box controlling luciferase gene expression. Three MMTV mutants were created from the wildtype (MMTVwt), deleting 
the upstream 3'-end including the AA domain (MMTVΔ1),  the 3'-end and the most distal HRE (MMTVΔ2), or the binding 
sites for nuclear factor 1 (NF-I) and octamer transcription factor 1 (Oct1) (MMTVΔNF-I/Oct1). (D) Luciferase reporter assay 
for GR mediated transcription. Hep3B cells were co-transfected with the firefly luciferase reporter plasmids MMTVwt-luc, 
MMTVΔ1, MMTVΔ2  or MMTVΔNF-I/Oct1, the expression plasmid for GR and increasing amounts of the expression plasmid 
for DC-SCRIPT. Cells were stimulated with vehicle (white bars) or 100 nM dexamethasone (black bars) for 24 h. Luciferase 
activity is displayed relative to luciferase production upon dexamethasone stimulation in the presence of MMTVwt and in 
the absence of DC-SCRIPT. Data from at least 3 independent experiments. Error bars correspond to +/- SEM. 
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element are deleted, respectively, whereas the MMTVΔNF-I/Oct1-luc reporter lacks the NF-I and 
Oct1 binding sites (33) (Fig. 2C). The wild-type MMTV-luc reporter was used as positive control. 
Deletion of the AA element or the NF-I/Oct1 binding sites reduced GR dependent luciferase 
expression compared to the wt reporter, which was even further decreased upon deletion of both 
AA and HRE1 (Fig 2D). On all MMTV reporters/mutants, DC-SCRIPT expression effectively repressed 
luciferase production.  These data imply that that the repressive function of DC-SCRIPT does not 
depend on the HRE1 and the AA element, nor the NF-I and Oct1 binding sites.   
 
 
DC-SCRIPT represses transcriptional activity of GR isoforms 
GR has been shown to be translated into 8 different isoforms using alternative translational start 
sites (Fig. 3A) (17). The GR expression vector includes all translational start sites, thus could express 
all GR isoforms. Indeed transfection of GR in HEK293 cells demonstrates expression of the full length 
GR-A, as well as the GR-B, -C, and, albeit at markedly lower levels, GR-D isoforms (Fig. 3A). To 
examine DC-SCRIPT function on different GR isoforms, we also cloned GR-C3 and GR-D3. Of note, the 
GR-C3 vector includes downstream ATGs, hence in addition to GR-C3, this vector could theoretically 
also express GR-D1, -D2, and -D3. However, only GR-C3 and GR-D1 could be detected (data not 
shown). The effect of DC-SCRIPT on transcription initiation of the reporter construct MMTV-luc by 
these isoforms was tested using luciferase transcription assays. GR isoforms expressed by both GR 
and GR-C3 expression vectors equally induced luciferase production in a ligand dependent manner. 
Cells expressing the GR-D3 isoform, however, were less potent in inducing luciferase expression, 
displaying a more than 4-fold reduction in luciferase production. Increasing expression levels of DC-
SCRIPT resulted in a dose- and ligand dependent repression of the transcriptional activity of all GR 
isoforms (Fig. 3B). This indicates that the 1-336 amino acid N-terminal part of GR that was deleted in 
Figure 3. Effect of DC-SCRIPT on translational 
isoforms of GR 
(A) Translational isoforms of GR. One GR mRNA 
generates 9 isoforms by means of alternative 
translation initiation. Numbers indicate N- and C-
terminal residue of each GR isoform. Different 
domains are indicated: the modulation domain 
contains the transactivation sequence, and is subject 
to phosphorylation and SUMOylation affecting 
protein interactions; the DNA binding domain (DBD); 
the hinge region and the ligand binding domain 
(LBD). Expression plasmids have been created for 
underscored isoforms. The western blot shows the 
GR-A, -B, -C and -D isoforms visualized with rat-anti-
HA in GR-HA transfected HEK293 cells . (B) 
Luciferase reporter assay for GR-A, GR-C and GR-D 
mediated transcription. Hep3B cells were co-
transfected with the firefly luciferase reporter 
plasmid MMTV-luc, expression plasmids for GR-A, 
GR-C or GR-D and increasing amounts of the 
expression plasmid for DC-SCRIPT. Cells were 
stimulated with vehicle (white bars) or 100 nM 
dexamethasone (black bars) for 24 h. Luciferase 
activity is displayed relative to luciferase production 
upon dexamethasone stimulation in the presence of 
GR-A and in the absence of DC-SCRIPT. Data from at 
least 3 independent experiments. Error bars 
correspond to +/- SEM. 
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the GR-D3 expression vector is not required for the effect of DC-SCRIPT on GR dependent 
transcription.  
 
DC-SCRIPT and GR expression in immature, mature and tolerogenic DCs  
Next, we investigated DC-SCRIPT and GR protein expression by western blotting and confocal laser 
scanning microscopy (CLSM)  in immature- (iDCs), mature- (mDCs) and tolerogenic DCs (tolDCs). 
Immature and mature DCs were obtained by stimulating immature moDCs with vehicle or 24 hours 
of LPS, respectively. Tolerogenic DCs were generated from immature moDCs through 24 hour 
stimulation with dexamethasone and subsequent 24 hours with LPS. Western blot analysis of DC-
SCRIPT and GR protein levels showed equal expression of both proteins in iDCs, mDCs and tolDCs (Fig. 
4A). The translational isoforms GR-A, -B and -C, but not GR-D which lacks the epitope for the anti-GR 
antibody, could be detected in all conditions.  
CLSM analysis revealed co-expression of DC-SCRIPT and GR protein in all three DC types tested. 
Expression of both proteins was observed predominantly in the nucleus, no major changes were 
detected between iDCs, mDCs and tolDCs (Fig. 4B). Co-localization between DC-SCRIPT and GR could 
be discerned but areas containing either GR or DC-SCRIPT were at least as abundant. As expected, 
nuclear expression of GR protein was increased upon 1 hour dexamethasone stimulation. In contrast, 
DC-SCRIPT localization was unaffected by dexamethasone treatment. Hence these data clearly 
demonstrate nuclear- and, to a lesser extent, cytoplasmic co-expression and partial co-localization of 
DC-SCRIPT and GR in moDCs.  
 
Knock-down of DC-SCRIPT enhances GILZ expression in moDCs 
To determine the physiological relevance of the interaction between DC-SCRIPT and GR, DC-SCRIPT 
expression was silenced in moDCs using siRNA electroporation. As DC-SCRIPT was demonstrated to 
repress GR mediated transcription on the MMTV promoter, we hypothesized a similar effect on the 
endogenous GR target GILZ in moDCs. DC-SCRIPT knock-down was therefore expected to enhance GR 
dependent transcription, which could be detected by an increase in GILZ expression.  
Human moDCs were electroporated at day 4 with an DC-SCRIPT specific  siRNA oligo (siSC) or an 
irrelevant control siRNA oligo. DC-SCRIPT protein expression was markedly reduced in siSC treated 
DCs 48- and 72 hours after electroporation (Fig. 5A), whereas GR expression remained unaltered (Fig. 
5B). At day 6 moDCs were treated with vehicle or the GR antagonist RU-486 for 1 hour and 
subsequently stimulated with vehicle or the GR agonist prednisolone for 24 hours. After stimulation 
GILZ mRNA levels were measured. As expected, little or no GILZ mRNA expression was detected in 
vehicle treated control DCs. Stimulation with prednisolone resulted in an upregulation of GILZ 
expression levels in control DCs (Fig. 5C) which could be effectively blocked by inhibiting GR 
activation with the GR antagonist RU-486. Strikingly, vehicle treated siSC DCs already demonstrated a 
significant (p=.05) increase in GILZ expression compared to control DCs. This upregulation appears to 
be GR independent, as it is also detected in the presence of the GR antagonist RU-486. In the 
absence of the GR antagonist, treatment with prednisolone further increased GILZ expression in DC-
SCRIPT knock down DC, with relative GILZ mRNA levels being significantly higher than in control 
siRNA treated DCs (p=.01). These data thus indicate DC-SCRIPT to function as co-repressor of GR 
mediated transcription of GILZ in DCs. Blocking GR activation with the GR antagonist abolished GILZ 
up-regulation in DC-SCRIPT knock-down DCs, confirming that this was indeed dependent on GR 
activation. These results indicate that DC-SCRIPT affects GR activity in DCs, and represses expression 
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of the endogenous GR target gene GILZ, a transcription factor that has been associated with the 
generation of tolerogenic DCs. 
 
Discussion 
The present study demonstrates that the NR co-regulator DC-SCRIPT modulates GR function in 
human moDCs. In cell-lines, DC-SCRIPT was present in GR containing protein complexes, and GR 
mediated transcription was found to be repressed by DC-SCRIPT. Human moDCs co-express DC-
SCRIPT and GR in the nucleus and cytoplasm, and DC-SCRIPT silencing resulted in enhanced 
expression of the GR target gene GILZ, a transcription factor that is instrumental for the generation 
of tolDCs.  
Co-presence of DC-SCRIPT and GR in protein complexes could be demonstrated in transfected 
HEK293 cells, however, we could not co-IP the endogenous complex from DCs. This could have 
several reasons. Human monocyte derived DCs express at least 20 different nuclear receptors (NRs) 
Figure 4. DC-SCRIPT and GR expression in iDCs, mDCs and tolDCs 
(A) Proteins from iDC, mDC and tolDC lysates were subjected to immunoblotting with anti-DC-SCRIPT or anti-GR 
antibodies and anti-actin as loading control. (B) CLSM analysis of DC-SCRIPT and GR expression in iDCs, mDCs and tolDCs. 
DC-SCRIPT was visualized with goat-anti-DC-SCRIPT (green), GR with mouse-anti-GR (red) and the nucleus with DAPI (not 
in merge). Immature and mature DCs were stimulated with vehicle or 100 nM dexamethasone for 1 hour. Representative 
data from 1 out of 3 donors.  
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of which at least 6 (GR, PR, ER, RAR, VDR, PPAR) possibly contain DC-SCRIPT in their repressor or 
activator complexes (19-22). Therefore, enrichment of a specific NR via DC-SCRIPT IP may be 
extremely difficult. Further, endogenous DC-SCRIPT not present in protein complexes may possibly 
bind more efficiently to the beads, and is therefore more likely to be purified. In addition, DC-SCRIPT 
and GR likely interact indirectly. Hence, lysis buffers need to be mild in order to keep the complex 
intact, but at the same time sufficiently stringent to properly lyse the nucleus. Nonetheless, our co-IP 
findings in HEK293 cells are further supported by functional data that demonstrate the effect of DC-
SCRIPT expression on GR-ligand mediated GR target gene expression, not only in HEK293 cells, but 
also in dendritic cells.  
The present data describing the interaction between DC-SCRIPT and GR in cell-lines is in line with our 
previous findings, suggesting that DC-SCRIPT interacts with NRs via other proteins present in NR 
protein complexes. DC-SCRIPT has been shown to bind the transcription co-repressors RIP140 
(receptor-interacting protein 140) and CtBP1, as well as histone de-acetylase (HDAC) 1, -3 and -6, all 
known to be present in NR protein complexes (5, 33, 34). The absence of a direct contact between 
DC-SCRIPT and GR is also consistent with the finding that deletion of the NR interaction motif LxxLL 
and the CtBP1 interaction motif in the acidic domain of DC-SCRIPT did not affect its repressive 
function on GR transcription. This implies that interaction with CtBP1 and the presence of the LxxLL 
motif is not required for the repressive effect of DC-SCRIPT. Interaction with NR complexes could, 
however, be facilitated via other, less defined NR interaction motifs (35-39). In addition to the LxxLL 
motif, DC-SCRIPT contains multiple putative NR interaction motifs that are possibly involved in the 
interaction with various NRs (data not shown).  
Co-expression of DC-SCRIPT and GR in DCs was demonstrated with CLSM, albeit areas containing 
either DC-SCRIPT or GR were equally abundant. Ligand dependent GR translocation was observed in 
iDCs. However, in the absence of its ligand, GR was also detected in the nucleus of iDCs. The nuclear 
GR expression most likely reflects the expression of GRβ isoforms, known to have restricted nuclear 
localization (18). DC-SCRIPT expression was found to be mostly nuclear, in line with previous 
localization studies and its function as a transcriptional (co)factor (3, 34, 40).  
Within DCs, DC-SCRIPT was shown to co-regulate GR function affecting expression of the well known 
GR target gene GILZ. Knock-down of DC-SCRIPT expression markedly increased GILZ expression upon 
GR activation, implicating co-repression of GR by DC-SCRIPT on the GILZ promoter in DCs. GILZ 
functions as an effector protein of GR activation in DCs, mediating the anti-inflammatory action of GR. 
Figure 5. DC-SCRIPT knock-
down in moDCs 
Day 4 human monocyte derived 
DCs were electorporated with 
control non-targeting siRNA 
(control, white bars) or DC-
SCRIPT siRNA (siSC, black bars) 
and differentiated to day 6 
immature DCs. At day 6 DCs 
were stimulated with vehicle or 
100 nM RU-486 for 1hr prior to 24 h stimulation with vehicle or 100 nM 
prednisolone. (A) DC-SCRIPT protein expression in protein lysates from day 
6 and day 7 DCs. (B) DC-SCRIPT knock-down does not affect GR expression 
in moDCs. GR mRNA expression is shown relative to PBGD in mRNA lysates 
from day 7 DCs. Data from 3 donors. Error bars correspond to +/- SEM. (C) 
GILZ mRNA expression relative to PBGD in mRNA lysates from day 7 DCs. 
Data from 6 donors. Error bars correspond to +/- SEM. 
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It has previously been shown that the immunosuppressive effect of GR can be reproduced in the 
absence of GR ligand by GILZ overexpression, whereas GILZ silencing abrogates the GR ligand effect 
(3). GILZ has been shown to interact with STAT, NF-κB, AP-1, 14-3-3, Raf-1 and Ras proteins, all of 
which lead to inhibition of inflammation (41). Hence, by regulating GR activity and GILZ expression, 
DC-SCRIPT may represent an important factor in DC biology, programming DCs towards immunity or 
tolerance. In line with this, we have recently demonstrated an important role for DC-SCRIPT in the 
repression of IL-10 secretion (40), an anti-inflammatory cytokine known to be produced in large 
amounts by tolDCs (42). In this study, DC-SCRIPT knock-down in immature moDCs significantly 
increased IL-10 expression levels upon TLR4 and -7/8 mediated maturation. The cell surface markers 
CD80, CD83, (40) and CD86 (data not shown), which show differential expression between mature 
DCs and tolDCs, were not affected by DC-SCRIPT knock-down, and resembled levels found on mature 
DCs. Nonetheless, elevated IL-10 levels subsequently impaired IL-12 secretion and T-cell proliferation, 
suggesting that DC-SCRIPT knock-down skews DCs towards tolerance. 
In addition to GILZ, we also investigated the expression of other genes known  to be induced by 
ligand dependent GR activation in other cells. However, identification of these other GR targets in DC 
and whether they are affected by DC-SCRIPT proved to be difficult (data not shown). For eight out of 
ten tested target genes no GR-ligand dependent upregulation in moDCs could be detected. This 
could be due to cell-type specific differences between DCs and other cells, like differences in the 
expression and function of the repressive GRα-D and GRβ isoforms. Increased expression upon GR 
activation was only detected for FKBP5 (51 kDa FK506-binding protein 5) and PTX3 (pentraxin 3), 
however, induction levels were low and DC-SCRIPT silencing did not affect expression of these genes 
(data not shown). One major reason could be the HRE sequence or the context of this sequence in 
the promoter of these genes. Meijsing et. al (2009) recently demonstrated that a single nucleotide 
change in the GRE sequence influences GR binding affinity and conformation, affecting co-factor 
recruitment and transcription activation (43). Similarly, the binding properties of DC-SCRIPT might 
differ depending on GR conformation and affect the binding of other co-factors. Furthermore, 
adjacent binding sites of other transcription factors can also affect GR mediated transcription and 
possibly DC-SCRIPT function (19). In line with this, we have preliminary data that suggests that DC-
SCRIPT can also activate GR dependent transcription, depending on the promoter context (data not 
shown). As soon as a suitable DC-SCRIPT antibodies for Chromatin-ImmunoPrecipitation (ChIP) 
become available, it would be extremely interesting to perform ChIP-sequencing studies and 
expression arrays, to further investigate gene regulation specifically in DCs with respect to DC-SCRIPT 
and GR activation and expression.  
Finally, besides GR, also other NRs are known to function in DC biology, affecting either 
differentiation, maturation, or both. The human NR superfamily contains 48 members, of which 20 
NRs have been described to be expressed in monocyte derived DCs (44). Since we have recently 
indentified DC-SCRIPT as a NR co-regulator in breast- (20) and prostate carcinoma (22), affecting both 
type I and type II NR function, it is tempting to speculate about a role for DC-SCRIPT as NR co-
regulator in DC biology. It would therefore be interesting to study target gene expression of various 
NRs after DC-SCRIPT knock-down in DCs. 
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Abstract 
Background Nuclear receptors (NR), including the Androgen Receptor (AR) and the Vitamin D 
Receptor (VDR) play an important role in prostate cancer etiology. We recently found that DC-SCRIPT 
is a prognostic marker in breast cancer and a unique NR coregulator differentially regulating different 
classes of NRs. Here we investigated the importance of DC-SCRIPT in prostate cancer.  
Methods DC-SCRIPT mRNA expression was measured by qPCR. Immunohistochemistry was used to 
detect DC-SCRIPT protein expression. The functional effects of DC-SCRIPT on the transcriptional 
activity of AR and VDR were assessed by luciferase reporter assays and qPCR assays on well-known 
AR and VDR target genes. 
Results DC-SCRIPT mRNA was readily detected in normal and malignant prostate tissue but could not 
be related to disease stage. DC-SCRIPT protein was found in morphologically normal prostate glands 
and in infiltrating immune cells. Strikingly, DC-SCRIPT protein expression was absent in malignant 
prostate epithelial tissue and prostate carcinoma cell lines. DC-SCRIPT protein expression appears to 
be lost prior to the basal cell marker HMW cytokeratin used in prostate carcinoma diagnostics. In 
addition, our data demonstrated that DC-SCRIPT repressed transcription mediated by wild-type and 
mutated AR while enhancing VDR mediated transcription. In addition, transient expression of DC-
SCRIPT expression in prostate carcinoma cells strongly repressed carcinoma cell growth.  
Conclusions DC-SCRIPT is a key regulator of nuclear receptors AR and VDR that play an opposite role 
in prostate cancer etiology and loss of DC-SCRIPT may be involved in the onset of prostate cancer. 
 
Key words: DC-SCRIPT/ZNF366, prostate carcinoma, Androgen Receptor, Vitamin D3 Receptor 
 
 
Introduction 
Prostate cancer is the most frequently diagnosed cancer in the Western male population. Initially 
prostate cancer can be successfully treated with targeted therapies, including inhibiting the function 
of the Androgen Receptor (AR), a member of the type I nuclear receptor (NR) family. Deregulation of 
AR and/or of AR coregulator expression or activity contributes to the transition to castration-
resistant stage of the disease in patients undergoing endocrine therapy (1,2). In addition to 
androgens that bind to the type I NR AR, also vitamin D3 that binds to the type II NR VDR (Vitamin D3 
Receptor) plays an important role in the etiology of prostate cancer. Functionally, the VDR ligand 
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1,25-(OH)2D3 (vitD3) has been shown to reduce the growth of several prostate cancer cell lines in 
vitro, as well as tumor growth in vivo (3-6).   
The activities of NRs such as AR and VDR are tightly regulated by coregulators. The balance of 
corepressors and coactivators determines NR transcriptional activity. Multiple studies have shown 
that in addition to alterations in NRs themselves, malfunction of coregulators of NRs are implicated 
in the development of cancer, including prostate cancer (7,8). Recently we have shown that DC-
SCRIPT is an important coregulator of multiple NRs and is expressed by dendritic cells (DC) and breast 
ductal epithelial cells. DC-SCRIPT expression inhibited the activity of the type I NRs ER and PR, known 
for their pro-proliferative and anti-apoptotic activities in breast cancer cells. In contrast, the 
transcriptional activities of the type II NRs RAR/RXR and PPAR/RXR, known for their anti-proliferative 
and pro-apoptotic effects in breast cancer cells, were enhanced (9-11). Interestingly, DC-SCRIPT 
mRNA expression in breast cancer patients constituted a strong and independent prognostic marker 
for breast cancer (11,12). These data suggest that DC-SCRIPT acts as a tumor suppressor in breast 
cancer. Whether DC-SCRIPT also plays a role in other cancer types in which NRs play an important 
role, is currently unknown. 
Herein we investigated DC-SCRIPT expression in normal and malignant prostate tissue and its relation 
with AR and VDR, two NR family members with opposite functions in prostate epithelial cells.  
 
Materials and Methods 
Cells 
HEK293 cells were cultured in DMEM containing GlutaMAX (Invitrogen), 10% FCS  (Greiner Bio-one), 
1% nonessential-amino-acids (Invitrogen), and 0.5% antibiotic – antimycotic (aa) (Invitrogen). LNCaP 
and 22Rv1 prostate epithelial cancer cells were cultured in RPMI-1640 medium (Invitrogen), 10% FCS, 
and 0.5% aa.  
 
Co-immunoprecipitation assays 
LNCaP and 22Rv1 were transfected with pHA-DC-SCRIPT using metafectene (Biontex, Germany) 
according to the manufacturers’ protocol. Following transfection for 40 hrs, the cells were lysed in 
CHAPS buffer (1% CHAPS, 150mM NaCl, 10mM Tris-HCl pH 7,5 and 2 mM MgCl2 pH 7.5) containing 
the protease inhibitors leupeptin (Sigma), aprotinin (Roche) and PMSF (Sigma). Lysates were used for 
immunoprecipitation (IP) of DC-SCRIPT using anti-DC-SCRIPT-coupled dynabeads (GE Healthcare). 
Isotype-coupled-dyna-beads were used as a control.  
Hek293 cells were transfected with pDC-SCRIPT-EYFP or pEYFP and HA-tagged VDR using 
metafectene.Following transfection for 24 hrs, the cells were lysed in RIPA buffer (50mM NaCl, 1% 
Triton, 0.1% SDS and 50mM Tris-HCl) containing the protease inhibitors leupeptin, aprotinin and 
PMSF. Lysates were used for  IP of YFP-tagged proteins using anti-GFP coupled Protein G beads. 
Uncoupled beads were used as a control.  
Proteins were subjected to electrophoresis and transferred onto Protan nitrocellulose transfer 
membranes (Schleicher and Schuell). DC-SCRIPT was detected with anti-DC-SCRIPT (R&D) and donkey 
anti-goat IRDye 800CW (Li-cor biosciences).  AR was detected with anti-AR (N20, santa cruz) and 
IRDye 800CW Goat Anti-Rabbit IgG (Li-cor biosciences). Blots were probed with a mouse-anti-GFP 
(Roche Applied Science) and IRDye 800CW Goat Anti-Mouse IgG (Li-cor biosciences) to detect YFP-
tagged proteins. HA-tagged VDR was detected with a rat anti-HA (3F10, Roche) and goat anti-rat 
alexa fluor 680 (Invitrogen). After staining, the membranes were scanned using the Odyssey™ 
Infrared Imaging system to visualize the labeled proteins. 
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Transcription assays 
PSA85-luc was kindly provided by Prof. Dr. Trapman (Erasmus Medical Center, Rotterdam). pGL3-
ARE-E1B-luc was kindly provided by Prof. Dr. Bernards (Netherlands Cancer Institute, Amsterdam). 
MMTV-luc was kindly provided by Prof. Dr. Stunnenberg (Nijmegen Centre for Molecular Life 
Sciences). The vitamin D3 reporters were obtained from SABioscience. pCATCH, pCATCH-DCSCRIPT, 
pEYFP-DC-SCRIPT and pEGFP-DC-SCRIPT have been described (9). 
22Rv1 cells were transfected using metafectene. Transfected cells were stimulated with 1nM R1881 
(sigma), 10nM DHT (sigma), 50nM vitD3 (sigma), 1µM AtRA (sigma), or vehicle for 24 hrs. Cells were 
lysed 40 hrs later and analyzed for luminescence according to manufacturer’s protocol (Dual-
Luciferase® Reporter assay, Promega) using a Victor3 luminometer (PerkinElmer). Relative light units 
(RLU) were calculated after correction for transfection efficiency based on the activity of the co-
transfected pRL-SV40 (Promega).  
 
Target gene assays 
For AR target gene experiments LNCaP cells were plated 3 days prior to transfection in RPMI, 10% 
charcoal-stripped FCS, ultraglutamine and aa. and transfected with pHA-DC-SCRIPT or pHA as a 
control using metafectene. Cells were stimulated with vehicle or R1881 for 24hrs. For VDR target 
gene experiments cells were plated in RMPI, 10% FCS, ultraglutamine and aa, 24 hrs prior to 
transfection. Cells were transfected with pHA-DC-SCRIPT or pHA as a control using metafectene. Cells 
were stimulated with vitD3 for 0 or 24hrs. RNA was isolated with the Quick-RNA MiniPrep kit 
(Zymoresearch). 
 
cDNA synthesis and Quantitative PCR  
Total RNA was extracted from tissue sections or cell cultures using Trizol reagent (Invitrogen). RNA 
quantity and purity were determined on a NanoDrop spectrophotometer. Two micrograms of total 
RNA was DNase-I-treated and cDNA was synthesized using random primers and SuperScript II-MMLV 
reverse transcriptase (Invitrogen). Upon quantification of the RT-reaction, 10 ng of cDNA was used for 
PCR analysis. 
mRNA levels for the genes of interest were determined with a Bio-rad CFX96  (Bio-rad) with SYBR 
Green (Roche) as the fluorophore. Reaction mixtures and program conditions were used that were 
recommended by the manufacturer (Bio-rad). Quantitative PCR data were analyzed with Bio-rad CFX  
manager (Biorad) and checked for correct amplification and dissociation of the products. As a 
reference gene TFRC was used (13). DC-SCRIPT levels relative to TFRC were calculated as: 2^- (Ct DC-SCRIPT 
– Ct TFRC). Primer sequences are available on request.  
 
Immunohistochemical studies 
Snap-frozen prostate specimens were embedded in Oct embedding matrix (CellPath), sectioned at 5 
µm intervals, placed on superfrost slides, fixed and incubated with anti-DC-SCRIPT (R&D Systems) 
and stained with biotinylated Horse-anti-Goat (Vector), ABC-AP (Vectastain) and fast red (Sigma) was 
used for signal development. HMW cytokeratin was stained with 34bE12 (Dako) and stained with 
biotinylated Horse-anti-mouse (Vector), ABC-AP and fast red. Isotype matched antibodies (gIgGs 
(R&D Systems) and mIgG1 (BD bioscience) respectively) were used as controls. Sections were 
counter-stained with hematoxylin to visualize the nucleus of the cells and analyzed on a Leica DMLB 
microscope.  
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Prostate cancer patient tissue specimens 
The use of patient material was approved by the local ethical committee of the Radboud University 
Nijmegen Medical Centre. Based on the pathology findings and the case records, patients with low 
grade (Gleason score < 7), high grade (Gleason score ≥ 7), and castration-resistant prostate cancer 
were selected for this study. Normal prostate (NPr) and benign prostatic hyperplasia (BPH) tissue 
specimens were used as non-malignant controls. Upon radical prostatectomy or transurethral 
resection of the prostate, specimens were snap-frozen. Normal, BPH and tumor prostatic tissues were 
selected and processed by step sectioning. 
 
Statistical analysis 
Differences in TFRC-normalized DC-SCRIPT mRNA expression levels between normal prostate tissue 
and tumor tissue from the same patient and between target gene expression of VDR and AR in 
control and DC-SCRIPT transfected cells were assessed using paired t tests. Two-sided P values less 
than 0.05 were a priori considered to be statistically significant. 
Figure 1. DC-SCRIPT mRNA and protein expression in prostate tissue samples  
(a) DC-SCRIPT mRNA levels in healthy tissues (black bars) and corresponding prostate tumor (white bars) tissue  (b) DC-
SCRIPT mRNA levels in 10 castration resistant prostate carcinoma, 10 low grade (<7) and 10 high grade (>=7) prostate 
tissue samples of prostate carcinoma patients.  Immunohistochemistry staining of (c) DC-SCRIPT and 34βE12 on frozen 
morphologically normal prostate tissue (d) DC-SCRIPT and isotype control in frozen prostate tissue with well 
differentiated prostate carcinoma cells containing a region with tumor infiltrating leucocytes (e) DC-SCRIPT and 34βE12 
on frozen prostate tissue with well differentiated prostate carcinoma cells.  
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Results 
DC-SCRIPT mRNA and protein expression in prostate epithelium 
The bifunctional NR coregulator DC-SCRIPT that is expressed in normal breast epithelial cells and at 
lower levels in their malignant counterparts represents a solid prognostic marker for breast 
carcinoma (11,12). Here we investigated whether DC-SCRIPT is expressed by normal and malignant 
prostate epithelial cells in which NRs also play an important role. DC-SCRIPT mRNA expression was 
determined in normal and malignant prostate tissue specimens from the same individual and in 
prostate carcinoma of different grades. The data revealed the presence of DC-SCRIPT mRNA in 
prostate tissue at levels comparable to those seen in breast cancer specimens, and a trend towards 
higher DC-SCRIPT expression in normal vs. tumor tissue that did not reach significance (P=.1978) (Fig. 
1a). The comparison of DC-SCRIPT mRNA levels in 10 low (Pca GG<7) grade patients, 10 high (Pca 
GG>=7) grade patients and 10 castration-resistant PCa patients did not reveal significant differences 
between the different subgroups (Fig. 1b). To confirm DC-SCRIPT expression at the protein level, 
frozen prostate cancer tissue sections were stained for DC-SCRIPT expression. The data showed DC-
SCRIPT expression in the basal epithelial cell layer of morphologically normal prostate tissue (Fig. 1c). 
Little or no expression of DC-SCRIPT was observed in cancerous prostate epithelial cells of patients 
with poorly differentiated prostate carcinoma (n=5) or with castration resistant disease (n=4). As 
expected, DC-SCRIPT was expressed in cells with DC morphology in regions containing tumor 
infiltrating leukocytes (TIL) (Fig. 1d). Of note, TIL are abundant in prostate carcinoma tissue relative 
to healthy prostate tissue. These data demonstrate that DC-SCRIPT is expressed by normal prostate 
epithelial cells and imply that infiltrating DCs expressing DC-SCRIPT contribute to DC-SCRIPT mRNA 
expression observed in advanced prostate cancer tissue.  
Subsequently, the expression of DC-SCRIPT was related to the expression of HMW (high molecular 
weight) cytokeratin (34βE12), which stains benign prostatic acini. Overall, DC-SCRIPT expression 
paralleled the expression of HMW cytokeratin in the basal prostate epithelial cells in healthy prostate 
tissue (Fig. 1e). HMW cytokeratin negative glands also did not express DC-SCRIPT and all glands that 
expressed DC-SCRIPT were also positive for HMW cytokeratin. More detailed analysis showed that 
Figure 2. Association of DC-SCRIPT with AR in 
prostate carcinoma cell lines 
Protein of cell lysates were immunoprecipitated 
(IP) with anti-DCSCRIPT antibody – or isotype 
control coupled beads. The IP-ed proteins were 
subjected to immunoblotting (WB) with anti-
DCSCRIPT to detect IP-ed DC-SCRIPT or anti-AR to 
detect  coimmunoprecipitated AR. Co-IPs were 
performed on (a) lysates from 22Rv1 cells 
cotransfected with DC-SCRIPT and with wt AR (b) 
lysates from 22RV1 cells transfected with DC-
SCRIPT and (c) lysates from LNCAP cells 
transfected with DC-SCRIPT. 
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DC-SCRIPT expression in the basal epithelial layer was lost in 32% (15 out of 36 cases of 19 pts) of the 
cases that uniformly (no focal disruptions) expressed HMW cytokeratin, while 53% (9/17 cases of 19 
pts) of the cases with focal disruptions in HMW cytokeratin expression were completely DC-SCRIPT 
negative. Since focal disruption is a pre-requisite for tumor progression/invasion (14), the loss of DC-
SCRIPT expression in glands with focal disruptions suggest that DC-SCRIPT expression is lost early 
upon malignant transformation. In line with this notion is the finding that no DC-SCRIPT mRNA 
expression is observed in all prostate cancer cell lines tested so far (DU145, LNCaP, DuCaP, 
DuCaP+R1881, 22Rv1 and LAPC-4, data not shown). Surprisingly, the hTERT-immortalized prostate 
basal epithelial cell line Ep156T (15) also does not express DC-SCRIPT, even when co-cultured with 
prostate-derived fibroblasts (data not shown). These results suggest that DC-SCRIPT expression is 
only present in non-dividing cells or cells present in complex organ structures providing the right 
microenvironment.  
 
DC-SCRIPT interacts with and represses AR  
As DC-SCRIPT is known to affect the function of multiple NRs (11), we investigated if DC-SCRIPT may 
also act as a coregulator for NRs important in prostate biology. Therefore, we first evaluated the 
interaction of DC-SCRIPT with AR by co-immunoprecipitation (co-IP) studies. For this, lysates were 
prepared from 22Rv1 prostate carcinoma cells co-transfected with cDNAs encoding DC-SCRIPT and 
wt AR. Immunoprecipitated DC-SCRIPT was readily able to co-IP wt AR, whereas no AR could be 
detected in the control IP (Fig. 2a). To further confirm this interaction, additional co-IP experiments 
were performed with DC-SCRIPT transfected 22Rv1 and LNCaP prostate cancer cell lines that 
endogenously expressed AR (Fig. 2b-c). Although weak, specific co-immuniprecipitation of 
endogenously expressed AR with DC-SCRIPT was observed in both 22Rv1 and LNCaP cells. These data 
thus show the co-presence of DC-SCRIPT in protein complexes containing AR.  
Next, we assessed the impact of DC-SCRIPT expression on the transcriptional activity of AR in 
luciferase reporter assays. Therefore 22Rv1 endogenously expressing the AR mutant T877A (16) were 
transfected with an androgen responsive MMTV-reporter construct. Upon provision of the AR-
ligands DHT or R1881, they produced luciferase as expected. Introduction of DC-SCRIPT revealed a 
dose-dependent repression of ligand-dependent AR mediated luciferase production (Fig. 3a). In 
addition, using another AR reporter construct, pGL3-ARE, we confirmed that DC-SCRIPT represses AR-
mediated transcription in an AR ligand- and dose-dependent manner (Fig. 3a). Moreover, DC-SCRIPT 
specifically repressed luciferase production from a reporter construct, PSA85luc (17), containing a 
genomic fragment of the AR responsive PSA-promoter (Fig. 3a). These data indicate that DC-SCRIPT 
specifically represses transcription mediated by endogenously expressed AR on 3 distinct promoters 
containing androgen response elements in a dose and ligand dependent manner. In addition, we 
show that DC-SCRIPT can repress ectopically expressed wildtype AR in Hep3b cells (data not shown). 
Finally, we investigated if DC-SCRIPT could also repress endogenous genomic AR targets in prostate 
cancer cells. Therefore, DC-SCRIPT was transiently transfected into the AR positive prostate cell line 
LNCaP and the expression of the AR target genes TMPRSS2 and SPDEF was monitored. Upon 
stimulation of control transfected cells with the AR agonist R1881 the expression of TMPRSS2 and 
SPDEF is clearly upregulated (Fig. 3b). R1881 stimulation of LNCaP cells transfected with DC-SCRIPT 
(10-20% transfection efficiency) resulted in significantly lower expression of both AR target genes. 
These data thus demonstrate that DC-SCRIPT can modulate the function of AR on genomic targets in 
prostate carcinoma cells.   
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DC-SCRIPT interacts with and activates VDR  
In contrast to the growth promoting role of AR, the type II NR VDR plays an important anti-
proliferative and pro-apoptotic role in prostate cancer. As we previously showed that DC-SCRIPT 
modulates type II NRs in addition to type I NRs, we investigated whether DC-SCRIPT is able to affect 
the function of VDR. Therefore, we performed co-IP experiments using lysates prepared from 
HEK293 cells cotransfected with constructs encoding YFP-tagged DC-SCRIPT or YFP- (control) and HA-
tagged VDR. Although YFP–DC-SCRIPT and the control protein YFP were both effectively 
immunoprecipitated with anti-GFP antibody–coupled beads, only in the YFP–DC-SCRIPT IP the HA-
tagged VDR could be detected (Fig. 4a), indicating a specific interaction between DC-SCRIPT and VDR.  
To determine the effect of DC-SCRIPT on the transcriptional activity of VDR, luciferase reporter 
assays were performed in 22rv1 cells. 22rv1 cells transfected with a VDRE luciferase reporter 
construct show luciferase activity upon stimulation with the VDR/RXRα ligand vitD3 (1,25-(OH)2D3), 
consistent with the expression of endogenous VDR and RXR. Strikingly and in contrast to the 
repressive effect on the type I steroid receptor AR, co-expression of increasing amounts of DC-SCRIPT 
resulted in a dose-dependent increase in luciferase activity upon addition of vitD3 (Fig. 4b). Removal 
of the VDR/RXR response elements in the reporter construct completely abolished the luciferase 
production, further demonstrating that the activating function of DC-SCRIPT is mediated via binding 
Figure 3. Effect of DC-SCRIPT expression on AR-mediated transcription  
 (a) 22Rv1 cells were transfected with the indicated reporter plasmids and increasing amounts of DC-SCRIPT expression 
plasmid. The cells were treated for 24 hrs with vehicle, 10 nM DHT or 1 nM R1881 Data are expressed as the mean values 
of at least four independent experiments +/- SD. (b) LNCaP cells were transiently transfected with a control or DC-SCRIPT 
expression vector and stimulated for 24 hrs with no or 1 nM R1881. SPDEF and TMPRSS2 mRNA levels are indicated relative 
to TFRC mRNA. Data are expressed as the mean values of three independent experiments +/- SEM. 
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of VDR/RXR to its response elements (data not shown). To demonstrate that DC-SCRIPT enhances 
expression mediated by VDR/RXR rather than RXR homodimers, cells were treated with the RAR/RXR 
ligand AtRA. As shown in Fig. 4b, DC-SCRIPT could only enhance luciferase production upon 
stimulation with vitD3 and not with AtRA or  R1881. Moreover, we show that DC-SCRIPT expression 
in LNCaP cells enhances the expression of vitD3 induced Cyp24A1 expression, the strongest known 
endogenous genomic target gene of VDR (Fig. 4c). These data indicate that DC-SCRIPT can activate 
VDR mediated transcription in prostate epithelial cells.  
 
DC-SCRIPT expression inhibits prostate carcinoma cell growth 
Prostate tumor growth is highly dependent on androgens, whereas vitD3 is mainly involved in the 
inhibition of prostate cell growth. Our current findings combined with our previous report (11) that 
DC-SCRIPT can repress the primarily proproliferative type I NR mediated transcription and can 
activate the primarily antiproliferative type II mediated transcription implies that DC-SCRIPT may also 
be involved in modulating the growth response of prostate carcinoma cells to hormones and 
vitamins. To test this, we transiently transfected DC-SCRIPT in 22Rv1 cells and monitored their cell 
growth. As shown in Fig. 5, both C-terminally GFP tagged DC-SCRIPT and N-terminally YFP tagged DC-
SCRIPT expression significantly represses cell growth compared to the YFP control transfected cells.  
 
Discussion 
Here, we investigated the importance of DC-
SCRIPT in prostate carcinoma biology. DC-SCRIPT 
mRNA expression was readily detected in normal 
and malignant prostate tissue but could not be 
related to differentiation grade. DC-SCRIPT 
protein expression was found in the basal 
epithelial cells of morphologically normal prostate 
glands, and was absent in malignant prostate 
epithelial tissue and prostate carcinoma cell lines. 
DC-SCRIPT protein expression appears to be lost 
prior to the basal cell marker HMW cytokeratin in 
Figure 4. Association and functional effects of DC-SCRIPT 
on VDR function.  
(a) Lysates from Hek293 cells cotransfected with YFP-DC-
SCRIPT and with VDR-HA were immunoprecipitated (IP) with 
Anti-GFP to IP YFP-tagged DC-SCRIPT or the control protein 
YFP.  The IP-ed proteins were subjected to immunoblotting 
(WB) with anti-GFP to detect IP-ed YFP-tagged DC-SCRIPT or 
GFP and anti-HA to detect coimmunoprecipitated AR (b) 
22Rv1 cells were transfected with the reporter plasmid 
VDRE-luc and increasing amounts of DC-SCRIPT expression 
plasmid. The cells were treated for 24 hrs with 0 nM vitD3 
(white bars), 1nM R1881 (light grey bars), 1µM AtRA (dark 
grey bars) or 50 nM vitD3 (black bars). Data are expressed 
as the mean values of at least four independent 
experiments +/- SD 
(c) LNCaP cells were transiently transfected with a control or 
DC-SCRIPT expression vector and subsequently stimulated 
for 0 or 24 hrs with vitD3. Cyp24A1 mRNA levels are 
indicated relative to TFRC mRNA. Data are expressed as the 
mean values of three independent experiments +/- SEM.  
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focally disrupted glands. Moreover, DC-SCRIPT repressed transcription mediated by AR while 
enhancing VDR mediated transcription in prostate epithelial cells. Finally, transient expression of DC-
SCRIPT in prostate carcinoma cells showed that DC-SCRIPT strongly represses cell growth. 
Prostate cancers are exquisitely dependent on androgens for development, growth and survival (18-
21). Therefore, suppressing AR activity by androgen deprivation and the use of AR antagonists are at 
the forefront of therapy regimens in prostate carcinoma for years (21-23). Deregulation of 
coregulators of AR has often been associated with prostate cancer biology (24,25) and demonstrate 
that also coregulators of AR play an important role in prostate carcinoma biology. 
DC-SCRIPT was previously shown to interact with several proteins known to be present in large 
multiprotein complexes modulating NR function (9,11,26,27). Here, we demonstrate that DC-SCRIPT 
is present in a protein complex together with AR and is able to repress the activity of WT and 
mutated AR in luciferase reporter assays. Moreover, upon stimulation with androgens DC-SCRIPT 
repressed the expression of several endogenous targets of AR. DC-SCRIPT expression in human 
prostate tissue was mostly confined to the basal epithelial cells. Although AR mRNA and protein 
expression has been identified in the basal cells (28,29), AR activity in these cells has often been 
described to be low. AR expression and activity are much more pronounced in the luminal cell layer 
in prostate glands (28). The finding that DC-SCRIPT is much more abundant in the basal cells relative 
to the luminal cells might therefore be part of the explanation for the low level of AR activity in the 
basal cells. The observation that DC-SCRIPT regulates AR function and prostate cell growth, both of 
which need to be tightly controlled in normal prostate physiology, is indicative for a crucial role of 
DC-SCRIPT in prostate biology. The exact molecular mechanism by which DC-SCRIPT regulates AR 
activity in basal epithelial cells is currently unknown. So far, the lack of suitable anti-DC-SCRIPT 
antibodies has hampered ChIP experiments to elucidate the molecular basis. 
Because DC-SCRIPT can modulate AR function in prostate epithelial cells we hypothesized that DC-
SCRIPT may play a role in prostate cancer. Our data revealed the presence of DC-SCRIPT mRNA in 
prostate cancer tissue and corresponding healthy tissue. However, DC-SCRIPT mRNA expression 
could not be related to disease stages. This may be explained by the fact that mRNA from the non-
microdissected tissue is not solely derived from tumor cells, but also from adjacent normal tissue, 
adipose tissue, blood vessels and immune infiltrates, the latter of which is known to express DC-
SCRIPT. Immunohistochemistry showed that DC-SCRIPT protein is expressed in the basal epithelial 
layer of morphologically normal prostate glands, but also in infiltrating DCs. In addition we found that 
DC-SCRIPT protein expression parallels 34βE12 expression. 34βE12 is normally used for the detection 
of basal cells of the prostatic acini and demonstration of this HMW cytokeratin in the basal cells of 
Figure 5. Effect of DC-SCRIPT 
expression on cell growth of 
22Rv1 prostate carcinoma cells 
22Rv1 cells were transfected with 
YFP, YFP-DC-SCRIPT or DC-
SCRIPT-GFP. Cells were counted 
24 hrs and 72 hrs after 
transfection and analyzed for YFP 
expression by means of FACS. 
Thereafter, the number of 
transfected cells was calculated. 
Number of cells plotted in the 
graph are relative to the number 
of YFP transfected cells. Data are 
expressed as the mean of 3 
experiments +/- SD.  
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prostatic acini is indicative of benignity (30,31). Our detailed analysis showed that the loss of DC-
SCRIPT expression in basal epithelial cells precedes the loss of HMW cytokeratin and that DC-SCRIPT 
expression is lost early upon malignant transformation. The basal cell population is the sole source of 
several tumor suppressors (14,32,33), together with the finding that DC-SCRIPT expression in 
prostate carcinoma cell lines inhibits their cell growth, it suggests that DC-SCRIPT may function as a 
tumor suppressor in prostate epithelial cells. 
Recently we have demonstrated that DC-SCRIPT plays an important role in breast cancer via 
modulating NR activity. DC-SCRIPT mRNA expression in breast cancer biopsies positively correlated 
with clinical outcome. Overexpression of DC-SCRIPT inhibited the activity of the type I NRs, ER and 
PR. In contrast, the transcriptional activities of the type II NRs, RAR/RXR and PPAR/RXR, were 
enhanced (11,12).  Functional crosstalk of type I and II NRs in breast carcinoma, especially between 
ER and RAR has been known for years, but the molecular mechanism has only recently been 
elucidated (34-36). ER has been reported to exhibit mainly pro-proliferative and anti-apoptotic 
activities in breast cancer cells (37-39), whereas RAR mainly has anti-proliferative and pro-apoptotic 
effects (37,40). For prostate cancer a similar functional link between AR and VDR has been described. 
In contrast to AR, VDR is associated with anti-proliferative and differentiating actions on prostate 
cells (5,6,41). Moreover, the growth inhibiting effects of VDR in prostate cells are most pronounced 
in the presence of androgens (42-45), further supporting the crosstalk between AR and VDR.  
Altogether, our data indicate that the reciprocal effect of DC-SCRIPT on type I and II NRs found in 
breast carcinoma, now can be extended to prostate carcinoma. As prostate epithelial cells do not 
only express the NRs AR and VDR, we hypothesize that the growth-inhibitory effects of DC-SCRIPT are 
not solely mediated via these NRs, but that it is rather a collective effect of DC-SCRIPT on multiple 
type I and II NRs expressed in these cells.   
DC-SCRIPT appears to be a key regulator of the NRs AR and VDR, which exhibit opposite functions in 
prostate cancer cells. In conclusion, DC-SCRIPT represents a potential novel marker for NR-
dependent tumors.  
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In a physiological context cells are not alone; they communicate with surrounding cells and interact 
with extracellular matrix. Cell derived signaling molecules and the nature of the ECM offer a highly 
dynamic setting for cells. Within their local microenvironment they experience complex mixtures of 
compounds and substrates ranging from growth factors and metabolic products over immune 
relevant cytokines and chemokines to hormones and vitamins. Hormones and vitamins manipulate 
the function of cells through downstream signaling via specific transcription factors, nuclear 
receptors (NR). The ligand activated NRs are expressed by virtually every cell of the body. NRs repress 
and induce gene transcription within a protein complex comprising corepressor and coactivator 
molecules. These multiprotein complexes control cellular function and are implicated in a variety of 
physiological processes like development, homeostasis, cell cycle and immunity. Coherently, NRs are 
associated with a multiplicity of pathologic conditions including diabetes, chronic inflammatory 
diseases and cancer. In this thesis, we investigated the role of NRs in dendritic cell (DC) and cancer 
biology. We show that both NRs and the versatile NR coregulator DC-SCRIPT critically influence the 
cellular functions of different DC subsets and prostate tumor cells. Therefore, we conclude that NRs 
and their ligands, hormones and vitamins, are orchestrators of DCs and cancer. This chapter 
evaluates our results and discusses prospective implications.  
 
Hormones and vitamins orchestrate DC function 
 
Dendritic cell heterogeneity – also a matter of residence 
DCs are pivotal decision makers in the balance between tolerance and immunity. Upon activation 
through pattern recognition receptor (PRR) signaling, they undergo maturation specific 
transcriptional changes that subsequently allow for the activation of effector cells, including T cells 
and B cells. DCs comprise a very heterogeneous family; they can generally be divided into 
conventional DCs (cDC) and plasmacytoid DCs (pDC). cDCs represent the classical DC subset; they are 
fast in antigen uptake and can efficiently present antigen to naïve T cells. DCs are highly capable to 
adapt to their microenvironment. In order to sense their surroundings and to react accurately, DCs 
express a huge variety of different receptors, like PRRs, cytokine receptors, chemokine receptors and 
NRs. We have shown that pDCs and cDCs from different lymphoid tissues, like spleen, bone marrow 
(BM), skin draining lymph nodes (SLN) and mesenteric lymph nodes (MLN) express the same 
repertoire of NRs (chapter 2). Moreover, mRNA levels of the different NRs within one DC subset 
were quite stable when compared between the organs. Different studies have shown that DCs from 
distinct tissues display characteristic functional responses towards pathogenic stimuli.1-7 Proietto et 
al. demonstrated that CD8α+ cDCs, CD8α- cDCs and pDCs from the spleen markedly differed in their 
production of cytokines/chemokines and in their ability to prime naïve T cells compared to their 
respective counterparts in the thymus.5 Remarkably, all three subsets from the thymus showed 
enhanced secretion of CCL-17, CCL-21, CCL-22 and CCL-25. As the individual subsets from both 
tissues expressed comparable levels of TLRs, it is likely that the difference in functional responses can 
be allocated to tissue specific microenvironmental factors, like hormones and vitamins. cDCs and 
pDCs from spleen and thymus are likely to express the same NR repertoire. The distinct composition 
of a given microenvironment will therefore potentially determine the immune response of the DCs 
rather than the cells’ receptor expression profile. The concept that the heterogeneity within a given 
DC subset is a matter of residency is further supported by the distinct functional characteristics of 
DCs in mucosal organs like the gut and skin.8,9 Vitamin A (VitA) is now well known to be necessary for 
optimal cDC function in MLNs and in the microenvironment of the gut.10-12 Epithelial cells of the gut 
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and stromal cells of the local MLNs secrete the VitA metabolite retinoic acid (RA) and thereby imprint 
the resident CD103+ intestinal DCs with their unique tolerogenic properties.11 A hallmark of this 
imprinting is the expression of the RA metabolizing enzyme retinal aldehyde dehydrogenase 
(RALDH).13,14 RA conditioned CD103+ DCs then produce RA themselves, a pivotal factor for the 
attraction of gut-homing regulatory T cells (Treg).15 The signaling of RA through the retinoid acid 
receptor (RAR) is therefore pivotal for the homeostasis of the tolerogenic microenvironment in the 
gut. Similar to the gut, the skin is a part of the first line of defense and also harbors various DCs, 
including the epidermal Langerhans cells (LC) and dermal DCs (DDC). Sunlight induced vitamin D 
(VitD) is a key environmental factor in the skin, responsible for the imprinting of skin resident DCs to 
promote epidermotropism of T cells.16 DCs in the skin express the VitD metabolizing enzymes 
Cyp27A1 and Cyp27B1 and actively convert VitD precursors to the active ligand calcitriol. The DC 
secreted calcitriol then binds to the VitD receptor (VDR) in the T cells and induces the expression of 
skin homing chemokine receptor CCR10, enabling the T cells to migrate towards the keratinocyte 
excreted CCL27.16 
In conclusion, DC heterogeneity is not only a matter of distinct subsets but also of tissue residence. 
Microenvironmental factors, like hormones and vitamins, play key roles in the orchestration of DC 
mediated immune responses in tissues like the gut and skin. Moreover, DCs themselves metabolize 
and secrete hormones and vitamins, i.e. VitA and VitD, to further coordinate T cell responses. 
 
Nuclear receptors in dendritic cell subsets 
pDCs comprise a unique DC subset, they are well known for their rapid and vast production of 
interferon alpha (IFNα). Yet, like cDCs, activated pDCs are efficient in antigen uptake, processing and 
presentation.17,18 Despite the appreciated effects of NR ligand stimulation on cDCs, very little is 
known regarding the expression and function of NRs in pDCs. In chapter 2 we compared the NR 
expression profile of cDCs and pDCs. Our data show that both DC subsets expressed the same NR 
repertoire, in vitro and ex vivo. The mRNA expression levels of individual receptors, however, differed 
between cDCs and pDCs, especially upon maturation with toll like receptor (TLR) ligands. These data 
indicate that NR expression in DCs is regulated in a subset specific manner and that NR ligand 
stimulation might differentially affect the function of cDCs and pDCs. 
The heterogeneous DC family extends beyond cDCs and pDCs. In human blood, cDCs can be further 
sub-divided into BDCA-1 (CD1c), BDCA-3 and CD16 expressing DCs. These three cDC subsets share 
the ability to produce IL-12 upon recognition of pathogen associated molecular patterns (PAMP). Yet, 
they distinctly differ in their expression of PRRs, production of cytokines/chemokines and T cell 
stimulating capacity.19,20 In the murine system, at least three cDC subsets are distinguished in the 
spleen: CD8α+/CD4-, CD8α-/CD4+ and double negative CD8α-/CD4- cDCs.21 These three murine cDC 
subsets each express a characteristic PRR repertoire and show distinct responses towards pathogenic 
stimuli.22,23 In addition to these migratory DCs, human and murine organs harbor tissue-resident DC 
subsets, like langerhans cells in the skin or CD103+ cDCs in the gut lamina propria. Little is known 
regarding the NR expression between the different cDC subsets. Given that murine cDCs (in general) 
and pDCs express an identical NR repertoire (chapter 2); it is tempting to speculate that the 
individual cDC subsets share the same NR profile as well. Resting DCs will therefore be shaped by the 
microenvironment of the tissue in which they reside. The expression dynamics of the NRs, however, 
are likely to differ between cDC subsets upon maturation, as seen for cDCs and pDCs. Inflammatory 
conditions induce distinct transcriptional responses in DCs to ensure that the cells can react 
appropriately and elicit efficient immune responses. We show that cDCs and pDCs regulate NR 
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expression levels upon maturation with TLR ligands. Therefore, it would be interesting to compare 
the NR expression profile of the different cDC subsets in steady state and following PRR stimulation. 
 
Hormones and vitamins orchestrate dendritic cell activation 
The outcome of an immune response largely depends on the integration of pathogen associated 
signals and microenvironmental cues by DCs. PRR signaling in DCs controls the expression of co-
stimulatory and co-inhibitory molecules like members of the B7 family, CD86 and PD-L1. Moreover, 
activation of PRRs leads to the expression of pro-inflammatory and anti-inflammatory cytokines, like 
IL-12 and IL-10.24-26 Hormones and vitamins in the local microenvironment are well known to steer 
the PRR mediated maturation of DCs by binding to their respective receptors. NR signaling can 
consequently either enhance or dampen the activation state of DCs.27,28 The retinoid acid receptor 
(RAR) and the liver X receptor (LXR) for example have been shown to amplify secretion of the pro-
inflammatory cytokines IL-12, IL-6 and TNFα and expression of the co-stimulatory molecule CD86 on 
cDCs.29,30 The glucocorticoid receptor (GR), the peroxisome proliferator-activated receptor (PPAR) 
and VDR on the other hand have been shown to inhibit the secretion of the pro-inflammatory 
cytokines IL-12 and TNFα, whereas they enhance the secretion of the anti-inflammatory cytokine IL-
10 by cDCs.31-34 NR ligands, i.e. hormones and vitamins, therefore partly steer the balance between 
pro-inflammatory and tolerogenic DCs (see chapter 1, Figure 3). 
 
Vitamin D renders DCs tolerogenic  
Tolerogenic DCs are characterized by the decreased expression of pro-inflammatory cytokines and 
surface receptors, the increased secretion of anti-inflammatory cytokines and surface receptors and 
consequently the impaired capacity to prime T cells. As aforementioned, different NRs and their 
ligands have been shown to induce a tolerogenic phenotype in cDCs, i.e. corticosteroids (GR), lipids 
(PPAR) and VitD (VDR). The latter has been extensively studied with respect to its inhibitory effect on 
DCs. Various studies have shown that the addition of VitD during the differentiation process of 
human monocytes towards DCs (moDC) in vitro renders moDCs tolerogenic. VitD treated cells 
express decreased levels of the co-stimulatory molecules CD40, CD80 and CD86 and increased levels 
of the inhibitory receptors ILT-3 and PD-L1. Moreover, they secrete lower amounts of the pro-
inflammatory cytokine IL-12 and higher amounts of the anti-inflammatory cytokine IL-10. 
Consequently, VitD treated DCs are less potent in the induction of T cell responses and activate the 
generation of Tregs. Furthermore, Penna and colleagues demonstrated that the production of IL-12 
and activation of T helper 1 responses of human blood derived BDCA1+ cDC is also inhibited by VitD, 
whereas pDCs were not affected by VitD. In line with these data we showed that VitD did not affect 
the secretion of IFNα, IL-6 and TNFα, or the expression of CD80, CD86, MHC-II and ILT3 in human 
pDCs (chapter 3). However, we clearly showed that VitD impaired the capacity of murine and human 
pDCs to induce T cell proliferation and secretion of IFNγ, thereby extending the tolerogenic effect of 
VitD from moDCs and cDCs to another unique DC subset, pDCs. 
The unaffected expression of cytokines and surface receptors of VitD treated pDCs and cDCs seems 
to be paradoxical to the clear impairment of T cell activation. However, the priming of T cells by DCs 
largely depends on three signals: 1) MHC-T cell receptor binding, 2) engagement of co-stimulatory 
receptors and 3) cytokine signaling. The outcome of the immune response is steered by the balance 
of all three factors. Downstream signaling of these pathways generally leads to activation of NfκB. 
Studies have shown that VitD treatment enhances the protein levels of the NfκB-inhibitor IκBα in 
human macrophages thereby leading to diminished NfκB transcriptional activity. In our experimental 
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settings we could not detect any significant differences in the protein levels of IκBα and its 
phosphorylation in VitD treated murine and human pDCs (unpublished data). Yet, the NfκB pathway 
is highly sensitive to stimulation kinetics and includes a large variety of proteins; therefore, 
involvement of NfκB cannot be excluded at this stage. However, pDCs comprise a very scarce 
population in human blood (appr. 0,5%); therefore it will be challenging to delineate elaborate 
kinetics on the different NfκB components in this DC subset. 
The activation of DCs via PRR ligands is mediated by complex signaling cascades involving multiple 
adaptor molecules and downstream transcription factors (TF). Most TLRs signal via the adaptor 
protein MyD88 (myeloid differentiation primary response gene 88) which further transduces signals 
culminating in the activation of the TFs NfκB and members of the interferon-regulatory factor family 
(IRF) with subsequent initiation of pro-inflammatory gene transcription.35 Interestingly, we found a 
significantly increased expression of IRF4 in VitD treated murine and human pDCs (unpublished 
data). IRF4 is a known inhibitory factor that competes with IRF5 for the binding sites on MyD88 and 
TRAF6 thereby blocking downstream gene transcription.36,37 Upregulation of IRF4 might therefore 
represent a mechanism of the tolerogenic effect of VitD treatment on pDCs. Experiments with 
murine IRF4 knockout pDCs or the application of human siRNA targeting IRF4 could verify this 
hypothesis.  
 
Nuclear receptor coregulators and inflammation 
 NRs are dependent on and form large multi-protein complexes together with coregulatory 
molecules to repress or activate transcription. These molecules are therefore divided into 
corepressors and coactivators. As NRs play key roles in the regulation of immune responses, it is not 
surprising that their coregulators are involved in the control of immunity and tolerance as well. 
Recent studies provide increasing evidence that corepressors actively inhibit inflammatory gene 
transcription in the absence of PAMPs. In macrophages, the nuclear receptor corepressor 1 (NCoR1) 
and silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) have been shown to 
sequester inflammatory gene transcription controlled by NfκB and AP-1, a mechanism referred to as 
corepressor dependent checkpoints.38,39 In steady state, NCoR1 is bound to the transcription factor c-
jun on AP-1 target sites while SMRT tethers the ETS transcription factor TEL and the p50 subunit of 
NfκB on their respective binding sites. Upon maturation of macrophages NCoR and SMRT are 
released and transcription of pro-inflammatory genes is initiated. The clearance of NCoR is triggered 
by LPS mediated signaling through TLR4 or TLR2 and subsequent activation of p65/IKKε kinase or 
calmodulin kinase (CaMKII), respectively.40,41 Repression by SMRT is inactivated by signaling through 
TLR4 or the interferon γ (IFNγ) receptor and a mitogen-activated protein kinase (MEKK) cascade. This 
inflammation dependent clearance of NCoR and SMRT has been shown to be inhibited by ligand 
induced activation of PPARγ and LXR, a process referred to as transrepression. The binding of ligand 
to PPARγ induces the sumoylation of its ligand binding domain and consequently the tethering of 
PPARγ to the inflammatory promoter bound NCoR/HDAC complex. This ligand dependent binding 
inhibits the ubiquitylation/19S proteosome machinery and thereby degradation of NCoR. As a result, 
inflammatory gene transcription remains repressed.42 Interestingly, transrepression by ligand 
activated LXR is very similar to the mechanisms utilized by PPARγ involving the sumoylation of LXR. 
Transrepression mediated by PPARγ and LXR thus represents a mechanism for the integration of 
inflammatory and anti-inflammatory signals that play essential roles in immunity and homeostasis. 
To date, it is unknown whether these NR corepressor dependent checkpoints of immune activation 
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also play a role in DCs. Moreover, the role of NR coregulators in general remains to be investigated in 
DCs. 
 
The nuclear receptor coregulator DC-SCRIPT orchestrates dendritic cell activation 
We have shown that the NR coregulator DC-SCRIPT has an important function in the immunobiology 
of DCs (chapters 4 and 5). DC-SCRIPT is a versatile NR coregulator that is specifically expressed by 
DCs within the immune system.43 It is an early hallmark of DC differentiation from human monocytes. 
In chapter 4 we show that expression of DC-SCRIPT in moDCs is dependent on IL-4 and that mRNA 
and protein levels remain present during the complete life cycle of the cells. Moreover, DC-SCRIPT 
protein is also expressed ex vivo in blood circulating BDCA1+ cDCs, pDCs and in vivo in DC-SIGN+ cDCs 
of human tonsils; thus DC-SCRIPT is a universal DC marker. In order to better understand the function 
of DC-SCRIPT in DCs we silenced its expression in moDCs with targeted siRNAs. Knockdown of DC-
SCRIPT results in enhanced expression of the anti-inflammatory cytokine IL-10 and subsequent IL-10 
dependent repression of the pro-inflammatory cytokine IL-12. Furthermore, silenced DC-SCRIPT 
expression in moDCs leads to enhanced expression of the GR target gene GILZ (chapter 5). GILZ is a 
known GR target gene and has been shown to be sufficient for the induction of tolerogenic DCs even 
in the absence of GR activation. Moreover, silencing of GILZ prevents tolerance.44 Our experiments 
showed that silencing of DC-SCRIPT in moDCs results in increased, GR dependent GILZ expression, 
suggesting that DC-SCRIPT represses GR transcriptional activity on the GILZ promoter. Accordingly, 
DC-SCRIPT inhibited GR dependent transcription in reporter assays. 
As DC-SCRIPT is a NR coregulator it is tempting to speculate about a putative IL-10 transrepression 
mechanism similar to the role of NCoR and SMRT in macrophages (see “Nuclear Receptor 
coregulators and inflammation”). In steady state, DC-SCRIPT may be bound to the IL-10 promoter 
and repress transcription while recognition of microbial stimuli may induce clearance of DC-SCRIPT 
and expression of IL-10. This hypothesis is supported by the fact that DC-SCRIPT has been shown to 
interact with the histone deacetylases HDAC-1, -3 and -6; proteins which allow for tight DNA 
wrapping and thereby block transcription (Figure 1).45 Binding of DC-SCRIPT to the promoter might 
be direct or through interaction with other important transcription factors like NfκB or AP-1. IL-10 is 
classically defined as an inhibitory cytokine induced by negative regulators of immune responses. 
Corinti et al. have shown that moDCs secrete significant amounts of IL-10 after stimulation with the 
TLR4 ligand LPS, a suggested autocrine, immune regulatory mechanism to prevent sustained 
inflammatory responses.46-48 The immune suppressive function of IL-10 has been demonstrated in 
vivo as IL-10 deficient mice have decreased bacterial loads after infection with mycobacterium 
tuberculosis, suggesting an enhanced inflammatory response in the absence of IL-10.49 In line with 
these data, blocking of the IL-10 receptor during vaccination against tuberculosis in mice significantly 
enhanced antigen specific IFN-γ and IL-17A responses and thereby protection against re-infection.50 
However, clinical trials studying the administration of IL-10 in inflammatory conditions like 
endotoxemia and psoriasis paradoxically showed that IL-10 treatment exacerbated inflammation 
suggesting a pro-inflammatory role of IL-10.51,52 Moreover, small amounts of IL-10 are thought to be 
necessary for the production of pro-inflammatory cytokines like IL-12. 
Taken together, the immune modulatory functions of IL-10 extend beyond immunosuppression 
towards more complex pleiotropic effects. The underlying mechanisms of the seemingly conflicting 
inhibitory and stimulatory properties of IL-10 remain to be elucidated but are likely to be cell-type 
and pathogen specific. The role of DC-SCRIPT in this process is currently unknown (Figure 1). 
Preliminary data suggest that DC-SCRIPT affects multiple different processes in moDCs, including the 
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phosphorylation status of crucial signaling molecules (J.N. Søndergaard, M. Ansems, G. Adema 
unpublished data). These pathways may be involved in the induction of IL-10 in the absence of DC-
SCRIPT; however, the exact molecular interactions are still to be investigated. Current experiments 
include chromatin immunoprecipitation assays (CHIP) with DC-SCRIPT in DCs to further elucidate the 
mechanism of IL-10 repression by DC-SCRIPT and to gain more insight into putative additional target 
genes. 
In conclusion, our data provide evidence that the NR coregulator DC-SCRIPT plays a key role in the 
immunobiology of DCs, regulating the expression of the pleiotropic cytokine IL-10. 
 
 
Hormones and vitamins orchestrate cancer 
A substantial part of carcinomas is associated with the endocrine system, as hormones and vitamins 
are important factors in the homeostasis of cell proliferation. Hormone dependent cancers typically 
evolve from glandular tissues like liver, pancreas, ovaries, testicles, prostate and breast. The latter 
has been particularly well studied with respect to the role of NRs during its development and 
progression. In breast cancer, the type I NR estrogen receptor (ER) and the type II NR RAR exert 
opposing effects on apoptosis, cell cycle regulation and growth factor signaling.53 Typically, estrogens 
are referred to as pro-tumorigenic, displaying proliferative and anti-apoptotic effects via ER 
activation, whereas RAR stimulation by retinoids is considered anti-tumorigenic, repressing cell 
growth while inducing differentiation and/or apoptosis. These observations indicate that balancing 
the activity of NR is of major importance in keeping a healthy cell phenotype. The effects of a 
particular NR ligand on a cell will thus not only depend on its own concentration, the expression 
levels of its receptor and its coregulators, but also on the presence or absence of other ligands, other 
NR and their coregulators. Indeed, NR coregulators, like the coactivators SRC-1 (steroid receptor 
coactivator 1) and AIB1 (amplified in breast cancer-1 also known as SRC3) and NR corepressors 
(NCoRs) play a key role in regulating the cell's response to NR ligands and have been associated with 
breast cancer.53,54 They play a central role in NR crosstalk, customizing the effect of NRs to each 
Figure 1. Hypothetical model of IL-10 repression by DC-SCRIPT in dendritic cells. IL-10 expression is 
sequestered by DC-SCRIPT. Repression maybe mediated through tethering to transcription factors (TF) and 
recruitment of histone deacetylases (HDAC). Alternatively, DC-SCRIPT might directly bind the IL-10 
promoter. In the absence of DC-SCRIPT the pleiotropic cytokine IL-10 is highly expressed. This expression 
might inhibit or favor immunity. 
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target in relation to the local environment. Recently, we showed that the versatile NR coregulator 
DC-SCRIPT is expressed in breast epithelial cells and that DC-SCRIPT is an independent prognostic 
marker.55,56 DC-SCRIPT was shown to interact with multiple NRs, including ER and RAR; it represses 
transcription mediated by ER and surprisingly enhances transcription mediated by RAR. Interestingly, 
exogenous DC-SCRIPT in the breast cancer cell line MCF-7 adversely regulates transcription mediated 
by multiple NR at the same time. In the presence of multiple NR ligands, DC-SCRIPT is able, in a single 
cell, to repress transcription mediated by the type I NR PR and activate transcription mediated by the 
type II receptor RAR.55 To our knowledge, there are currently no known coregulators that have such a 
distinct effect on type I and type II mediated transcription. So far, studies investigating crosstalk 
between ER and RAR have mostly been performed in MCF-7 cells. As this cell line and all other cell 
lines tested so far are essentially negative for DC-SCRIPT, in contrast to breast epithelial cells, the 
effect of DC-SCRIPT on the estrogen and RA signaling pathways in breast cancer cells remains to be 
investigated. This may shed novel insight into the crosstalk between ER and RAR. 
In chapter 6 we further extend the role of DC-SCRIPT in hormone dependent carcinomas from breast 
cancer to prostate cancer. DC-SCRIPT is expressed in morphologically normal prostate epithelial cells 
and similar to breast cancer, expression is rapidly lost upon malignant transformation of these cells. 
Moreover, DC-SCRIPT expression is also absent in the prostate carcinoma cell lines 22RV1 and LNCaP. 
In luciferase based reporter assays DC-SCRIPT represses transcription mediated by the type I NR AR 
(androgen receptor), whereas it activates transcription mediated by the type II NR VDR. In line with 
these data, exogenous expression of DC-SCRIPT in 22RV1 and LNCaP cells leads to reduced 
expression of the AR target genes TMPRSS2 and SPDEF and increased expression of the VDR target 
gene Cyp24A1. AR and VDR play opposing roles in the etiology of prostate cancer with AR promoting 
and VDR inhibiting cancer progression.57-60 The opposing effect of DC-SCRIPT on these prostate 
cancer associated NRs suggests that DC-SCRIPT counter regulates their effects on cell cycle, 
promoting apoptosis and repressing cell growth. Indeed, exogenous expression of DC-SCRIPT in 
22RV1 and LNCaP in vitro inhibits cell proliferation. 
Our data show that the NR coregulator DC-SCRIPT plays an important role in the etiology of breast 
and prostate cancer. Moreover, it is tempting to speculate about a possible function of DC-SCRIPT in 
additional hormone dependent cancers like ovarian carcinoma. Its role in breast and prostate 
carcinoma is likely to be mediated by its opposing effects on the transcriptional activity of type I and 
type II NRs. Whether this hypothesis holds true is yet to be determined and objective to current 
studies. CHIP based assays will shed more light on the NR target genes of DC-SCRIPT but may also 
provide insight into putative direct targets in epithelial cells. 
 
Hormones and vitamins – therapeutic applications 
Hormones, vitamins and their receptors are implicated in and orchestrate a wide variety of 
physiological processes like homeostasis, cell growth, development and immunity. Pathological 
conditions within these processes are consequently also associated with NRs. The ligand dependent 
activity of NRs designates them as ideal targets for pharmaceutical intervention. Among the most 
prevailing synthetic NR agonists and antagonist used in the clinic are tamoxifen for the ER (targeted 
in breast cancer), casodex for the AR (targeted in prostate cancer) and dexamethasone for the GR 
(targeted in inflammatory diseases).61 Dexamethasone and other pharmaceutical glucocorticoids are 
used in the clinic for their anti-inflammatory effects mediated by binding of the GR. Systemic 
treatment with GR agonists is applied for a wide variety of inflammatory disorders including 
rheumatoid arthritis, asthma, psoriasis and inflammatory bowel disease. Moreover, glucocorticoids 
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are used to prevent graft rejection in transplantation settings. The underlying mechanisms of the 
immune suppressive function of these treatment modalities include the inhibition of pro-
inflammatory cytokine production and enhancement of anti-inflammatory cytokine expression.62 
Target cells within the immune system thereby range from T- and B cells, over granulocytes to DCs.63 
 
Hormones and vitamins targeting NRs in dendritic cells 
The key role of DCs within the immune system designates these cells as strategic targets of 
immunotherapy. In chapter 3 we show that both murine and human pDCs are inhibited by VitD 
signaling through the VDR and suggest that impaired pDC responses may be an underlying 
mechanism of efficient VitD treatment in psoriasis (Figure 2). Interestingly, in addition to psoriasis, 
pDCs have been implicated in the onset and progression of systemic lupus erythematosus (SLE). 
Autoantigen immune complexes released by apoptotic cells in SLE patients activate pDCs which in 
turn induce activation of cDCs subsequently leading to the priming of autoreactive T- and B cells.64 
Similar to psoriasis, SLE is also associated with VitD deficiency suggesting a role of reduced anti-
inflammatory signaling via the VDR in the pathogenesis of SLE.65 A recent clinical trial with VitD 
supplementation in SLE patients indeed showed reduced inflammatory marker expression.66 
Therefore, it is tempting to speculate about a putative role for VitD mediated inhibition of pDCs and 
cDCs in patients with SLE. 
 
 
 
About 15 years ago, DCs have first been exploited for anti-cancer immunotherapy by Ralph 
Steinman.67 Studies then and nowadays mostly make use of in vitro generated moDCs that are 
loaded with tumor associated antigens in the form of mRNA or peptide. The primed moDCs are 
subsequently activated and administered to the patient where they are thought to induce the 
activation of tumor specific cytotoxic T cells, amongst other immune cells, and thereby an antitumor 
7 
Figure 2. Hypothetical model of the suppressive effect of vitamin d in inflammatory skin diseases. 
Plasmacytoid dendritic cells (pDC) are implicated in the onset of different inflammatory skin diseases like 
psoriasis and SLE. Topical application of vitamin D (VitD) analogs is an effective treatment of against skin 
inflammation. This effect might be mediated by the VitD induced inhibition of pDCs and subsequent 
impairment of T cell proliferation and secretion of IFNγ. 
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immune response. DC vaccines have been proven to be non-toxic and effective but clinical responses 
still hold short. Different strategies are exploited to improve DC based anti-cancer vaccines aiming to 
induce the most optimal immunogenic phenotype of DCs. Hormones and vitamins orchestrate the 
function and phenotype of DCs and therefore NRs may represent useful targets for the improvement 
of DC-based vaccines. Recently, the NR4A orphan receptor NOR1 has been shown to induce 
apoptosis in DCs and silencing of NOR1 significantly inhibited activation-induced cell death of DCs.68 
Moreover, knockdown of NOR1 enhanced the antitumor efficacy of DC vaccines in mice. 
Interestingly, we have preliminary data that Nur77, another NR4A orphan receptor, inhibits the 
immune response of pDCs and cDCs. The combined silencing of NOR1 and Nur77 could therefore 
result in a hyperactive, immunogenic DC with enhanced survival. These two NR4A receptors 
therefore represent suitable targets to improve DC-based vaccines. 
 
Concluding remarks 
In summary, this thesis extends the current knowledge on how hormones and vitamins orchestrate 
DCs and cancer. We show that different DC subsets and prostate cancer are functionally affected by 
NRs, their ligands and the NR coregulator DC-SCRIPT. The targeted modification of NRs and their 
coregulators may represent a suitable approach to improve DC-based vaccination strategies for 
malignant diseases. Further research is essential to provide a more comprehensive understanding of 
different hormones and vitamins in DC and cancer biology and thus a rationale basis for therapeutic 
applications. The important role of hormones and vitamins as orchestrators of DCs and cancer 
explains the plasticity of cells and highlights that cells should not be seen individually but rather as a 
part of their given microenvironment. 
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Nederlandse Samenvatting 
 
Het menselijk lichaam is opgebouwd uit miljarden kleine bouwstenen die we met het blote oog niet 
kunnen zien, de zogenaamde cellen. Al deze cellen kunnen verschillende functies hebben en vormen 
onze organen, zo hebben we speciale hersencellen, huidcellen, hartcellen, maagcellen etc. In een 
orgaan staan al deze cellen met elkaar in contact om te waarborgen dat een orgaan goed 
functioneert. Om goed met elkaar te kunnen communiceren scheiden cellen verschillende 
‘boodschapper’ stofjes uit die er voor zorgen dat de informatie efficiënt van de ene cel naar de 
andere cel komt. Een voorbeeld van deze belangrijke chemische boodschappers in ons lichaam zijn 
hormonen en vitamines. 
 
Hormonen en Vitamines 
In ons lichaam worden hormonen geproduceerd door gespecialiseerde organen, de zogenaamde 
endocriene klieren. Voorbeelden hiervan zijn de geslachtsorganen, de alvleesklier, de hypofyse en de 
schildklier. Elk orgaan zorgt voor de productie van een bepaald repertoire aan hormonen. Hormonen 
reguleren belangrijke processen in ons lichaam, zoals lichamelijke groei, voortplanting, metabolisme 
en immunologische reacties. Verstoringen in de hormonale balans kunnen derhalve leiden tot 
ziekten zoals osteoporose, onvruchtbaarheid, diabetes en auto-immuun syndromen. 
“Eet je groente op!”, is een zin die we in onze jeugd bijna allemaal dagelijks hebben gehoord en is 
sterk gekoppeld met de vraag “Waarom?”. Vitamines kunnen worden gedefinieerd als essentiële 
voedingsstoffen, dat wil zeggen stoffen die we in ons lichaam zelf niet in voldoende mate kunnen 
produceren, welke wij constant door middel van voedsel tot ons moeten nemen. Met uitzondering 
van vitamine B12, die alleen in dierlijke producten voorkomt, komen alle andere 13 vitamines voor in 
onze dagelijkse portie groenten. Vitamines zijn voor ons lichaam essentiële voedingsstoffen en een 
tekort aan vitamines kunnen resulteren in pathologische effecten zoals bijvoorbeeld blindheid en 
osteoporose. 
 
Nucleaire Receptoren 
Cellen zijn uitgerust met zogenaamde nucleaire receptoren (NR) welke instaat zijn om hormonen en 
vitamines te herkennen en te binden. Echter deze NRs herkennen niet alleen hormonen en 
vitamines, maar zijn ook instaat om vetten en andere stofwisselingsproducten te binden. In het 
menselijk lichaam kunnen we wel 50 verschillende typen NRs onderscheiden, en elk van deze 
receptoren wordt geactiveerd door een specifieke stof, het ligand. Zo bindt de oestrogeen receptor 
het vrouwelijk hormoon oestrogeen, en wordt door zonlicht geactiveerd vitamine D door de 
Vitamine D receptor gebonden. Over het algemeen kunnen NRs worden ingedeeld in twee 
hoofdcategorieën op basis van hun werkingsmechanisme: 1) Type I nucleaire receptoren en 2) type II 
nucleaire receptoren. Bekende voorbeelden van type I NRs zijn de oestrogeen receptor (ER), de 
progesteron receptor (PR), de androgeen receptor (AR, bindt testosteron) en de glucocorticoid 
receptor (GR, bindt cortisol). Type II nucleaire receptoren werken samen met de retinoic X receptor 
(RXR) om hun functie uit te kunnen oefenen. Voorbeelden van type II nucleaire receptoren zijn de 
vitamine D receptor (VDR), all-trans-retinoic acid receptor (RAR) en peroxisoom proliferator-
geactiveerde receptor (PPAR, bindt vetzuren). Een derde categorie omvat de zogenaamde ‘orphan’ 
receptoren waarvoor geen ligand bestaat of welke nog niet is gevonden. Als NRs hun liganden 
binden, leidt dit tot de productie en secretie van bepaalde eiwitten door cellen wat er voor zorgt dat 
cellen adequaat reageren. De activiteit van NRs is afhankelijk van specifieke eiwitten, de zogenaamde 
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coregulatoren. Op dit moment zijn er meer dan 300 coregulatoren bekend en beschreven. Sommige 
van deze coregulatoren kunnen de functie van NRs activeren (co-activatoren), terwijl anderen 
coregulatoren de functie van NRs remmen (co-repressoren). Een speciale coregulator is het eiwit DC-
SCRIPT (dendritic cell specific transcript). DC-SCRIPT is instaat om enerzijds de functie van type I NRs 
te remmen terwijl het tegelijkertijd de functie van type II NRs kan activeren. 
Kort samengevat, vitamines, hormonen en hun bijbehorende NRs en coregulatoren reguleren veel 
belangrijke processen in ons lichaam en worden daarom geassocieerd met verschillende klinische 
syndromen. In dit proefschrift wordt dieper ingegaan op enkele aspecten van vitamines en 
hormonen en welke rol ze spelen in het immuunsysteem en kanker. 
 
Het Immuunsysteem 
Ons immuunsysteem beschermt ons dagelijks tegen allerlei verschillende ziekteverwekkers van 
buitenaf, zoals bacteriën, virussen en parasieten. Bovendien verschaft ons immuunsysteem, in de 
meeste gevallen, ook bescherming tegen veranderde lichaamseigen cellen, zoals kankercellen, terwijl 
gezonde normale cellen niet worden dood gemaakt. Deze efficiënte immunologische afweer tegen 
ziekteverwekkers en gevaarlijke cellen enerzijds en de tolerantie voor gezonde lichaamseigen cellen 
anderzijds is een complex en fijn afgestemd systeem. Het immuunsysteem bestaat uit verschillende 
gespecialiseerde cellen en factoren die met elkaar communiceren en op een gecoördineerde wijze 
informatie uitwisselen. In het algemeen kunnen twee mechanismen van het immuunsysteem worden 
onderscheiden: 1) de aangeboren en 2) de verworven immuniteit. In eerste instantie worden 
bacteriën en virussen geconfronteerd met de mechanische en fysiologische barrières van het 
immuunsysteem. Onze huid en de slijmvliezen van bijvoorbeeld de ogen, mond en neus kunnen de 
invasie van bacteriën en virussen voorkomen. Mochten de pathogenen toch binnenvallen, dan 
stuiten ze op toxische antimicrobiële stoffen en de aanval van de witte bloedcellen van het 
aangeboren immuunsysteem, zoals granulocyten, mestcellen, macrofagen en dendritische cellen. 
Deze bescherming van het aangeboren immuunsysteem is zeer snel en valt pathogenen op een niet-
specifieke wijze aan. Het verworven (adaptieve) immuunsysteem is vele malen langzamer dan het 
aangeboren immuunsysteem, maar heeft als grote voordeel dat het pathogeen-specifiek is. De witte 
bloedcellen van het adaptieve immuunsysteem, T en B cellen, herkennen specifieke eiwitten die op 
het oppervlak van ziekteverwekkers voorkomen en reageren hier op. Voordat T en B cellen 
pathogenen kunnen herkennen, moeten ze worden geactiveerd en getraind door zogenaamde 
antigeen presenterende cellen. Deze cellen hebben de capaciteit om pathogenen op te nemen, om 
ze vervolgens intern te verteren en in kleine stukjes te verwerken en daarna deze stukjes te 
presenteren op hun celoppervlak aan de T en B cellen. Na activatie door antigeen presenterende 
cellen zijn B cellen instaat om pathogeen-specifieke antilichamen uit te scheiden die zorgen voor een 
betere pathogeen herkenning en zijn T cellen instaat om virus-geïnfecteerde cellen of tumorcellen te 
doden. De familie van de meest professionele antigeen presenterende cellen zijn dendritische cellen 
(DC). 
 
Hormonen & Vitamines in de context met dendritische cellen  
DCs zijn witte bloedcellen die in ons lichaam patrouilleren en voortdurend op zoek zijn naar 
ziekteverwekkers. DCs zijn te vinden in ons bloed en ook in organen waar zij in een immature staat 
verblijven. In deze immature staat zijn DCs zeer efficiënt in het opsporen en registreren van 
ziekteverwekkers. Tijdens een infectie worden DCs geactiveerd door specifieke structuren die zich op 
het oppervlak van pathogenen bevinden. Na activatie zullen de DCs vanuit de organen naar de 
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lymfeknopen migreren waar ze vervolgens zorgen voor het instrueren en activeren van T en B cellen. 
De DC familie is zeer heterogeen en bestaat uit verschillende cellen met allemaal hun eigen 
specifieke eigenschappen. De twee belangrijkste subsets zijn de klassieke DCs (cDC) en de 
plasmacytoide DCs (pDC). cDCs zijn uitgerust met vele moleculen om snel en goed pathogenen in hun 
omgeving op te nemen en te verwerken, terwijl pDCs voornamelijk bekend staan om hun snelle 
productie van grote hoeveelheden van het antivirale eiwit interferon alfa (IFNα). DCs beschikken 
over een grote verscheidenheid aan receptoren, waaronder NRs, die ze gebruiken om hun omgeving 
te herkennen en om zich aan hun omgeving aan te passen. Het is bekend dat hormonen en 
vitamines, door te binden aan NRs, de functies van DCs kunnen reguleren. Zo is vitamine A zeer 
belangrijk in onze darmen om de functie van de lokale DCs te remmen, zodat de darmbacteriën, die 
belangrijk voor ons zijn, niet worden aangetast. Vergelijkbaar met de functie van vitamine A in de 
darm, speelt door de zon geïnduceerde vitamine D een belangrijke rol in de huid. Ook vitamine D 
onderdrukt de activatie van DCs en voorkomt daarmee de vernietiging van belangrijke bacteriën op 
en in de huid. Hoewel het lichaam de natuurlijke eigenschappen van hormonen en vitamines al 
gebruikt om de functie van DCs te controleren, kunnen we uiteraard in de geneeskunde ook gebruik 
maken van deze eigenschappen. Een voorbeeld hiervan is cortisol, een anti-inflammatoire stof, die 
de glucocorticoïde receptor bindt en hierdoor de activiteit van vele immuun cellen (waaronder DCs) 
verhinderd. Hoewel we redelijk veel weten wat de invloed is van vitamines en hormonen op klassieke 
DCs, weten we relatief weinig over hun effect op pDCs. In Deel II van dit proefschrift hebben we 
daarom verschillende aspecten van de functie van NRs in pDCs onderzocht. 
In hoofdstuk 2, hebben we de aanwezigheid van 28 verschillende NRs in cDCs en pDCs vergeleken. 
Onze gegevens tonen aan dat cDCs en pDCs in vitro, dat wil zeggen buiten het lichaam in het 
laboratorium, en geïsoleerd uit lymfoïde organen hetzelfde repertoire NRs vertonen. Echter, er is wel 
een verschil in de hoeveelheid van individuele NRs in cDCs of pDCs, en deze verschillen worden 
vooral duidelijk in geactiveerde cellen. 
In hoofdstuk 3 onderzoeken we de effecten van vitamine D op pDCs. Het is bekend dat vitamine D de 
functie van het immuunsysteem kan remmen en in het bijzonder cDCs (zie hierboven). Daarom 
worden vitamine D bevattende zalven vooral toegepast voor de behandeling van auto-
immuunziekten zoals systemische lupus erythematodes en psoriasis. Echter, het exacte 
werkingsmechanisme van deze therapie is tot op heden niet bekend. Voor verschillende auto-
immuunziekten, zoals systemische lupus erythematodes,  is beschreven dat pDCs een belangrijke rol 
spelen in de ontwikkeling en progressie van deze auto-immuunziekten. Wij laten zien dat pDCs die 
behandeld zijn met vitamine D verminderde functies hebben en niet goed instaat zijn om T cellen te 
activeren (Hoofdstuk 3). Voor de behandeling van immunologische huidziekten zouden we kunnen 
profiteren van de beschreven remmende eigenschappen van pDCs door patiënten te behandelen 
met vitamine D preparaten. 
Zoals eerder beschreven is de activiteit van NRs afhankelijk van coregulator eiwitten. De meeste 
coregulatoren hebben de capaciteit om NRs zowel te kunnen remmen als te activeren. In Deel III van 
dit proefschrift werd onderzoek gedaan naar de coregulator DC-SCRIPT, een speciaal eiwit dat zowel 
negatieve als positieve regulerende functies heeft. In de hoofdstukken 4 en 5, hebben we de rol van 
DC-SCRIPT in DCs onderzocht. Onze gegevens tonen aan dat DC-SCRIPT in cDCs en pDCs de productie 
van immuun activerende moleculen genaamd cytokines beïnvloedt. DC-SCRIPT remt de productie 
van de immuun onderdrukkende cytokine IL-10, waardoor het tegelijkertijd de productie van de 
immuun stimulerende cytokine IL-12 bevordert (Hoofdstuk 4). Als gevolg lijkt het dat DC-SCRIPT de 
immuun stimulerende eigenschappen van DCs versterkt. In hoofdstuk 5 laten we zien dat DC-SCRIPT 
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de werking van de glucocorticoid receptor (GR) remt. Verder laten we zien dat in de afwezigheid van 
DC-SCRIPT het GR geactiveerde molecuul ‘Gilz’ in grotere hoeveelheden in DCs aanwezig is. GR is 
bekend om zijn remmende effecten op DCs, en DC-SCRIPT lijkt dus de immuunsysteem 
onderdrukkende eigenschappen van DCs te remmen. Samengevat, de resultaten beschreven in de 
hoofdstukken 2 tot 5 geven nieuwe inzichten en benadrukken de belangrijke effecten van 
hormonen, vitamines, NRs en hun coregulatoren op de functie van DCs en daarmee op 
immunologische reacties. 
 
Hormonen & Vitamines in de context van kanker  
Kanker betekend in de geneeskunde het ontstaan van nieuwe kwaadaardige weefsels. Door 
verschillende mechanismen kunnen in het genetisch materiaal (DNA) vastgelegde kenmerken van 
een gezonde cel veranderen (muteren), wat tot gevolg kan hebben dat een cel ongecontroleerd gaat 
delen en dochtercellen gaat vormen wat uiteindelijk leidt tot de formatie van een kwaadaardige 
weefselmassa (gezwel). Het is bekend dat tumorcellen verschillende eigenschappen van hun gezonde 
moedercellen overnemen. Dit concept is vooral duidelijk bij tumoren van klierweefsels, zoals bij 
borstkanker en prostaatkanker. De gezonde ontwikkeling van de borst is afhankelijk van de 
vrouwelijke hormonen oestrogeen en progesteron. Gedurende transformatie behouden 
borsttumoren deze eigenschappen en is ook hun groei grotendeels afhankelijk van deze hormonen 
en daarmee ook van de aanwezigheid van de oestrogeen en progesteron receptor (ER en PR). Andere 
NRs, zoals PPAR en RAR kunnen daarentegen de groei van tumorcellen remmen. Wederom is het ook 
hier mogelijk om deze kennis toe te passen voor het ontwikkelen van nieuwe therapeutische 
behandelingen. Zo bestaat de mogelijkheid al om patiënten met hormoonafhankelijke tumoren te 
behandelen met het geneesmiddel tamoxifen. Tamoxifen is een anti-oestrogeen. Dat wil zeggen dat 
het de werking van het vrouwelijke geslachtshormoon oestrogeen tegengaat. 
Recent is aangetoond dat de NR coregulator DC-SCRIPT een belangrijke rol speelt in de ontwikkeling 
van borstkanker. Hoewel het DC-SCRIPT eiwit in gezonde cellen in de borst tot expressie komt, is het 
vele malen lager te vinden in borst tumorcellen. Interessant genoeg remt DC-SCRIPT de functie van 
de groeibevorderende receptoren ER en PR, en activeert het de functie van de groeionderdrukkende 
receptoren PPAR en RAR. Bovendien correleert de aanwezigheid van grote hoeveelheden DC-SCRIPT 
met een betere prognose van borstkankerpatiënten. Net als de ontwikkeling van borstkanker is de 
gezonde ontwikkeling van de prostaat en ook de groei van kwaadaardige prostaat tumoren op 
soortgelijke wijze afhankelijk van het mannelijke hormoon testosteron wat weer bindt aan de 
nucleaire androgeen receptor (AR). Daarentegen is het voor de vitamine D receptor (VDR) 
beschreven dat het juist de groei van tumorcellen remt. Prostaatkankerpatiënten ontvangen 
geneesmiddelen die ofwel de testosteron niveaus verminderen of AR direct remmen. In hoofdstuk 6, 
gaan we dieper in op de rol van DC-SCRIPT in tumoren en hebben we onderzocht wat de functie is 
van DC-SCRIPT in prostaatkanker. We tonen aan dat in gezonde prostaat cellen het eiwit DC-SCRIPT 
aanwezig is,  terwijl in prostaat tumorcellen DC-SCRIPT niet meer aantoonbaar is. Bovendien blijkt uit 
onze resultaten dat DC-SCRIPT de groeistimulerende werking van AR remt en de functie van de 
groeionderdrukkende VDR activeert. Samengevat is het dus waarschijnlijk dat DC-SCRIPT een 
belangrijke rol speelt in de ontwikkeling van prostaatkanker. 
In hoofdstuk 7, beschrijf en bediscussieer ik de resultaten die in dit proefschrift zijn beschreven en 
implementeer en combineer ik de betekenis van deze resultaten in de bredere context omtrent het 
effect van vitamines, hormonen en hun bijbehorende NRs in DCs en kanker. 
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Perspectief 
De in dit proefschrift beschreven resultaten geven nieuwe inzichten over de effecten die hormonen 
en vitamines kunnen hebben op dendritische cellen en kanker cellen. We zien dat de functie van 
verschillende soorten dendritische cellen en de functie van prostaattumoren wordt beïnvloed door 
hormonen, vitamines, NRs en de NR coregulator DC-SCRIPT. De specifieke modificatie van NRs en 
hun coregulatoren kan bijdragen tot de verbetering van bestaande en het ontwikkeling van nieuwe 
innovatieve vormen van immuuntherapie. Echter, naar mijn mening zijn er ook nog vele deuren die 
geopend dienen te worden om de exacte rol van NRs te begrijpen in gezondheid en ziekte. 
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Deutsche Zusammenfassung 
 
Der menschliche Körper besteht aus Milliarden von kleinen Bausteinen, die wir mit bloßem Auge 
nicht sehen können, den sogenannten Zellen. Diese Zellen formen wiederum all unsere Organe. So 
haben wir spezielle Herzzellen, Hautzellen, Gehirnzellen, Magenzellen usw. Die Zellen eines 
bestimmten Organs stehen miteinander in Kontakt, um zu gewährleisten, dass ein Organ gut 
funktioniert. Um miteinander kommunizieren zu können, scheiden Zellen unterschiedliche 
Botenstoffe aus, die Informationen von einer Zelle zur anderen transportieren. Wichtige chemische 
Botenstoffe unseres Körpers sind Hormone und Vitamine. 
Hormone und Vitamine 
Hormone werden in unserem Körper von spezialisierten Organen produziert, den sogenannten 
endokrinen Drüsen. Beispiele sind Geschlechtsorgane, die Bauchspeicheldrüse, die Hirnanhangsdrüse 
und die Schilddrüse. Jedes einzelne Organ produziert dabei ein spezifisches Hormonrepertoire. 
Hormone regulieren wichtige Prozesse unseres Körpers wie z. B. Wachstum, Fortpflanzung, 
Stoffwechsel und immunologische Abwehrreaktionen. Störungen des Hormonhaushaltes führen 
demnach zu Krankheiten wie Osteoporose, Unfruchtbarkeit, Diabetes und Autoimmunsyndromen. 
„Iss dein Gemüse auf!“ Ein Satz, der uns alle in unserer Kindheit begleitet hat und der verbunden ist 
mit der Frage: „Warum eigentlich?“ Vitamine sind definiert als essentielle Nährstoffe, d. h. Stoffe, die 
unser Körper nicht in ausreichender Menge produzieren kann und die wir folglich mit der Nahrung 
aufnehmen müssen. Mit Ausnahme von Vitamin B12, das ausschließlich in tierischen Produkten 
enthalten ist, sind alle 13 Vitamine in Gemüse zu finden. Vitamine sind notwendige Nährstoffe und 
Vitaminmängel haben somit pathologische Auswirkungen wie z. B. Erblindung und Osteoporose. 
 
Nukleäre Rezeptoren 
Hormone und Vitamine werden in Zellen von sogenannten Nukleären Rezeptoren (NR) erkannt. 
Diese NRs binden nicht nur Hormone und Vitamine, sondern auch Fette und andere 
Stoffwechselprodukte. Der Mensch verfügt über 50 verschiedene NRs und jeder dieser Rezeptoren 
wird durch einen spezifischen Stoff aktiviert, den Liganden. So bindet der Östrogen Rezeptor das 
weibliche Hormon Östrogen und der Vitamin D Rezeptor das sonnenlichtaktivierte Vitamin D. Im 
Allgemeinen werden NRs anhand ihrer Wirkweise in zwei Hauptkategorien eingeteilt: Typ I NRs und 
Typ II NRs. Bekannte Beispiele von Typ I NRs sind der Östrogen Rezeptor (ER), der Progesteron 
Rezeptor (PR), der Androgen Rezeptor (AR, bindet Testosteron) und der Glukokortikoid Rezeptor (GR, 
bindet Kortisol). Typ II NRs interagieren mit dem Retinsäure-X-Rezeptor (RXR) um ihre Funktion zu 
erfüllen. Beispiele sind der Vitamin D Rezeptor (VDR), der all-trans-Retinsäure-Rezeptor (RAR) und 
der peroxisom-proliferator-aktivierte Rezeptor (PPAR, bindet Fettsäuren). Eine dritte Kategorie 
umfasst die sogenannten Waisen-Rezeptoren, für die kein Ligand existiert oder noch nicht gefunden 
wurde. Wenn NRs ihre Liganden binden, lösen sie die Produktion von bestimmten Proteinen aus 
wodurch die Zelle angemessen reagieren kann. Die Aktivität von NRs ist dabei abhängig von 
regulatorischen Proteinen, den sogenannten Koregulatoren. Mehr als 300 Koregulatoren sind bisher 
bekannt. Einige dieser Proteine, Koaktivatoren, können die Funktion von NRs aktivieren, während 
andere, Korepressoren, die Funktion von NRs hemmen. Ein besonderer Koregulator ist das Protein 
DC-SCRIPT (dendritic cell specific transcript). DC-SCRIPT kann einerseits die Funktion von Typ I NRs 
hemmen und andererseits die Funktion von Typ II NRs aktivieren. 
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Zusammenfassend ist also festzuhalten, dass Vitamine, Hormone, ihre Nukleären Rezeptoren und 
Koregulatoren eine Vielzahl wichtiger Prozesse in unserem Körper regulieren und folglich im 
Zusammenhang mit unterschiedlichen Krankheitsbildern stehen. Die vorliegende Dissertation 
untersucht einige Aspekte im Hinblick auf das Immunsystem und Krebs, welche im Folgenden weiter 
erläutert werden. 
Das Immunsystem 
Unser Immunsystem schützt uns täglich vor unterschiedlichen Krankheitskeimen, wie z. B. Bakterien, 
Viren und Parasiten. Darüber hinaus bietet uns das Immunsystem in den meisten Fällen auch Schutz 
gegen veränderte körpereigene Zellen, wie Krebszellen, während normale Zellen nicht angefallen 
werden. Die effiziente immunologische Abwehr gegen gefährliche Erreger und Zellen einerseits und 
die Toleranz gegenüber gesunden körpereigenen Zellen andererseits setzt ein komplexes und fein 
abgestimmtes System voraus. Das Immunsystem ist aus einer Vielzahl von spezialisierten Zellen und 
Faktoren, welche koordiniert miteinander kommunizieren und Informationen austauschen. Im 
Allgemeinen werden zwei Mechanismen des Immunsystems unterschieden: 1) die angeborene und 
2) die erworbene Immunabwehr. Die angeborene Immunabwehr ist sehr schnell und greift 
Krankheitserreger in unspezifischer Weise an. Bakterien und Viren werden in erster Instanz mit den 
mechanischen und physiologischen Barrieren des Immunsystems konfrontiert. Unsere Haut und die 
Schleimhäute von z. B. Augen, Mund und Nase verhindern das Eindringen von Bakterien und Viren. 
Gelingt es den Erregern trotzdem einzudringen, dann treffen sie auf toxische, antimikrobielle Stoffe 
und greifen die weißen Blutzellen des angeborenen Immunsystems, wie z. B. Granulozyten, Mast 
Zellen, Makrophagen und Dendritische Zellen, an. Die erworbene Immunabwehr ist viele Male 
langsamer als das angeborene Immunsystem, jedoch ist sie erregerspezifisch. Die weißen Blutzellen 
des erworbenen Immunsystems, T- und B-Zellen, erkennen spezifische Proteine auf der Oberfläche 
von Krankheitserregern und antworten hierauf. B-Zellen scheiden spezifische Antikörper gegen die 
Erreger aus, und T-Zellen töten virusinfizierte Zellen oder auch Tumorzellen. Bevor B- und T-Zellen 
Krankheitskeime spezifisch erkennen können, müssen sie von sogenannten Antigen-präsentierenden 
Zellen aktiviert werden. Diese Zellen nehmen Erreger auf, verdauen sie innerlich und präsentieren 
anschließend kleine Stücke des Erregers auf ihrer Zelloberfläche an T- und B-Zellen. Eine Familie von 
Antigen-präsentierenden Zellen sind die Dendritischen Zellen (DC), die professionellen Spezialisten 
unter den Antigen-präsentierenden Zellen.  
 
Hormone, Vitamine und Dendritische Zellen im Kontext 
DCs sind weiße Blutzellen, die unseren Körper ständig patrouillieren und nach Krankheitserregern 
suchen. Sie sind in unserem Blut und in unseren Organen zu finden, wo sie in unreifem Zustand 
verkehren. Unreife DCs sind sehr effizient in der Erkennung und Aufnahme von Keimen. Während 
einer Infektion werden DCs durch spezifische Strukturen auf der Oberfläche von Erregern aktiviert. 
Hierdurch können die DCs aus den Organen in unsere Lymphknoten migrieren, wo sie T- und B-Zellen 
aktivieren. Die DC-Familie besteht aus verschiedenen Kategorien von Zellen. Die zwei wichtigsten 
Sorten sind einerseits die klassischen DCs (cDC) und andererseits die plasmazytoiden DCs (pDC). 
Beide Sorten haben spezielle Funktionen; cDCs sind sehr schnell in der Aufnahme von Erregern und 
pDCs sind bekannt für ihre schnelle Produktion von großen Mengen des antiviralen Interferon Alpha 
(IFNα). DCs verfügen über eine Vielzahl von Rezeptoren, um ihre Umgebung zu erkennen und sich 
entsprechend anzupassen, mitunter haben sie auch Nukleäre Rezeptoren. Es ist bekannt, dass 
Hormone und Vitamine die Funktion von DCs steuern können. So ist das Vitamin A in unserem Darm 
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wichtig, um die Funktion der örtlichen DCs zu hemmen, so dass die für uns wichtigen Darmbakterien 
nicht angegriffen werden. Ähnlich zu der Funktion von Vitamin A im Darm bekleidet das Sonnenlicht-
induzierte Vitamin D eine wichtige Rolle in der Haut. Auch Vitamin D unterdrückt die Aktivierung von 
DCs und verhindert somit die Zerstörung von wichtigen Hautbakterien. Neben diesen natürlichen 
Funktionen, werden die prägenden Eigenschaften von Vitaminen und Hormonen auf DCs auch in der 
Medizin ausgeschöpft. Das entzündungshemmende Kortisol ist ein Stoff, der den Glukokortikoid 
Rezeptor bindet und neben anderen Immunzellen auch DCs in ihrer Aktivität hindert. Obwohl wir viel 
über den Einfluss von Vitaminen, Hormonen und ihren NRs auf klassische DCs wissen, ist hinsichtlich 
pDCs noch wenig bekannt. In Teil II der vorliegenden Dissertation haben wir darum Aspekte der 
Funktion von NRs in pDCs erforscht. 
In Kapitel 2 verglichen wir die Anwesenheit von 28 verschiedenen NRs in cDCs und pDCs. Unsere 
Daten belegen, dass cDCs und pDCs in vitro, d. h. außerhalb des Körpers im Labor, und isoliert aus 
lymphatischen Organen dasselbe NR Repertoire aufweisen. Die Menge von individuellen NRs in cDCs 
oder pDCs ist jedoch unterschiedlich; diese Unterschiede sind besonders deutlich in aktivierten 
Zellen. 
In Kapitel 3 untersuchen wir die Effekte von Vitamin D auf pDCs. Es ist bekannt, dass Vitamin D die 
Funktion des Immunsystems und insbesondere von cDCs inhibieren kann. Aus diesem Grund werden 
Vitamin D-haltige Salben zur Behandlung von Autoimmunkrankheiten, wie Schuppenflechte und 
Schmetterlingsflechte, eingesetzt. Die exakten Wirkmechanismen dieser Therapie sind jedoch nicht 
bekannt. pDCs sind in entscheidendem Maße beteiligt an der Entwicklung und dem Verlauf der 
genannten Autoimmunsymptome. Wir demonstrieren, dass Vitamin D behandelte pDCs verminderte 
Funktionen haben und T-Zellen somit nicht vollständig aktivieren können (Kapitel 3). Das Vermögen 
der repressiven Eigenschaften von pDCs in therapeutischen Anwendungen könnte somit von der 
klinischen Verfügbarkeit von Vitamin D Präparaten zur Behandlung von immunologischen 
Hautkrankheiten profitieren. 
Wie zuvor beschrieben, ist die Aktivität von NRs abhängig von koregulatorischen Proteinen. Die 
meisten Koregulatoren können NRs entweder hemmen oder aktivieren. Teil III dieser Arbeit 
untersucht DC-SCRIPT, ein besonderes Protein, welches sowohl die negativen als auch die positiven 
regulatorischen Funktionen erfüllen kann. In Kapitel 4 und 5 haben wir die Rolle von DC-SCRIPT in 
DCs ermittelt. Unsere Daten belegen, dass DC-SCRIPT in cDCs und pDCs anwesend ist und die 
Produktion von immunaktiven Molekülen, den sogenannten Zytokinen, beeinflusst. DC-SCRIPT 
hemmt die Produktion des immunrepressiven Zytokins IL-10 und fördert damit die Produktion des 
immunstimulierenden Zytokins IL-12 (Kapitel 4). Demzufolge scheint DC-SCRIPT die 
immunstimulierenden Eigenschaften von DCs zu verstärken. In Kapitel 5 zeigen wir, dass DC-SCRIPT 
die Funktion des Glukokortikoid Rezeptors (GR) hemmt. Übereinstimmend zeigen wir, dass in 
Abwesenheit von DC-SCRIPT das GR aktivierte Molekül GILZ in größerer Menge in DCs anwesend ist. 
GR ist bekannt für seine repressiven Effekte auf DCs, und DC-SCRIPT scheint somit die 
immunrepressiven Eigenschaften von DCs zu unterdrücken. 
Zusammenfassend geben unsere Daten aus den Kapiteln 2 bis 5 neue Einsichten und stellen die 
bedeutenden Effekte von Hormonen, Vitaminen ihren NRs und Koregulatoren auf die Funktion von 
DCs und somit auf immunologische Abwehrreaktionen nachdrücklich heraus. 
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Hormone, Vitamine und Krebs im Kontext 
Krebs bezeichnet in der Medizin die bösartige Neubildung von Gewebe. Durch verschiedene 
Mechanismen werden die im Erbgut (der DNA) festgelegten Eigenschaften einer gesunden Zelle 
verändert (mutiert), und somit ist diese in der Lage, sich ungehemmt zu teilen, Tochterzellen zu 
formen und eine bösartige Gewebemasse zu bilden. Es ist bekannt, dass Tumorzellen verschiedene 
Eigenschaften von ihren gesunden Mutterzellen übernehmen. Dieses Konzept ist besonders deutlich 
bei Tumoren von Drüsengeweben, wie z. B. Brust- und Prostatakrebs, zu beobachten. Die gesunde 
Entwicklung der Brust ist abhängig von den weiblichen Hormonen Östrogen und Progesteron. 
Brusttumoren behalten diese Eigenschaft, und auch ihr Wachstum ist abhängig von diesen 
Hormonen und somit von der Anwesenheit des Östrogen- und Progesteron Rezeptors (ER und PR). 
Andere NRs, PPAR und RAR, hemmen das Wachstum der Tumorzellen. Die Medizin nutzt die 
Hormonabhängigkeit der Tumore, indem Patienten mit dem ER hemmenden Arzneistoff Tamoxifen 
behandelt werden. Unlängst wurde gezeigt, dass der NR Koregulator DC-SCRIPT eine wichtige Rolle in 
der Entstehung von Brustkrebs spielt. Gesunde Zellen der Brust beinhalten das Protein DC-SCRIPT 
während Tumorzellen weitaus geringere Mengen aufweisen. Interessanterweise hemmt DC-SCRIPT 
die Funktion von den Wachstum steigernden Rezeptoren ER und PR und aktiviert die Funktion der 
Wachstum unterdrückenden Rezeptoren PPAR und RAR. Darüber hinaus korreliert die Anwesenheit 
von größeren Mengen DC-SCRIPT mit der besseren Prognose von Brustkrebspatienten. Auf ähnliche 
Weise wie die Entwicklung von Brustkrebs ist die gesunde Entwicklung der Prostata und auch das 
Wachstum von bösartigen Prostatatumoren abhängig von dem männlichen Hormone Testosteron 
(bindet den Androgen Rezeptor, AR). Der Vitamin D Rezeptor hingegen hemmt das Wachstum der 
Tumorzellen. Prostatakrebspatienten erhalten Mittel, die den Testosteronspiegel senken oder AR 
hemmen. In Kapitel 6 vertiefen wir unser Wissen bezüglich DC-SCRIPT und Brustkrebs und 
untersuchen die Funktion von DC-SCRIPT in Prostatakrebs. Wir zeigen, dass gesunde 
Prostatakrebszellen das Protein DC-SCRIPT beinhalten, während veränderte Prostatatumorzellen kein 
DC-SCRIPT mehr aufweisen. Weiterhin zeigen unsere Daten, dass DC-SCRIPT die Funktion des 
Wachstum stimulierenden AR hemmt und die Funktion des Wachstum unterdrückenden VDR 
aktiviert. Zusammenfassend ist es demnach wahrscheinlich, dass DC-SCRIPT eine wichtige Rolle bei 
der Entwicklung von Prostatakrebs spielt. 
In Kapitel 7 fasse ich die erworbenen Erkenntnisse dieser Dissertation zusammen und erörtere die 
Bedeutung unserer Daten im Kontext des aktuellen Forschungsstandes. 
 
Perspektive 
Die vorliegende Dissertation erweitert den aktuellen Forschungsstand hinsichtlich der Effekte von 
Hormonen und Vitaminen auf Dendritische Zellen und Krebs. Wir konnten nachweisen, dass die 
Funktion verschiedener Sorten DCs und die Funktion von Prostatatumoren von Hormonen, 
Vitaminen, NRs und dem NR Koregulator DC-SCRIPT beeinflusst wird. Die gezielte Modifizierung von 
NRs und ihrer Koregulatoren könnte zur Verbesserung von existierenden und zur Entwicklung von 
neuen Immuntherapien beitragen. Die sinnvolle Entwicklung und Verbesserung von Therapien setzt 
jedoch umfassende Kenntnis und somit weitere Forschungsstudien voraus. 
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